ticlopidine has been researched along with Apoplexy in 915 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This comparison of PRAsugrel and clopidogrel in Japanese patients with ischemic STROke (PRASTRO)-I trial investigates the noninferiority of prasugrel to clopidogrel sulfate in the prevention of recurrence of primary events (ischemic stroke, myocardial infarction, and death from other vascular causes), and the long-term safety of prasugrel in Japanese patients with non-cardioembolic stroke." | 9.27 | A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial. ( Abe, K; Ikeda, Y; Kitagawa, K; Kitazono, T; Matsumoto, M; Minematsu, K; Nagao, T; Nagata, I; Nanto, S; Nishikawa, M; Ogawa, A; Tanahashi, N; Toyoda, K; Uchiyama, S; Yamagami, H, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "We consecutively enrolled 523 patients with ischemic stroke receiving clopidogrel." | 9.27 | Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2. ( Cheng, W; Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "Rationale and aim Little is known about the safety and efficacy of the combination of ticagrelor and aspirin in acute ischemic stroke." | 9.24 | Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design. ( Cao, Y; Chen, G; Chen, W; Li, H; Li, J; Li, X; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wang, Z; Wu, J; Xu, Y; Zhang, G; Zhao, X, 2017) |
| "To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA." | 9.24 | Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017) |
| "To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk." | 9.24 | Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017) |
| "In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 9.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
| " Patients with ischemic stroke were randomized to receive either clopidogrel napadisilate 75 mg or clopidogrel bisulfate 75 mg." | 9.22 | Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in stroke patients: multicenter, randomized, open-label, phase 4, non-inferiority clinical trial. ( Kang, K; Kim, BK; Kim, HJ; Koh, SH; Lee, SJ, 2016) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 9.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| "The objective of this study was to evaluate the efficacy and safety of intravenous vinpocetine administration as part of a comprehensive treatment for acute cerebral infarction in a Chinese population." | 9.22 | Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. ( Hu, H; Huang, Y; Kong, Y; Li, C; Li, Y; Nao, J; Song, Y; Tan, L; Zhang, J; Zhang, W, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 9.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 9.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 9.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 9.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding." | 9.20 | Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015) |
| "To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke." | 9.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| "The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination." | 9.20 | Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "The role of the CYP2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss-of-function variant carriers taking clopidogrel after percutaneous coronary intervention; however, data are limited regarding the association between CYP2C19 genetic variants and outcomes in stroke patients." | 9.20 | CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. ( Benavente, OR; Field, TS; Gong, Y; Horenstein, RB; Johnson, JA; Lewis, JP; McClure, LA; McDonough, CW; Mitchell, BD; Shuldiner, AR; Talbert, RL, 2015) |
| "We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA." | 9.20 | Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. ( Fang, J; Hu, B; Johnston, SC; Li, H; Liu, L; Meng, X; Wang, A; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Zhao, X, 2015) |
| "Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist." | 9.20 | Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015) |
| "To study whether Clopidogrel-Aspirin combined treatment for high risk transient ischaemic attack (TIA) or minor stroke results in increased number of lesions associated with anti-thrombotic cerebral haemorrhage or cerebral micro-bleeds (CMB) than aspirin alone treatment." | 9.20 | Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. ( Wang, P; Wang, Y; Wang, Z; Xin, H; Xu, C, 2015) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 9.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 9.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "Clopidogrel is used to prevent the recurrence of non-cardiogenic ischemic stroke, but individual responsiveness to the drug varies." | 9.19 | Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients. ( Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Sehara, Y; Tanahashi, N, 2014) |
| "We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism." | 9.19 | Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 9.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "Among patients who had angiography who took prasugrel there were fewer cardiovascular deaths, myocardial infarctions, or strokes than in those who took clopidogrel." | 9.17 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. ( Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD, 2013) |
| "Stroke victims often exhibit clopidogrel resistance (CR)." | 9.17 | Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction. ( Deng, YH; Guan, HT; Liu, ZF; Shi, HT; Wang, R; Zhang, M; Zhou, BR, 2013) |
| " clopidogrel in patients with acute coronary syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial (PLATO)." | 9.17 | Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. ( Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L, 2013) |
| "On average, acute coronary syndrome patients treated with prasugrel experience fewer ischemic complications, but more bleeding, than those receiving clopidogrel." | 9.17 | Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. ( Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K, 2013) |
| "We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 9.16 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 9.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 9.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| " Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks." | 9.16 | Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012) |
| "we conducted a nested case-control study of all Ontario residents aged ≥ 66 years newly treated with clopidogrel after a stroke between April 1, 2002, and September 30, 2008." | 9.15 | The safety of proton pump inhibitors and clopidogrel in patients after stroke. ( Gladstone, DJ; Gomes, T; Juurlink, DN; Kapral, MK; Mamdani, MM, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 9.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 9.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "Two Phase III studies comparing the safety and efficacy of clopidogrel with ticlopidine as antiplatelet agents for the secondary prevention of vascular events in patients with prior stroke were performed in Japan." | 9.14 | The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials. ( Fukuuchi, Y; Uchiyama, S; Yamaguchi, T, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 9.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding." | 9.14 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009) |
| "The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke." | 9.14 | Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)." | 9.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| "8%) patients had a definite adjudicated stroke and a follow-up assessment of the mRS at 3 months poststroke, of whom 202 had been randomly assigned clopidogrel and 234 placebo (relative risk reduction 14%, 95% CI: -4% to 29%, P=0." | 9.14 | Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. ( Bhatt, DL; Brennan, DM; Easton, JD; Fox, KA; Hacke, W; Hankey, GJ; Johnston, SC; Mas, JL; Topol, EJ, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 9.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention." | 9.13 | Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "Patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80 mg telmisartan or placebo once per day." | 9.13 | Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; VanderMaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 9.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 9.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Aspirin offers modest reduction in stroke in patients with atrial fibrillation." | 9.13 | Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008) |
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 9.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| "Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy." | 9.12 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 9.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 9.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 9.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 9.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 9.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study." | 9.11 | Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005) |
| "In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks." | 9.10 | Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003) |
| " In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke." | 9.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients." | 9.10 | Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 9.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 9.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 8.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial." | 8.95 | Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. ( Chen, W; Han, Y; Huang, L; Johnston, SC; Li, X; Liu, L; Pan, Y; Wang, G; Wang, Y; Xu, Y; Yang, Q; Yi, X; Zhang, Q; Zhao, X, 2017) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 8.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "It remains controversial whether dual antiplatelet therapy reduces stroke more than aspirin alone." | 8.91 | Effect of addition of clopidogrel to aspirin on stroke incidence: Meta-analysis of randomized trials. ( Anderson, DC; Benavente, OR; Birnbaum, LA; Hart, RG; Palacio, S; Pearce, LA; Sharma, M, 2015) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 8.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients." | 8.91 | Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015) |
| " A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0." | 8.91 | Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 8.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 8.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 8.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| " These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 8.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
| "Literature is scarce regarding the use of clopidogrel during pregnancy and the potential hazard to maternal and fetal health." | 8.90 | Successful gestation and delivery using clopidogrel for secondary stroke prophylaxis: a case report and literature review. ( Cuesta-Fernandez, A; Kayaleh, OR; Reilly, CR, 2014) |
| "Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk." | 8.90 | Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014) |
| "Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications." | 8.90 | Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 8.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| " In the large Phase III trial, PLATO, ticagrelor significantly reduced the composite of cardiovascular death, myocardial infarction, or stroke as well as cardiovascular and all-cause mortality compared with clopidogrel in patients presenting with acute coronary syndromes." | 8.89 | Ticagrelor for acute coronary syndromes. ( Bansilal, S; Bonaca, MP; Sabatine, MS, 2013) |
| "This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions." | 8.89 | Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013) |
| "Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling of clopidogrel was developed from pooled data from healthy volunteers (n = 44) and stroke patients (n = 35)." | 8.88 | Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ( Han, S; Hwang, Y; Kang, W; Lee, HW; Lee, J; Lim, MS; Seong, SJ; Sohn, DR; Yim, DS; Yoon, YR, 2012) |
| "Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide." | 8.88 | Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012) |
| "To identify confounding factors that may explain the incoherence between direct and indirect evidence in a published analysis comparing extended-release dipyridamole (ERDP) plus aspirin to clopidogrel for the reduction of stroke." | 8.88 | Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention. ( Dewilde, S; Hawkins, N, 2012) |
| "To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI." | 8.88 | Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 8.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| "This review aims to determine whether it is cost-effective to replace aspirin and warfarin with more effective, yet more costly, treatments for secondary stroke prevention." | 8.86 | Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? ( Hankey, GJ, 2010) |
| "Oral antiplatelet drugs, including aspirin, clopidogrel and extended-release dipyridamole, are widely prescribed for the secondary prevention of vascular events, including stroke." | 8.86 | Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. ( Greer, DM, 2010) |
| "To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke." | 8.85 | Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009) |
| "The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)." | 8.84 | Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008) |
| "The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention." | 8.84 | Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention. ( Chaturvedi, S, 2008) |
| "One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement." | 8.80 | Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. ( Bennett, CL; Bennett, RH; Davidson, CJ; Feldman, MD; Raisch, DW; Weinberg, PD, 1999) |
| "The most widely studied and prescribed antiplatelet agent for the prevention of stroke and other serious vascular events among high vascular risk patients is aspirin." | 8.80 | Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Dunbabin, DW; Hankey, GJ; Sudlow, CL, 2000) |
| "Background The objective of the study was to assess the cost-effectiveness of cilostazol (a selective phosphodiesterase 3 inhibitor) added to aspirin or clopidogrel for secondary stroke prevention in patients with noncardioembolic stroke." | 8.12 | Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. ( de Havenon, A; Kraler, L; Lansberg, MG; Zhou, LW, 2022) |
| "Clopidogrel is a common antiplatelet used as secondary prevention of ischemic stroke, known to have better efficacy than aspirin, with a equivalent safety profile." | 8.12 | Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia. ( Harahap, AR; Harris, S; Herqutanto, H; Hidayat, R; Listyaningsih, E; Loho, T; Louisa, M; Nabilah, RA; Rambe, AS; Rasyid, A, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 8.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting." | 7.96 | Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 7.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 7.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 7.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "The relationship of CYP2C19 genotype and clinical efficacy in stroke or transient ischemic attack (TIA) patients treated with clopidogrel monotherapy or clopidogrel plus aspirin remains unknown." | 7.88 | Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis. ( Cui, M; Gu, ZC; Li, WY; Pan, MM; Yao, JC, 2018) |
| "Clopidogrel HTPR does not seem to be a major contributor to recurrent ischemic events in Danish ischemic stroke patients." | 7.88 | Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. ( Jørgensen, NR; Rath, CL; Wienecke, T, 2018) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 7.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "To assess the association of CYP2C19 gene polymorphisms with the incidence of ischemic stroke among patients receiving clopidogrel therapy following coronary stenting for coronary artery disease." | 7.85 | [Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation]. ( Chen, J; Ding, N; Li, G; Peng, L; Shao, Y; Wang, Y; Xu, Z; Zhang, C, 2017) |
| "We consecutively enrolled 375 patients with IS after they received clopidogrel therapy, and venous blood samples were subjected to genotyping allelic variants of genes modulating clopidogrel absorption (ATP binding cassette subfamily B1, ABCB1), metabolic activation (cytochrome P450[CYP] 3A and CYP2C19), and biologic activity (platelet membrane receptor [ P2Y12, P2Y1)], and glycoprotein IIIa [ GPIIIa]) and statistically analyzing their interactions with clopidogrel sensitivity (CS) and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up." | 7.85 | Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. ( Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2017) |
| "Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 7.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 7.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 7.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS)." | 7.83 | Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis. ( Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D, 2016) |
| "We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)." | 7.83 | Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016) |
| "The risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel." | 7.83 | Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. ( Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY, 2016) |
| " Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment." | 7.83 | Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 7.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban." | 7.83 | Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016) |
| "We observed a potential late treatment effect for prasugrel versus clopidogrel for a reduced risk of ischemic stroke in medically managed patients with ACS aged <75 years." | 7.83 | Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial. ( Armstrong, PW; Chin, CT; Corbalán, R; Fox, KA; Magnus Ohman, E; Neely, B; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016) |
| "Research regarding clopidogrel resistance (CR) and ischemic stroke (IS) recurrence related to IS is scanty." | 7.83 | Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. ( Cheng, W; Lin, J; Wang, C; Wu, L; Yi, X; Zhou, Q, 2016) |
| "Clopidogrel is an antiplatelet drug primarily used to treat or prevent acute ischemic stroke (IS) or myocardial infarction (MI)." | 7.83 | Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( Cheng, W; Chi, L; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2016) |
| " The associated SNPs studied may be useful to predict clopidogrel resistance in Chinese patients with ischemic stroke." | 7.83 | Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. ( Cai, YF; Chen, XM; Chen, YB; Huang, M; Jin, J; Li, JL; Liu, R; Yu, WB; Zhao, M; Zhao, YQ; Zhou, ZY, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 7.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Despite clopidogrel has been widely applied to patients with ischemic stroke combined with aspirin, decreased metabolic activation of clopidogrel still occurs because of genetic variations in CYP2C19." | 7.83 | Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel. ( Cai, H; Liu, X; Wang, Y; Zhang, Z; Zhou, G, 2016) |
| "Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents." | 7.81 | Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. ( Hua, K; Huang, Z; Ji, H; Sheng, X; Wang, X; Xu, J; Yang, C; Zhang, Y, 2015) |
| " We hypothesized that cytochrome P450 2C19 (CYP2C19) genotype influences the incidence of early recurrence on DWI in acute stroke patients treated with clopidogrel." | 7.81 | CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel. ( Chun, S; Jeong, TD; Kang, DW; Kim, HJ; Kim, SM; Kwon, SU; Lee, W; Min, WK, 2015) |
| "PPIs of interest did not increase the rate of ischemic stroke among clopidogrel users when compared with pantoprazole, a PPI thought to be devoid of the potential to interact with clopidogrel." | 7.81 | Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. ( Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE, 2015) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 7.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| " The aim of this study was to validate the predictive value of HRPR measured by flow cytometry for clinical outcomes in ischemic stroke patients during clopidogrel therapy." | 7.81 | Predictive value of high residual platelet reactivity by flow cytometry for outcomes of ischemic stroke patients on clopidogrel therapy. ( Han, RF; Li, X; Liu, J; Qiu, LN; Wang, L; Xia, XS, 2015) |
| "Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)." | 7.81 | Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015) |
| "This study sought to evaluate the influence of the genetic polymorphisms on platelet reactivity and clinical outcomes in acute ischemic stroke patients taking clopidogrel." | 7.81 | Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. ( Dong, Q; Guan, YT; Han, Y; Jiang, JM; Li, SX; Liu, X; Luo, Z; Lv, HH; Wu, S; Xu, JF; Yang, XL; Zhang, Y; Zheng, Y; Zhu, DS, 2015) |
| "The objective of this study was to compare nonresponders (NR) and responders (R) to clopidogrel with respect to presence of microvascular and macrovascular pathology in a cohort of patients with recent minor ischemic stroke (IS) or transient ischemic attack (TIA)." | 7.81 | Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. ( Gigante, B; Höeg Dembrower, K; Jörneskog, G; Laska, AC; Laurencikas, E; Lundström, A; von Arbin, M; Wallén, H, 2015) |
| "The relation between high on-treatment platelet reactivity (HPR), and the level of glucose intolerance and insulin resistance (IR) was studied in clopidogrel-treated patients with minor ischemic stroke or TIA." | 7.80 | Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA. ( Jörneskog, G; Laska, AC; Lundström, A; Von Arbin, M; Wallén, H, 2014) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 7.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "During the first days following an acute ischemic stroke, a consistently good antiplatelet effect of clopidogrel is important due to the increased risk of recurrent ischemia." | 7.80 | Clopidogrel high-on-treatment platelet reactivity in acute ischemic stroke patients. ( Endres, HG; Krogias, C; Krüger, JC; Meves, SH; Neubauer, H; Schröder, KD, 2014) |
| "Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel." | 7.80 | Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014) |
| "A total of 129 noncardiogenic ischemic stroke patients receiving 75 mg/day of clopidogrel for ≥1 week were evaluated." | 7.80 | Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients. ( Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Tanahashi, N, 2014) |
| "We prospectively enrolled patients older than 20 years who had a history of noncardioembolic strokes, including transient ischemic attacks, were treated with ticlopidine for at least 6 months." | 7.80 | Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. ( Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014) |
| "Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown." | 7.80 | Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. ( Johnston, SC; Liu, G; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Zhao, K; Zhao, X, 2014) |
| "To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel." | 7.80 | Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014) |
| "Clopidogrel resistance(CR)is found in non-cardioembolic ischemic stroke (NCIS) patients." | 7.80 | VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( Huang, L; Lai, X; Li, W; Xiong, Z; Xu, A; Zhang, S, 2014) |
| "Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients." | 7.79 | Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013) |
| "The Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence trial raised concern that loading doses of clopidogrel may increase hemorrhagic complications." | 7.79 | Short-term bleeding events observed with clopidogrel loading in acute ischemic stroke patients. ( Albright, KC; Beasley, TM; Boehme, AK; Jones, EM; Leung, LY; Martin-Schild, S; Pletsch, GR; Shah, KR; Siegler, JE; Tarsia, J, 2013) |
| "Little research regarding genotypes and clopidogrel response related to acute ischemic stroke has been published." | 7.79 | CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. ( Chen, C; Chen, ZB; Jia, DM; Jin, JL; Shao, Y; Xia, YQ; Xu, Y; Yang, WJ; Zhang, CL; Zhang, MJ, 2013) |
| " We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)." | 7.79 | Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013) |
| "Study population included 111 patients with the history of ischemic stroke being on clopidogrel monotherapy and 140 controls." | 7.79 | Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy. ( Bagoly, Z; Csiba, L; Kappelmayer, J; Magyar, T; Muszbek, L; Pongrácz, E; Sarkady, F, 2013) |
| "Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common." | 7.79 | Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013) |
| " Among 4408 stroke-free individuals who underwent brain magnetic resonance imaging for the detection of CMBs, we identified 121 ever-users and 4287 never-users of clopidogrel before magnetic resonance imaging." | 7.79 | Clopidogrel use is associated with an increased prevalence of cerebral microbleeds in a stroke-free population: the Rotterdam study. ( Akoudad, S; Darweesh, SK; Hofman, A; Ikram, MA; Leening, MJ; Loth, DW; Stricker, BH; Vernooij, MW, 2013) |
| "This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)." | 7.79 | Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013) |
| "Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable." | 7.78 | Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012) |
| "To examine healthcare costs among patients hospitalized for transient ischemic attack or ischemic stroke (TIA/stroke) and prescribed aspirin plus extended-release dipyridamole (ASA-ERDP) or clopidogrel (CLOPID) within 30 days post-discharge using a retrospective claims database from a large US managed care organization." | 7.78 | One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. ( Burton, TM; Lacey, M; Lang, K; Liu, F; Monsalvo, ML; Sander, S; Yu, Y, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 7.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "9 years) with ischemic stroke or carotid artery stenting who received clopidogrel (75 mg) for >7 days at our hospital between October 2009 and March 2010." | 7.77 | Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay. ( Deguchi, I; Dembo, T; Fukuoka, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagoya, H; Takeda, H; Tanahashi, N, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 7.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel." | 7.76 | Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. ( Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA, 2010) |
| "In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding." | 7.76 | Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 7.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 7.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update." | 7.76 | Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 7.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| "In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications." | 7.76 | Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| " As compared with the conventional 300-mg dose, pretreatment with a 600-mg loading dose of clopidogrel significantly reduced periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI)." | 7.75 | Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). ( Byun, KH; Cho, JR; Choi, S; Jung, JH; Lee, N; Lee, SH; Min, PK; Sung, CW, 2009) |
| "Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke." | 7.74 | ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008) |
| "In clinical practice, early therapy with clopidogrel, in addition, to aspirin in patients with NSTEMI is associated with a significant reduction of the combined endpoint of death, non-fatal reinfarction and non-fatal stroke after one year." | 7.74 | Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Köth, O; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2008) |
| "The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)." | 7.73 | The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 7.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy." | 7.72 | Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. ( Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H, 2003) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 7.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 7.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "Stress hyperglycemia was measured by glucose/glycated albumin (GA) ratio." | 6.84 | Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack: The CHANCE Study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Cai, X; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wei, T; Zhao, X, 2017) |
| "Patients with API (lacunar infarcts or branch atheromatous disease) admitted within 48 hours after onset were enrolled." | 6.82 | [Argatroban, Aspirin, and Clopidogrel Combination Therapy for Acute Penetrating Artery Infarction: A Pilot Study]. ( Kobayashi, Y; Mano, T; Matsuo, K; Nishi, R, 2016) |
| "The primary outcome is IS recurrence." | 6.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "Fatal bleeding was low and did not differ between groups." | 6.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 6.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| " Although administration of antiplatelet agents has been confirmed to be one of the major approaches for secondary prevention of noncardioembolic stroke, the short-term or long-term use of aspirin plus clopidogrel for secondary stroke prevention remains to be controversial." | 6.52 | Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention. ( Chen, W; Wang, Y, 2015) |
| " Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1." | 6.47 | Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 5.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 5.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 5.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "The EUCLID trial investigated the effect of monotherapy with ticagrelor versus clopidogrel in 13,885 patients with peripheral artery disease (PAD); the primary endpoint was cardiovascular death, myocardial infarction, or ischaemic stroke." | 5.27 | Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. ( Baumgartner, I; Berger, JS; Björck, M; Blomster, JI; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Wojdyla, DM, 2018) |
| "This comparison of PRAsugrel and clopidogrel in Japanese patients with ischemic STROke (PRASTRO)-I trial investigates the noninferiority of prasugrel to clopidogrel sulfate in the prevention of recurrence of primary events (ischemic stroke, myocardial infarction, and death from other vascular causes), and the long-term safety of prasugrel in Japanese patients with non-cardioembolic stroke." | 5.27 | A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial. ( Abe, K; Ikeda, Y; Kitagawa, K; Kitazono, T; Matsumoto, M; Minematsu, K; Nagao, T; Nagata, I; Nanto, S; Nishikawa, M; Ogawa, A; Tanahashi, N; Toyoda, K; Uchiyama, S; Yamagami, H, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "We consecutively enrolled 523 patients with ischemic stroke receiving clopidogrel." | 5.27 | Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2. ( Cheng, W; Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "Rationale and aim Little is known about the safety and efficacy of the combination of ticagrelor and aspirin in acute ischemic stroke." | 5.24 | Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design. ( Cao, Y; Chen, G; Chen, W; Li, H; Li, J; Li, X; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wang, Z; Wu, J; Xu, Y; Zhang, G; Zhao, X, 2017) |
| "To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA." | 5.24 | Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017) |
| "The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone." | 5.24 | Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death." | 5.24 | Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017) |
| "To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk." | 5.24 | Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017) |
| " However, the greatest anti-ischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding events arise during chronic treatment." | 5.24 | Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. ( Aradi, D; Dézsi, CA; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Klopotowski, M; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, RHG; Sibbing, D; Trenk, D, 2017) |
| "In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 5.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
| "Accordingly, 50 mg clopidogrel plus aspirin, and 75 mg clopidogrel plus aspirin were all superior to aspirin alone as stroke prevention in patients with cerebral infarction or transient ischemic attack combined with intracranial and extracranial arteriostenosis." | 5.24 | The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( Dong, AQ; Liu, H; Liu, JQ; Su, N; Wu, HJ; Zuo, FT, 2017) |
| "Clopidogrel is an antiplatelet agent recommended for secondary prevention of ischemic stroke (IS) and transient ischemic attack (TIA)." | 5.22 | The role of ( Bath, PM; Leach, M; McDermott, JH; Newman, WG; Sen, D; Smith, CJ, 2022) |
| "Long-term therapy with aspirin, clopidogrel, or aspirin plus extended-release dipyridamole is recommended for secondary stroke prevention in patients with noncardioembolic ischemic stroke." | 5.22 | Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. ( Moustafa, B; Testai, FD, 2022) |
| " Patients with ischemic stroke were randomized to receive either clopidogrel napadisilate 75 mg or clopidogrel bisulfate 75 mg." | 5.22 | Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in stroke patients: multicenter, randomized, open-label, phase 4, non-inferiority clinical trial. ( Kang, K; Kim, BK; Kim, HJ; Koh, SH; Lee, SJ, 2016) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Among patients with STEMI undergoing PPCI, ticagrelor reduces the incidence of MACCE and the composite end point of cardiovascular death, nonfatal MI, and stroke compared with clopidogrel." | 5.22 | Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. ( Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 5.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| " Ticagrelor, a potent, reversibly binding P2Y12 receptor antagonist, is beneficial in patients with acute coronary syndrome and prior myocardial infarction." | 5.22 | Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2016) |
| "Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation." | 5.22 | 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016) |
| "The objective of this study was to evaluate the efficacy and safety of intravenous vinpocetine administration as part of a comprehensive treatment for acute cerebral infarction in a Chinese population." | 5.22 | Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. ( Hu, H; Huang, Y; Kong, Y; Li, C; Li, Y; Nao, J; Song, Y; Tan, L; Zhang, J; Zhang, W, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 5.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 5.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| " In a previous study, we found that the number of MESs is associated with stroke recurrence and that clopidogrel plus aspirin more effectively reduce the number of MESs than does aspirin alone." | 5.22 | The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016) |
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 5.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 5.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding." | 5.20 | Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015) |
| "To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke." | 5.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| "Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction." | 5.20 | Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015) |
| "Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke." | 5.20 | Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. ( Bath, PM; Dineen, R; Pocock, S; Robson, K; Sprigg, N; Woodhouse, LJ, 2015) |
| "The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial randomized minor ischemic stroke or TIA patients to antiplatelet therapy of clopidogrel plus aspirin or aspirin alone." | 5.20 | Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. ( Li, J; Lin, J; Liu, L; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination." | 5.20 | Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "The role of the CYP2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss-of-function variant carriers taking clopidogrel after percutaneous coronary intervention; however, data are limited regarding the association between CYP2C19 genetic variants and outcomes in stroke patients." | 5.20 | CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. ( Benavente, OR; Field, TS; Gong, Y; Horenstein, RB; Johnson, JA; Lewis, JP; McClure, LA; McDonough, CW; Mitchell, BD; Shuldiner, AR; Talbert, RL, 2015) |
| "We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA." | 5.20 | Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. ( Fang, J; Hu, B; Johnston, SC; Li, H; Liu, L; Meng, X; Wang, A; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Zhao, X, 2015) |
| "Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist." | 5.20 | Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015) |
| "To study whether Clopidogrel-Aspirin combined treatment for high risk transient ischaemic attack (TIA) or minor stroke results in increased number of lesions associated with anti-thrombotic cerebral haemorrhage or cerebral micro-bleeds (CMB) than aspirin alone treatment." | 5.20 | Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. ( Wang, P; Wang, Y; Wang, Z; Xin, H; Xu, C, 2015) |
| "We examined the efficacy and safety of dual antiplatelets in patients with transient ischemic attack or minor stroke, defined as National Institute of Health Stroke Scale scores 0-3, in a subgroup analysis of Clopidogrel plus aspirin versus Aspirin alone for Reducing embolization in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR) study." | 5.19 | Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study. ( Chen, C; Fu, J; Han, Z; Huang, Y; Lau, AY; Leung, TW; Markus, HS; Ratanakorn, D; Suwanwela, NC; Tan, KS; Wong, KS; Zhao, Y, 2014) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 5.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 5.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "Altogether 574 patients with acute (≤2 days) large-artery atherosclerosis stroke were randomly assigned to receive either combined clopidogrel and aspirin or aspirin alone." | 5.19 | A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14." | 5.19 | An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. ( Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R, 2014) |
| "Clopidogrel is used to prevent the recurrence of non-cardiogenic ischemic stroke, but individual responsiveness to the drug varies." | 5.19 | Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients. ( Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Sehara, Y; Tanahashi, N, 2014) |
| "We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism." | 5.19 | Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014) |
| " Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only." | 5.17 | Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. ( Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013) |
| "High residual platelet reactivity (RPR) on clopidogrel treatment has been associated with increased risk for ischemic events during follow-up in patients with acute coronary syndromes." | 5.17 | Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). ( Campo, G; De Palma, R; Guastaroba, P; Guiducci, V; Magnavacchi, P; Manari, A; Marino, M; Marzocchi, A; Saia, F; Sangiorgio, P; Taglieri, N; Tondi, S; Valgimigli, M; Varani, E, 2013) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 5.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "The recurrent stroke and cardiovascular event rates following discontinuation of aspirin plus extended-release dipyridamole (ASA + ERDP) or clopidogrel were compared to the event rates in the on-treatment populations (patients who had discontinued their antiplatelet medication due to an outcome event were kept in the on-treatment population in order not to underestimate the on-treatment stroke rate)." | 5.17 | Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. ( Bath, PM; Cotton, D; Diener, HC; Sacco, RL; Sha, N; Weber, R; Weimar, C, 2013) |
| "The aim of POINT is to determine whether clopidogrel plus aspirin taken <12 h after transient ischemic attack or minor ischemic stroke symptom onset is more effective in preventing major ischemic vascular events at 90 days in the high-risk, and acceptably safe, compared with aspirin alone." | 5.17 | Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. ( Barsan, W; Battenhouse, H; Conwit, R; Dillon, C; Easton, JD; Elm, J; Farrant, M; Johnston, SC; Lindblad, A; Morgenstern, L; Palesch, Y; Poisson, SN, 2013) |
| "Among patients who had angiography who took prasugrel there were fewer cardiovascular deaths, myocardial infarctions, or strokes than in those who took clopidogrel." | 5.17 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. ( Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD, 2013) |
| "Stroke victims often exhibit clopidogrel resistance (CR)." | 5.17 | Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction. ( Deng, YH; Guan, HT; Liu, ZF; Shi, HT; Wang, R; Zhang, M; Zhou, BR, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "The TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) enrolled 13,608 patients with an acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), and randomized them to clopidogrel or prasugrel." | 5.17 | Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio ( Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD, 2013) |
| " clopidogrel in patients with acute coronary syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial (PLATO)." | 5.17 | Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. ( Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L, 2013) |
| " Patients were assessed at baseline [≤ 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke], and at 14 days and ≥ 90 days after changing treatment from (i) no medication to aspirin monotherapy (N = 26) or (ii) aspirin to clopidogrel monotherapy (N = 22)." | 5.17 | High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2013) |
| "We selected all patients with a CHADS(2) score of 1 from the AVERROES and ACTIVE trials who were treated with acetylsalicylic acid with or without clopidogrel and calculated the incidences of ischaemic or unspecified stroke or systemic embolus (SSE) according to their CHA(2)DS(2)-VASc score." | 5.17 | The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. ( Connolly, SJ; Coppens, M; Dorian, P; Eikelboom, JW; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2013) |
| "On average, acute coronary syndrome patients treated with prasugrel experience fewer ischemic complications, but more bleeding, than those receiving clopidogrel." | 5.17 | Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. ( Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K, 2013) |
| "Low dose aspirin reduces the secondary incidence of myocardial infarction and stroke." | 5.17 | Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. ( FitzGerald, GA; Fries, S; Grant, GR; Grosser, T; Kapoor, SC; Lawson, JA, 2013) |
| "In the PLATelet inhibition and patient Outcomes (PLATO) study, 18 624 patients presenting with acute coronary syndromes randomly received ticagrelor (n=9333) or clopidogrel (n=9291)." | 5.17 | Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. ( Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L, 2013) |
| "The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess device-specific outcomes relative to different duration of dual antiplatelet therapy (DAPT) after Everolimus- (EES), Paclitaxel (PES), Zotarolimus- (ZES-S) eluting, or bare metal stents (BMS)." | 5.17 | Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). ( Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P, 2013) |
| "The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation." | 5.17 | Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. ( Buchbinder, M; Doshi, SK; Halperin, JL; Holmes, D; Huber, K; Neuzil, P; Reddy, VY; Sievert, H, 2013) |
| "We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibition and Patient Outcomes (PLATO) trial." | 5.16 | Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. ( Angiolillo, DJ; Cannon, CP; Cantor, WJ; Clare, R; Goodman, SG; Harrington, RA; Husted, S; James, SK; Kilhamn, J; Mahaffey, KW; Nicolau, JC; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L, 2012) |
| "A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident." | 5.16 | Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012) |
| "We identified 9 independent risk factors for SICH: baseline National Institutes of Health Stroke Scale, serum glucose, systolic blood pressure, age, body weight, stroke onset to treatment time, aspirin or combined aspirin and clopidogrel, and history of hypertension." | 5.16 | Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. ( Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N, 2012) |
| "We analyzed MRI of 133 patients admitted consecutively for intra- and extracranial stenting for symptomatic large artery atherosclerosis who received aspirin and clopidogrel." | 5.16 | Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention. ( Abrigo, J; Ahuja, AT; Leung, TW; Ng, N; Siu, DY; Soo, YO; Wong, LK; Yu, S, 2012) |
| "We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 5.16 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012) |
| "In patients undergoing nonurgent percutaneous coronary intervention and in comparison with clopidogrel, intravenous and oral elinogrel therapy did not significantly increase thrombolysis in myocardial infarction major or minor bleeding, although bleeding requiring medical attention was more common." | 5.16 | A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC ( Angiolillo, DJ; Berdan, LG; Bhatt, DL; French, WJ; Gibson, CM; Gretler, DD; Gurbel, PA; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, G; Rao, SV; Thompson, VP; Welsh, RC; Zeymer, U, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 5.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 5.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| " Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks." | 5.16 | Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012) |
| "Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel." | 5.16 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012) |
| "we conducted a nested case-control study of all Ontario residents aged ≥ 66 years newly treated with clopidogrel after a stroke between April 1, 2002, and September 30, 2008." | 5.15 | The safety of proton pump inhibitors and clopidogrel in patients after stroke. ( Gladstone, DJ; Gomes, T; Juurlink, DN; Kapral, MK; Mamdani, MM, 2011) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| " The lowest risk of cardiovascular death, myocardial infarction, or stroke with ticagrelor compared with clopidogrel is associated with a low maintenance dose of concomitant aspirin." | 5.15 | Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 5.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 5.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "Two Phase III studies comparing the safety and efficacy of clopidogrel with ticlopidine as antiplatelet agents for the secondary prevention of vascular events in patients with prior stroke were performed in Japan." | 5.14 | The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials. ( Fukuuchi, Y; Uchiyama, S; Yamaguchi, T, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 5.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "Prasugrel reduced cardiovascular events as compared with clopidogrel in TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) but with increased bleeding." | 5.14 | The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla ( Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD, 2009) |
| "In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding." | 5.14 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009) |
| "The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke." | 5.14 | Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)." | 5.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| "The use of dual antiplatelet therapy for a period longer than 12 months in patients who had received drug-eluting stents was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes." | 5.14 | Duration of dual antiplatelet therapy after implantation of drug-eluting stents. ( Chae, JK; Cheong, SS; Choi, YJ; Chung, WS; Han, KH; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2010) |
| "The clopidogrel plus aspirin for infarction reduction in acute stroke or transient ischaemic attack patients with large artery stenosis and microembolic signals (CLAIR) trial was a randomised, open-label, blinded-endpoint trial." | 5.14 | Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. ( Chang, HM; Chen, C; Chollate, P; Fu, J; Han, Z; Hao, Q; Huang, YN; Koh, A; Markus, HS; Ratanakorn, D; Suwanwela, NC; Tan, KS; Wong, KS; Zhao, Y, 2010) |
| "In the Bavarian Reperfusion Alternatives Evaluation (BRAVE)-3 study upstream administration of abciximab additional to 600 mg clopidogrel loading did not reduce the infarct size in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary interventions." | 5.14 | One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. ( Birkmeier, KA; Dirschinger, J; Dotzer, F; Huber, K; Kastrati, A; Mehilli, J; Moshage, W; Ndrepepa, G; Schömig, A; Schulz, S; Seyfarth, M, 2010) |
| "8%) patients had a definite adjudicated stroke and a follow-up assessment of the mRS at 3 months poststroke, of whom 202 had been randomly assigned clopidogrel and 234 placebo (relative risk reduction 14%, 95% CI: -4% to 29%, P=0." | 5.14 | Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. ( Bhatt, DL; Brennan, DM; Easton, JD; Fox, KA; Hacke, W; Hankey, GJ; Johnston, SC; Mas, JL; Topol, EJ, 2010) |
| " In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5." | 5.14 | Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 5.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "The study will randomize 5,100 Chinese patients with acute TIA or minor stroke to receive a 3-month regimen of clopidogrel initiated with a loading dose of 300 mg followed by 75 mg/d, combined with aspirin 75 mg/d during the first 21 days, or a 3-month regimen of aspirin 75 mg/d alone." | 5.14 | Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. ( Johnston, SC; Wang, Y, 2010) |
| "In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention." | 5.13 | Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "Patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80 mg telmisartan or placebo once per day." | 5.13 | Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; VanderMaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 5.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 5.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Aspirin offers modest reduction in stroke in patients with atrial fibrillation." | 5.13 | Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008) |
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 5.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| "Thirty chronic ischemic stroke patients taking aspirin alone followed by aspirin-clopidogrel combined therapy had platelet reactivity tests performed over 3 months: ex vivo platelet aggregation, platelet recruitment and urinary 11-dehydro-thromboxane B(2) (11-dhTxB(2))excretion." | 5.13 | Platelet aggregation and recruitment with aspirin-clopidogrel therapy. ( Brace, LD; Cursio, J; Grossi, E; Helgason, CM; Pandey, D; Valika, A, 2008) |
| " Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes." | 5.12 | Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006) |
| "Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy." | 5.12 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006) |
| " The antiplatelet agent clopidogrel has become a mainstay of treatment for patients with acute coronary syndromes and stroke, and to reduce ischemic complications after percutaneous coronary and peripheral interventions." | 5.12 | Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience. ( Fasano, MB; Horwitz, PA; Walker, NE, 2006) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 5.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| "PRoFESS is the largest secondary stroke prevention trial to date and will directly compare two antiplatelet regimens as well as the benefit of telmisartan versus placebo." | 5.12 | Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with ( Diener, HC; Sacco, R; Yusuf, S, 2007) |
| " The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7." | 5.12 | Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Hamm, CW; Hankey, GJ; Hu, T; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2007) |
| "Immediately after TIA or minor stroke, patients are at high risk of stroke, which might be reduced by using clopidogrel in addition to aspirin." | 5.12 | Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. ( Buchan, AM; Demchuk, AM; Eliasziw, M; Hill, MD; Kennedy, J; Ryckborst, KJ, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 5.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "The ACTIVE W (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) was a trial comparing OAC to combined antiplatelet therapy with aspirin and clopidogrel for prevention of vascular events in 6,706 AF patients." | 5.12 | Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. ( Connolly, SJ; Healey, JS; Hohnloser, SH; Pajitnev, D; Pfeffer, MA; Pogue, J; Yusuf, S, 2007) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 5.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel." | 5.11 | Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004) |
| "In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke." | 5.11 | Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. ( Fox, KA; Gersh, BJ; Lakkis, N; Mehta, SR; Peters, R; Yusuf, S; Zhao, F, 2004) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 5.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 5.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "The Clopidogrel for the Reduction of Events During Observation (CREDO) trial, a randomized trial of 2,116 patients, showed the effectiveness of antiplatelet therapy with clopidogrel 300 mg before PCI and 75 mg daily for one year afterward compared with placebo load and placebo days 29 to 365 in reducing the combined risk of death, myocardial infarction, and stroke." | 5.11 | Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria ( Beinart, SC; Bouin, O; Caro, J; Chen, R; Gabriel, S; Jackson, J; Kolm, P; Mahoney, EM; Steinhubl, S; Topol, E; Veledar, E; Weintraub, WS; Zhang, Z, 2005) |
| "Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study." | 5.11 | Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005) |
| "In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks." | 5.10 | Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003) |
| " In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke." | 5.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients." | 5.10 | Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 5.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 5.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| "For stroke prevention in elderly patients with IS or TIA, DAPT is superior to aspirin monotherapy but appears to be equivalent to clopidogrel monotherapy, and is accompanied by an increased risk of bleeding." | 4.98 | Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. ( Ding, L; Peng, B, 2018) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 4.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial." | 4.95 | Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. ( Chen, W; Han, Y; Huang, L; Johnston, SC; Li, X; Liu, L; Pan, Y; Wang, G; Wang, Y; Xu, Y; Yang, Q; Yi, X; Zhang, Q; Zhao, X, 2017) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 4.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "Dual antithrombotic regimen of warfarin and clopidogrel is comparable to the recommended triple therapy in respect to the prevention of thromboembolic outcomes of MI/ death and ischemic stroke, while the risk of bleeding is similar in those patients with indications for chronic oral anticoagulation undergoing percutaneous coronary intervention with stent implantation." | 4.93 | [Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation]. ( Du, M; Ma, G; Shi, Y; Zhang, D, 2016) |
| "Physicians considering prescription of P2Y12-receptor antagonist for long-term (>1 year) protection of patients post-myocardial infarction face the trilemma of selecting between clopidogrel, prasugrel, or ticagrelor." | 4.93 | Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma? ( Alexopoulos, D; Lekakis, J; Moulias, A; Xanthopoulou, I, 2016) |
| "It remains controversial whether dual antiplatelet therapy reduces stroke more than aspirin alone." | 4.91 | Effect of addition of clopidogrel to aspirin on stroke incidence: Meta-analysis of randomized trials. ( Anderson, DC; Benavente, OR; Birnbaum, LA; Hart, RG; Palacio, S; Pearce, LA; Sharma, M, 2015) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 4.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients." | 4.91 | Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015) |
| " A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0." | 4.91 | Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 4.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 4.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "New P2Y12 inhibitors decreased death in patients undergoing PCI compared with clopidogrel with a considerable safety and tolerability profile; however, the risk/benefit ratio of ischemic and bleeding events should be further investigated." | 4.91 | Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. ( Ding, SL; Fang, D; Fang, Q; Gan, XD; Li, KY; Peng, S; Wan, J; Wei, BZ, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 4.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "In the overall population, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in comparison to aspirin monotherapy reduced the relative risk of total stroke by 20% (risk ratio [RR], 0." | 4.90 | Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. ( Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M, 2014) |
| " These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 4.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
| "Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved." | 4.90 | Oral antiplatelet therapy for acute ischaemic stroke. ( Cecconi, E; Counsell, C; Sandercock, PA; Tseng, MC, 2014) |
| "Literature is scarce regarding the use of clopidogrel during pregnancy and the potential hazard to maternal and fetal health." | 4.90 | Successful gestation and delivery using clopidogrel for secondary stroke prophylaxis: a case report and literature review. ( Cuesta-Fernandez, A; Kayaleh, OR; Reilly, CR, 2014) |
| "Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk." | 4.90 | Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014) |
| "Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications." | 4.90 | Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014) |
| " In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis." | 4.90 | Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014) |
| "The impact of PPI use on the 1-year primary end point (ischemic stroke, myocardial infarction [MI], or vascular death) in the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial and the 28-day (all-cause death, MI, or urgent target vessel revascularization) and 1-year (all-cause death, MI, or stroke) primary end points in the Clopidogrel for Reduction of Events During Observation (CREDO) trial were examined." | 4.89 | Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. ( Bauer, D; Berger, PB; Charnigo, RJ; Dunn, SP; Steinhubl, SR; Topol, EJ, 2013) |
| "The role of aspirin in the early management of stroke is well established." | 4.89 | Pharmacokinetic considerations for antithrombotic therapies in stroke. ( Apostolakis, S; Lip, GY; Shantsila, E, 2013) |
| " Three preventive strategies were identified: (i) intra-operative transcranial Doppler (TCD) ultrasound and completion angioscopy which virtually abolished intra-operative stroke, primarily through the removal of residual luminal thrombus prior to restoration of flow; (ii) dual antiplatelet therapy with a single 75-mg dose of clopidogrel the night before surgery in addition to regular 75 mg aspirin which virtually abolished post-operative thromboembolic stroke and may also have contributed towards a decline in stroke/death following major cardiac events; and (iii) the provision of written guidance for managing post-CEA hypertension which was associated with virtual abolition of intracranial haemorrhage and stroke as a result of hyperperfusion syndrome." | 4.89 | Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy. ( Bell, PR; Bown, MJ; Dennis, MJ; London, NJ; McCarthy, MJ; Nasim, A; Naylor, AR; Sayers, RD, 2013) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 4.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| " As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors." | 4.89 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013) |
| "Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0." | 4.89 | Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013) |
| " The combination of acetylsalicylic acid (ASA) plus dipyridamole (DP) was more protective against recurrent stroke than ASA alone (RR = 0." | 4.89 | Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. ( Donovan, JL; Kanaan, AO; Malloy, RJ; Silva, MA, 2013) |
| " In the large Phase III trial, PLATO, ticagrelor significantly reduced the composite of cardiovascular death, myocardial infarction, or stroke as well as cardiovascular and all-cause mortality compared with clopidogrel in patients presenting with acute coronary syndromes." | 4.89 | Ticagrelor for acute coronary syndromes. ( Bansilal, S; Bonaca, MP; Sabatine, MS, 2013) |
| "Drugs that prevent platelets from sticking together-ie, aspirin, dipyridamole, and clopidogrel-are an important part of therapy to prevent recurrence of ischemic stroke of atherosclerotic origin." | 4.89 | Antiplatelet therapy to prevent recurrent stroke: Three good options. ( Mansoor, AH; Mujtaba, MT; Silver, B, 2013) |
| "This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions." | 4.89 | Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013) |
| "Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling of clopidogrel was developed from pooled data from healthy volunteers (n = 44) and stroke patients (n = 35)." | 4.88 | Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ( Han, S; Hwang, Y; Kang, W; Lee, HW; Lee, J; Lim, MS; Seong, SJ; Sohn, DR; Yim, DS; Yoon, YR, 2012) |
| " In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3." | 4.88 | Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012) |
| "Although the addition of aspirin to clopidogrel resulted in small relative reductions in major cardiovascular events, myocardial infarction, and stroke, it also resulted in a relative increase in major bleeding events." | 4.88 | Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. ( He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH, 2012) |
| "Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide." | 4.88 | Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012) |
| "To identify confounding factors that may explain the incoherence between direct and indirect evidence in a published analysis comparing extended-release dipyridamole (ERDP) plus aspirin to clopidogrel for the reduction of stroke." | 4.88 | Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention. ( Dewilde, S; Hawkins, N, 2012) |
| "In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)." | 4.88 | Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012) |
| "To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI." | 4.88 | Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012) |
| "Although the exact prevalence of antiplatelet resistance in ischemic stroke is not known, estimates about the two most widely used antiplatelet agents - aspirin and clopidogrel - suggest that the resistance rate is high, irrespective of the definition used and parameters measured." | 4.87 | Antiplatelet resistance in stroke. ( Arsava, EM; Ay, H; Topçuoglu, MA, 2011) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 4.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| "This review aims to determine whether it is cost-effective to replace aspirin and warfarin with more effective, yet more costly, treatments for secondary stroke prevention." | 4.86 | Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? ( Hankey, GJ, 2010) |
| " We give an overview of several new antiplatelet agents that are currently investigated in secondary stroke prevention: adenosine 5'-diphosphonate receptor antagonists, cilostazol, sarpogrelate, terutroban and SCH 530348." | 4.86 | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. ( Diener, HC; Weber, R, 2010) |
| "Oral antiplatelet drugs, including aspirin, clopidogrel and extended-release dipyridamole, are widely prescribed for the secondary prevention of vascular events, including stroke." | 4.86 | Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. ( Greer, DM, 2010) |
| "In primary prevention trials conducted in low-risk subjects, aspirin is associated with a small reduction in ischemic strokes in women." | 4.85 | Antiplatelet drugs for ischemic stroke prevention. ( Balucani, C; Cordonnier, C; Leys, D, 2009) |
| " Currently, aspirin is generally prescribed for the primary prevention of stroke despite a number of trial results on effectiveness proving inconclusive." | 4.85 | Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease? ( Beckman, JA, 2009) |
| "To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke." | 4.85 | Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009) |
| "The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)." | 4.84 | Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008) |
| "The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention." | 4.84 | Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention. ( Chaturvedi, S, 2008) |
| "Aspirin should be used to treat patients with acute myocardial infarction (MI) and continued indefinitely to reduce vascular death, nonfatal MI, and nonfatal stroke." | 4.84 | Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence. ( Aronow, WS, 2007) |
| "To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease." | 4.84 | Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. ( Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H, 2007) |
| "Low dose aspirin is effective in secondary stroke prevention." | 4.84 | Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. ( Kirshner, HS, 2007) |
| "Recent trials of antiplatelet therapy for stroke prevention indicate that the combination of clopidogrel (75 mg/d) plus low-dose aspirin (75-162 mg/d) was not more effective than low-dose aspirin alone in the long-term prevention of major vascular events among patients at high risk of atherothrombotic events, nor was it more effective than oral anticoagulation in patients with atrial fibrillation." | 4.84 | Antiplatelet therapy for stroke prevention. ( Hankey, GJ, 2007) |
| "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published." | 4.83 | MATCH results: implications for the internist. ( Lutsep, HL, 2006) |
| " The CURE study evaluated the efficacy and safety of clopidogrel on top of acetylsalicylic acid (ASA) versus standard therapy (including ASA) in over 12,000 patients with unstable angina or non-ST-segment elevation myocardial infarction (MI)." | 4.82 | Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. ( Teal, PA, 2004) |
| "Based on the established fact that anticoagulation with warfarin is superior to antiplatelet agents in the prevention of thromboembolic events in atrial fibrillation (AF), we propose that, in contrast to atherothrombotic disorders, the risk of developing a stroke or thromboembolic event in AF is more likely to be affected by the coagulation pathway than by platelet activity." | 4.82 | Atrial fibrillation: should we target platelets or the coagulation pathway? ( Lip, GY; Tan, KT, 2003) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "Warfarin therapy achieving an International Normalized Ratio between 2 and 3 has been shown to be effective in preventing stroke." | 4.82 | New possibilities in anticoagulant management of atrial fibrillation. ( Waldo, AL, 2004) |
| " Pooled data from trials comparing antithrombotic treatment with placebo show that warfarin reduces the risk of stroke by 62% and that aspirin alone reduces the risk by 22%." | 4.82 | [Preventing cerebrovascular accidents during atrial fibrillation]. ( Boccara, F; Cohen, A; Ederhy, S; Hammoudi, N; Janower, S; Meuleman, C, 2005) |
| "Aspirin is a relatively inexpensive and effective agent for secondary stroke prevention, and lower doses of aspirin appear as effective as higher doses." | 4.81 | Antiplatelet agents for secondary prevention of ischemic stroke. ( Delanty, N; Kantor, J; Majid, A, 2001) |
| " In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis." | 4.81 | From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002) |
| "One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement." | 4.80 | Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. ( Bennett, CL; Bennett, RH; Davidson, CJ; Feldman, MD; Raisch, DW; Weinberg, PD, 1999) |
| "At the acute phase of cerebral infarction, two recent large studies found that the use of aspirin reduces both mortality and the risk of the recurrence of stroke." | 4.80 | [Aspirin and cerebral ischemic accidents]. ( Bousser, MG; Crassard, I; Niclot, P, 2000) |
| "The most widely studied and prescribed antiplatelet agent for the prevention of stroke and other serious vascular events among high vascular risk patients is aspirin." | 4.80 | Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Dunbabin, DW; Hankey, GJ; Sudlow, CL, 2000) |
| "Aspirin is the treatment of first choice for long-term secondary prevention of vascular events in patients with confirmed non-cardioembolic ischaemic stroke or TIA." | 4.80 | Prevention of ischaemic stroke--antiplatelets. ( Brown, MM; McCabe, DJ, 2000) |
| " Classic antiplatelet therapy with aspirin to prevent occlusive stroke offers significant clinical benefit (20-25% risk reduction), yet is less effective than in prevention of coronary artery occlusion (up to 50% risk reduction of myocardial infarction in unstable angina)." | 4.80 | Antiplatelet agents in stroke prevention. combination therapy: present and future. ( Weksler, BB, 2000) |
| "The CHANCE-2 study compared 3 weeks of aspirin-ticagrelor to aspirin-clopidogrel in CYP2C19 loss-of-function (LOF) allele carriers following a transient ischemic attack (TIA)/minor stroke and demonstrated a modestly lower risk of stroke recurrence with aspirin-ticagrelor." | 4.31 | Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective. ( Demchuk, AM; Jahn, B; Menon, BK; Micieli, A; Siebert, U; Singh, N, 2023) |
| "To compare the effectiveness of aspirin-clopidogrel dual antiplatelet therapy (DAPT) with aspirin or clopidogrel antiplatelet monotherapy (AM) in patients with ischemic stroke." | 4.31 | Comparative effectiveness of dual antiplatelet therapy versus monotherapy in patients with ischemic stroke. ( Algarni, RA; Alshargi, O; Alshehri, S; Alshibani, M; Althagafi, AA, 2023) |
| "Background The objective of the study was to assess the cost-effectiveness of cilostazol (a selective phosphodiesterase 3 inhibitor) added to aspirin or clopidogrel for secondary stroke prevention in patients with noncardioembolic stroke." | 4.12 | Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. ( de Havenon, A; Kraler, L; Lansberg, MG; Zhou, LW, 2022) |
| "Clopidogrel is a common antiplatelet used as secondary prevention of ischemic stroke, known to have better efficacy than aspirin, with a equivalent safety profile." | 4.12 | Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia. ( Harahap, AR; Harris, S; Herqutanto, H; Hidayat, R; Listyaningsih, E; Loho, T; Louisa, M; Nabilah, RA; Rambe, AS; Rasyid, A, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 4.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke." | 4.02 | Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021) |
| "It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting." | 3.96 | Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 3.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 3.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| " After multivariate logistic regression, 10 variables remained independent predictors of sICH to compose the STARTING-SICH (systolic blood pressure, age, onset-to-treatment time for thrombolysis, National Institutes of Health Stroke Scale score, glucose, aspirin alone, aspirin plus clopidogrel, anticoagulant with INR ≤1." | 3.88 | STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke. ( Bonetti, B; Bovi, P; Cappellari, M; Forlivesi, S; Toni, D; Turcato, G; Zivelonghi, C, 2018) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 3.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "The relationship of CYP2C19 genotype and clinical efficacy in stroke or transient ischemic attack (TIA) patients treated with clopidogrel monotherapy or clopidogrel plus aspirin remains unknown." | 3.88 | Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis. ( Cui, M; Gu, ZC; Li, WY; Pan, MM; Yao, JC, 2018) |
| "Clopidogrel HTPR does not seem to be a major contributor to recurrent ischemic events in Danish ischemic stroke patients." | 3.88 | Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. ( Jørgensen, NR; Rath, CL; Wienecke, T, 2018) |
| "Clopidogrel plus aspirin is associated with a reduced risk for myocardial infarction and ischemic stroke and an increased risk for major bleeding compared with aspirin alone among patients at high risk for or with an established cardiovascular disease but without a coronary stent." | 3.88 | Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. ( Bellesini, M; Donadini, MP; Squizzato, A, 2018) |
| "From January 2014 to September 2014, a single center continuously enrolled patients with minor ischemic stroke or high-risk TIA and gave them antiplatelet therapy consisting of aspirin with clopidogrel." | 3.85 | The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. ( Cao, Y; Dong, K; Liu, L; Rao, Z; Wang, A; Wang, F; Wang, Y; Zhao, X; Zheng, H, 2017) |
| "Among 33,943 post-MI continuous clopidogrel users without history of stroke, TIA, or bleeding, 22% had diabetes, whereas angina and renal impairment were less prevalent (5% and 7%, respectively)." | 3.85 | Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database. ( Chase, MR; Hanson, ME; Heithoff, K; Mavros, P; Patel, MD; Simpson, RJ; Wu, D, 2017) |
| " A substantial proportion of patients with stroke on ASA were "resistant", and the treatment with Clopidogrel was accompanied by even higher rates of unresponsiveness." | 3.85 | Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. ( Bigliardi, G; Dell'Acqua, ML; Ferraro, D; Lelli, N; Mimmi, S; Nichelli, P; Pentore, R; Picchetto, L; Rosafio, F; Trenti, T; Vandelli, L; Zini, A, 2017) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 3.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| " However, the risk of rebleeding remains high, especially in patients with chronic ICH and those pretreated with clopidogrel." | 3.85 | Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage. ( Baschin, M; Greinacher, A; Kohlmann, T; Schroeder, HW; Selleng, S; Thiele, T; Westphal, A; Zeden, JP, 2017) |
| "To assess the association of CYP2C19 gene polymorphisms with the incidence of ischemic stroke among patients receiving clopidogrel therapy following coronary stenting for coronary artery disease." | 3.85 | [Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation]. ( Chen, J; Ding, N; Li, G; Peng, L; Shao, Y; Wang, Y; Xu, Z; Zhang, C, 2017) |
| "Clopidogrel is an antiplatelet drug widely used in patients with acute coronary syndromes or stroke." | 3.85 | The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry. ( Bălaşa, R; Bănescu, C; Dobreanu, M; Maier, S; Mărginean, A; Mărginean, M; Moldovan, V; Scridon, A; Ţăruşi, M, 2017) |
| "We consecutively enrolled 375 patients with IS after they received clopidogrel therapy, and venous blood samples were subjected to genotyping allelic variants of genes modulating clopidogrel absorption (ATP binding cassette subfamily B1, ABCB1), metabolic activation (cytochrome P450[CYP] 3A and CYP2C19), and biologic activity (platelet membrane receptor [ P2Y12, P2Y1)], and glycoprotein IIIa [ GPIIIa]) and statistically analyzing their interactions with clopidogrel sensitivity (CS) and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up." | 3.85 | Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. ( Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2017) |
| "Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)." | 3.85 | Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017) |
| "Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 3.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
| "Aspirin and clopidogrel are both acceptable antiplatelet options for the secondary prevention of noncardioembolic ischemic stroke." | 3.85 | Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up. ( Dai, H; He, P; Li, W; Lin, H; Ping, Y; Xu, H, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 3.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 3.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS)." | 3.83 | Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis. ( Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D, 2016) |
| "We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)." | 3.83 | Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016) |
| "The risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel." | 3.83 | Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. ( Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY, 2016) |
| " Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment." | 3.83 | Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 3.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (n = 10,135), we analyzed outcomes in patients with coronary artery disease (n = 1827) according to treatment with triple antithrombotic therapy (defined as concurrent therapy with an oral anticoagulant, a thienopyridine, and aspirin) or dual antithrombotic therapy (comprising either an oral anticoagulant and one antiplatelet agent [OAC plus AA] or 2 antiplatelet drugs and no anticoagulant [DAP])." | 3.83 | Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. ( Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L, 2016) |
| "A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban." | 3.83 | Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016) |
| "We observed a potential late treatment effect for prasugrel versus clopidogrel for a reduced risk of ischemic stroke in medically managed patients with ACS aged <75 years." | 3.83 | Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial. ( Armstrong, PW; Chin, CT; Corbalán, R; Fox, KA; Magnus Ohman, E; Neely, B; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016) |
| "Research regarding clopidogrel resistance (CR) and ischemic stroke (IS) recurrence related to IS is scanty." | 3.83 | Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. ( Cheng, W; Lin, J; Wang, C; Wu, L; Yi, X; Zhou, Q, 2016) |
| "Clopidogrel is an antiplatelet drug primarily used to treat or prevent acute ischemic stroke (IS) or myocardial infarction (MI)." | 3.83 | Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( Cheng, W; Chi, L; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2016) |
| "From a cohort of 1900 patients with ischemic stroke, we selected 42 patients treated with clopidogrel, including 21 with a recurrent vascular event and 21 without vascular recurrence during the first year of follow-up." | 3.83 | TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke. ( Carrera, C; Cullell, N; Fernandez-Cadenas, I; Fontana, P; Gallego-Fabrega, C; Krupinski, J; Martí-Fàbregas, J; Montaner, J; Muiño, E; Pera, J; Pezzini, A; Reny, JL; Segura, T; Serrano-Heras, G; Slowik, A, 2016) |
| " The associated SNPs studied may be useful to predict clopidogrel resistance in Chinese patients with ischemic stroke." | 3.83 | Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. ( Cai, YF; Chen, XM; Chen, YB; Huang, M; Jin, J; Li, JL; Liu, R; Yu, WB; Zhao, M; Zhao, YQ; Zhou, ZY, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 3.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Despite clopidogrel has been widely applied to patients with ischemic stroke combined with aspirin, decreased metabolic activation of clopidogrel still occurs because of genetic variations in CYP2C19." | 3.83 | Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel. ( Cai, H; Liu, X; Wang, Y; Zhang, Z; Zhou, G, 2016) |
| "Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism." | 3.83 | Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu ( Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M, 2016) |
| "Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents." | 3.81 | Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. ( Hua, K; Huang, Z; Ji, H; Sheng, X; Wang, X; Xu, J; Yang, C; Zhang, Y, 2015) |
| " We hypothesized that cytochrome P450 2C19 (CYP2C19) genotype influences the incidence of early recurrence on DWI in acute stroke patients treated with clopidogrel." | 3.81 | CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel. ( Chun, S; Jeong, TD; Kang, DW; Kim, HJ; Kim, SM; Kwon, SU; Lee, W; Min, WK, 2015) |
| "PPIs of interest did not increase the rate of ischemic stroke among clopidogrel users when compared with pantoprazole, a PPI thought to be devoid of the potential to interact with clopidogrel." | 3.81 | Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. ( Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE, 2015) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 3.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| " The aim of this study was to validate the predictive value of HRPR measured by flow cytometry for clinical outcomes in ischemic stroke patients during clopidogrel therapy." | 3.81 | Predictive value of high residual platelet reactivity by flow cytometry for outcomes of ischemic stroke patients on clopidogrel therapy. ( Han, RF; Li, X; Liu, J; Qiu, LN; Wang, L; Xia, XS, 2015) |
| "Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)." | 3.81 | Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015) |
| "This study sought to evaluate the influence of the genetic polymorphisms on platelet reactivity and clinical outcomes in acute ischemic stroke patients taking clopidogrel." | 3.81 | Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. ( Dong, Q; Guan, YT; Han, Y; Jiang, JM; Li, SX; Liu, X; Luo, Z; Lv, HH; Wu, S; Xu, JF; Yang, XL; Zhang, Y; Zheng, Y; Zhu, DS, 2015) |
| "Patients on prasugrel had fewer cardiovascular events as compared to patients on clopidogrel twice daily with no difference in bleeding events." | 3.81 | Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population. ( Khatri, S; Pierce, T, 2015) |
| "The objective of this study was to compare nonresponders (NR) and responders (R) to clopidogrel with respect to presence of microvascular and macrovascular pathology in a cohort of patients with recent minor ischemic stroke (IS) or transient ischemic attack (TIA)." | 3.81 | Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. ( Gigante, B; Höeg Dembrower, K; Jörneskog, G; Laska, AC; Laurencikas, E; Lundström, A; von Arbin, M; Wallén, H, 2015) |
| "Patients admitted for a suspected acute ischemic stroke, while under APD (aspirin and/or clopidogrel), were prospectively included." | 3.81 | Interest of Antiplatelet Drug Testing after an Acute Ischemic Stroke. ( Coignion, C; Debruxelles, S; Freyburger, G; Poli, M; Renou, P; Rouanet, F; Sagnier, S; Sibon, I, 2015) |
| "In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke." | 3.81 | Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015) |
| "To assess the association of genetic polymorphisms of CYP2C19*2,*3,*17 with the recurrence risk of ischemic stroke during clopidogrel prevention in ethnic Han Chinese from Fujian Province." | 3.81 | [Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian]. ( Fang, L; Huang, H; Lin, M; Wang, N; Yang, Z; Zhao, Y, 2015) |
| "The relation between high on-treatment platelet reactivity (HPR), and the level of glucose intolerance and insulin resistance (IR) was studied in clopidogrel-treated patients with minor ischemic stroke or TIA." | 3.80 | Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA. ( Jörneskog, G; Laska, AC; Lundström, A; Von Arbin, M; Wallén, H, 2014) |
| "A retrospective review of all patients with stroke and transient ischemic attack (TIA) tested for the clopidogrel CYP2C19 genotype was performed, with a collection of data including race/ethnicity, CYP2C19 status, and the presence of recurrent vascular events." | 3.80 | Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events. ( Barazangi, N; Chen, C; Jaramillo, V; Rose, J; Spokoyny, I; Tong, D; Wong, C, 2014) |
| "To compare the lifetime cost and effectiveness of five alternative chronic atrial fibrillation (AF) management strategies: rivaroxaban, warfarin, aspirin plus clopidogrel, aspirin and no prevention." | 3.80 | Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. ( He, B; Kun, L; Liu, X; Wu, B, 2014) |
| " The odds of an adverse incidence of death/myocardial infarction/stroke 1 year after discharge was significantly reduced in patients receiving aspirin and clopidogrel for ≥9 months and was consequently higher in patients in whom dual antiplatelet therapy was discontinued or prescribed for <9 months." | 3.80 | Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. ( Chiang, FT; Hou, CJ; Hwang, JJ; Kuo, C; Kuo, CT; Lai, WT; Li, AH; Li, YH; Lin, SJ; Mar, GY; Shyu, KG; Wen, MS; Wu, CJ, 2014) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 3.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| " However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding." | 3.80 | Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "During the first days following an acute ischemic stroke, a consistently good antiplatelet effect of clopidogrel is important due to the increased risk of recurrent ischemia." | 3.80 | Clopidogrel high-on-treatment platelet reactivity in acute ischemic stroke patients. ( Endres, HG; Krogias, C; Krüger, JC; Meves, SH; Neubauer, H; Schröder, KD, 2014) |
| "Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel." | 3.80 | Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014) |
| "A total of 129 noncardiogenic ischemic stroke patients receiving 75 mg/day of clopidogrel for ≥1 week were evaluated." | 3.80 | Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients. ( Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Tanahashi, N, 2014) |
| "Anonymous surveys on treatment practices in patients with ICAS were sent to physicians at 3 time points: before publication of the NIH-funded Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial (pre-WASID survey, 2004), 1 year after WASID publication (post-WASID survey, 2006) and 1 year after the publication of the NIH-funded Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial (post-SAMMPRIS survey, 2012)." | 3.80 | Intracranial stenosis: impact of randomized trials on treatment preferences of US neurologists and neurointerventionists. ( Chimowitz, MI; Cotsonis, G; Derdeyn, CP; Fiorella, D; Lynn, MJ; Stern, BJ; Swanson, S; Turan, TN; Williams, JE; Wooley, RH, 2014) |
| "We prospectively enrolled patients older than 20 years who had a history of noncardioembolic strokes, including transient ischemic attacks, were treated with ticlopidine for at least 6 months." | 3.80 | Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. ( Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014) |
| "We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke." | 3.80 | Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014) |
| " Platelet reactivity was assessed in 18 patients with ischemic stroke/transient ischemic attack (TIA) 7 days (D7) and 90 days (D90) after prescription of clopidogrel, using four methods: light transmission aggregometry with 5 μmol/l ADP (LTA-ADP), vasodilator-stimulated phosphoprotein (VASP), Verify Now P2Y12 and platelet function analyzer (PFA) P2Y." | 3.80 | High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease: assessment of prevalence and stability over time using four platelet function tests. ( Arroyo, AB; Bernal, A; Guiú, IS; Iniesta, JA; Jover, E; Lozano, ML; Martínez, C; Rivera, J; Rodríguez, JM; Vicente, V, 2014) |
| "Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown." | 3.80 | Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. ( Johnston, SC; Liu, G; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Zhao, K; Zhao, X, 2014) |
| "To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel." | 3.80 | Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014) |
| "Clopidogrel resistance(CR)is found in non-cardioembolic ischemic stroke (NCIS) patients." | 3.80 | VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( Huang, L; Lai, X; Li, W; Xiong, Z; Xu, A; Zhang, S, 2014) |
| "A total of 2141 patients with coronary artery disease treated exclusively with Cypher sirolimus-eluting stents (SES) or Endeavor zotarolimus-eluting stents (ZES) were considered for retrospective analysis." | 3.79 | Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents. ( Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y, 2013) |
| "Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients." | 3.79 | Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013) |
| "The Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence trial raised concern that loading doses of clopidogrel may increase hemorrhagic complications." | 3.79 | Short-term bleeding events observed with clopidogrel loading in acute ischemic stroke patients. ( Albright, KC; Beasley, TM; Boehme, AK; Jones, EM; Leung, LY; Martin-Schild, S; Pletsch, GR; Shah, KR; Siegler, JE; Tarsia, J, 2013) |
| "Little research regarding genotypes and clopidogrel response related to acute ischemic stroke has been published." | 3.79 | CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. ( Chen, C; Chen, ZB; Jia, DM; Jin, JL; Shao, Y; Xia, YQ; Xu, Y; Yang, WJ; Zhang, CL; Zhang, MJ, 2013) |
| " We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)." | 3.79 | Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013) |
| "Study population included 111 patients with the history of ischemic stroke being on clopidogrel monotherapy and 140 controls." | 3.79 | Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy. ( Bagoly, Z; Csiba, L; Kappelmayer, J; Magyar, T; Muszbek, L; Pongrácz, E; Sarkady, F, 2013) |
| "The current study sought to evaluate the clinical impact of newly reported genetic variations and their association with clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation." | 3.79 | The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. ( Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL, 2013) |
| "Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common." | 3.79 | Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013) |
| " Among 4408 stroke-free individuals who underwent brain magnetic resonance imaging for the detection of CMBs, we identified 121 ever-users and 4287 never-users of clopidogrel before magnetic resonance imaging." | 3.79 | Clopidogrel use is associated with an increased prevalence of cerebral microbleeds in a stroke-free population: the Rotterdam study. ( Akoudad, S; Darweesh, SK; Hofman, A; Ikram, MA; Leening, MJ; Loth, DW; Stricker, BH; Vernooij, MW, 2013) |
| "This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)." | 3.79 | Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013) |
| " The patient was subsequently found to have incomplete inhibition of platelet activity despite being on clopidogrel 150 mg and aspirin 81 mg daily and having a normal CYP-2C19 genotype, suggesting that suboptimal antiplatelet inhibition, secondary to morbid obesity, contributed to his in-stent thrombosis." | 3.79 | Obesity and intracranial in-stent thrombosis. ( Koch, S; Reyes-Iglesias, Y; Rose, DZ; Yavagal, DR, 2013) |
| "Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable." | 3.78 | Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012) |
| "For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel." | 3.78 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012) |
| "Clopidogrel is an inhibitor of platelet-aggregation used in the prevention of secondary stroke." | 3.78 | The effect of the CYP 2C19*2 polymorphism on stroke care. ( Gál, A; Inczédy-Farkas, G; Molnár, MJ; Nyírő, G; Pál, Z; Reményi, V, 2012) |
| " The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine." | 3.78 | Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. ( Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J, 2012) |
| "In patients with ischemic stroke or transient ischemic attack, 43% (n=128) and 35% (n=54) were nonresponders to aspirin and clopidogrel, respectively." | 3.78 | Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. ( Bakdash, S; Bhatt, DL; Depta, JP; Fowler, J; Katzan, I; Kottke-Marchant, K; Novak, E, 2012) |
| "The pharmacodynamic analysis end point was clopidogrel on-treatment platelet reactivity (OPR) and the clinical analysis end point was the composite of cardiac death, non-fatal myocardial infarction, ischaemic stroke and stent thrombosis at 12 months post-PCI." | 3.78 | Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. ( Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM, 2012) |
| "Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge." | 3.78 | Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012) |
| "On July 20, 2011, the Food and Drug Administration (FDA) approved ticagrelor (Brilinta™) for use during acute coronary syndromes." | 3.78 | Ticagrelor FDA approval issues revisited. ( Serebruany, VL, 2012) |
| "We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years." | 3.78 | [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012) |
| "To examine healthcare costs among patients hospitalized for transient ischemic attack or ischemic stroke (TIA/stroke) and prescribed aspirin plus extended-release dipyridamole (ASA-ERDP) or clopidogrel (CLOPID) within 30 days post-discharge using a retrospective claims database from a large US managed care organization." | 3.78 | One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. ( Burton, TM; Lacey, M; Lang, K; Liu, F; Monsalvo, ML; Sander, S; Yu, Y, 2012) |
| " Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel." | 3.78 | Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 3.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "Despite changes in international guidelines, aspirin monotherapy should retain its position as the main antiplatelet agent for secondary prevention of non-cardioembolic ischaemic stroke." | 3.78 | Secondary stroke prevention: misguided by guidelines? ( Molenberghs, G; Vanstreels, L; Voigt, JU, 2012) |
| "We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age." | 3.78 | [Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012) |
| "In this study, clopidogrel use during CEA resulted in a significant risk for developing a neck hematoma, particularly when using a Dacron-patch." | 3.77 | Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy. ( Alden, PB; Goldman, JA; Graber, JN; Rizvi, AZ; Rosenbaum, A; Sullivan, TM; Tretinyak, AS, 2011) |
| "Among patients receiving clopidogrel for coronary artery disease, concomitant therapy with proton pump inhibitors (PPIs) has been associated with an increased risk for recurrent coronary events." | 3.77 | Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. ( Escudero, D; Monreal, M; Muñoz-Torrero, JF; Pascual, MT; Sanclemente, C; Suárez, C; Trujillo-Santos, J; Zamorano, J, 2011) |
| "9 years) with ischemic stroke or carotid artery stenting who received clopidogrel (75 mg) for >7 days at our hospital between October 2009 and March 2010." | 3.77 | Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay. ( Deguchi, I; Dembo, T; Fukuoka, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagoya, H; Takeda, H; Tanahashi, N, 2011) |
| " Preoperative treatment with clopidogrel, particularly when it is continued to the day before surgery, and postoperative arterial hypertension seem to be associated with a higher risk of neck bleeding after CEA, requiring re-exploration in most cases." | 3.77 | Predictors of neck bleeding after eversion carotid endarterectomy. ( Ballotta, E; Baracchini, C; Gruppo, M; Lorenzetti, R; Mazzalai, F; Meneghetti, G, 2011) |
| "Current American Heart Association/American Stroke Association guidelines identify warfarin use as a class IA indication in patients with atrial fibrillation (AF) and ischemic stroke (IS) or transient ischemic attack (TIA)." | 3.77 | Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. ( Bushnell, CD; Lopes, RD; Olson, DM; Pan, W; Peterson, ED; Shah, BR; Zhao, X, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 3.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis." | 3.77 | Clopidogrel (plavix). ( Comin, J; Kallmes, D, 2011) |
| "To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel." | 3.76 | Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. ( Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA, 2010) |
| "In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding." | 3.76 | Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010) |
| "Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization." | 3.76 | Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 3.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 3.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update." | 3.76 | Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 3.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| " One hundred eighty patients were not on AP prior to their stroke, 76 were on aspirin, 15 were on clopidogrel, 2 were on aspirin-dipyridamole combination, 2 were on both aspirin and clopidogrel, and 9 patients on subtherapeutic coumadin." | 3.76 | Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke? ( Al-Hussain, F; Alexandrov, AV; Demchuk, AM; Hussain, M; Ibrahim, MM; Khan, K; Molina, C; Saqqur, M; Sebastian, J; Uchino, K, 2010) |
| "In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications." | 3.76 | Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| "We consecutively enrolled 2208 patients presenting with an acute myocardial infarction in a nationwide French registry and receiving clopidogrel therapy." | 3.75 | Genetic determinants of response to clopidogrel and cardiovascular events. ( Becquemont, L; Danchin, N; Drouet, E; Ferrières, J; Mary-Krause, M; Méneveau, N; Quteineh, L; Simon, T; Steg, PG; Verstuyft, C, 2009) |
| " As compared with the conventional 300-mg dose, pretreatment with a 600-mg loading dose of clopidogrel significantly reduced periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI)." | 3.75 | Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). ( Byun, KH; Cho, JR; Choi, S; Jung, JH; Lee, N; Lee, SH; Min, PK; Sung, CW, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "We sought to correlate the inhibition of platelet aggregation (IPA) with plasma levels of unchanged clopidogrel (UC), active thiol metabolite (ATM), and inactive carboxyl metabolite (ICM) in a large cohort of patients with coronary artery disease and ischemic stroke treated with clopidogrel." | 3.75 | Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". ( Atar, D; Booze, C; Cherala, G; Kuliczkowski, W; Serebruany, V; Surigin, S; Williams, C, 2009) |
| "In the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial, the combination of acetylsalicylic acid (50 mg) and extended-release dipyridamole (400 mg) (ASA+Dip) was compared with clopidogrel (75 mg) in patients with a recent transient ischaemic attack (TIA) or minor disabling stroke." | 3.74 | [Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial]. ( Kappelle, LJ, 2008) |
| "Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke." | 3.74 | ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008) |
| "In patients undergoing coronary stenting, long-term dual antiplatelet therapy with aspirin and clopidogrel reduces atherothrombotic events but also increases the risk of bleeding." | 3.74 | Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. ( Angiolillo, DJ; Bass, TA; Della Rovere, F; Gavazzi, A; Lettieri, C; Mantovani, P; Mihalcsik, L; Molfese, M; Musumeci, G; Rossini, R; Sirbu, V, 2008) |
| "Secondary post hoc analysis of an existing dataset consisting of 711 patients after coronary stenting (n = 601) and ischemic stroke (n = 110) treated previously with aspirin for at least 1 month, and then with aspirin + clopidogrel for at least 7 days was performed." | 3.74 | Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients. ( Atar, D; Malinin, AI; Serebruany, VL, 2007) |
| "Patients with ischemic stroke enrolled in the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) study underwent long-term prospective assessment of their modified Rankin Scale (mRS) score." | 3.74 | Rate, degree, and predictors of recovery from disability following ischemic stroke. ( Bego, G; Carita, P; Gabriel, S; Hakimi, Z; Hankey, GJ; Spiesser, J, 2007) |
| "In clinical practice, early therapy with clopidogrel, in addition, to aspirin in patients with NSTEMI is associated with a significant reduction of the combined endpoint of death, non-fatal reinfarction and non-fatal stroke after one year." | 3.74 | Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Köth, O; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2008) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| "We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)." | 3.74 | Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008) |
| "Clopidogrel and dipyridamole-aspirin are used frequently after stroke or transient ischemic attack." | 3.74 | Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack. ( Hills, NK; Johnston, SC, 2008) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "Utilizing data from the Global Registry of Acute Coronary Events, we studied 15 693 patients admitted with non-ST-segment elevation myocardial infarction (MI) or unstable angina, dividing them according to discharge medications: aspirin alone (group I); aspirin + clopidogrel (group II); aspirin + statin (group III); aspirin + clopidogrel + statin (group IV)." | 3.73 | Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. ( Agnelli, G; Dabbous, OH; Dibenedetto, D; Eagle, KA; Gore, JM; Kline-Rogers, EM; Lim, MJ; Mehta, RH; Spencer, FA, 2005) |
| "We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)." | 3.73 | Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005) |
| "The CREDO trial demonstrated the clinical efficacy of 12-month antiplatelet therapy with clopidogrel compared to standard 28-day treatment with a 27% relative reduction in the combined risk of death, myocardial infarction, or stroke in patients undergoing percutaneous coronary intervention (PCI) and being treated with aspirin." | 3.73 | The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. ( Jönsson, B; Lindgren, P; Ringborg, A, 2005) |
| "The rapid and significant decline of MES in our stroke and TIA patients suggests the possible efficacy of dual antiplatelet therapy with aspirin and clopidogrel in patients with MES and symptomatic large-artery occlusive disease." | 3.73 | Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases. ( Chang, HM; Chen, CL; Esagunde, RU; Gan, HY; Lee, MP; Wong, KS; Wong, MC, 2006) |
| "The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)." | 3.73 | The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006) |
| " Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy." | 3.73 | Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. ( Galor, A; Hoffman, GS; Lee, MS; Smith, SD, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 3.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "A 73-year-old female treated with clopidogrel for vascular disease presented with sudden onset of back pain, urinary retention and paraplegia." | 3.73 | Nontraumatic spinal epidural hematoma associated with clopidogrel. ( Das, K; Karabatsou, K; Rainov, NG; Sinha, A, 2006) |
| "Aspirin is the drug of choice in most patients with acute stroke, if thrombolysis is contraindicated." | 3.72 | [Anticoagulation and antiaggregation in neurological patients]. ( Arnold, M; Mattle, HP; Nedeltchev, K, 2003) |
| "In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy." | 3.72 | Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. ( Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H, 2003) |
| "Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial." | 3.72 | Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2004) |
| "The results with GP in acute ischemic stroke are promising and further studies should be initiated using especially tirofiban, but with monitoring by cerebral diffusion-weighted MRI before and after treatment." | 3.72 | [Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice]. ( Haerten, K; Krabbe, C; Raiber, M, 2004) |
| "1% was seen for the clopidogrel/ASA combination for the first primary outcome (death from cardiovascular causes, non-fatal myocardial infarction (MI), or stroke), compared to ASA alone." | 3.72 | A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes. ( Boucher, M; Pharand, C; Skidmore, B, 2004) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 3.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "Aspirin has been the mainstay of antiplatelet therapy in stroke prevention for 30 years." | 3.71 | Newer antiplatelet therapies in stroke prevention. ( Davis, SM; Donnan, GA, 2001) |
| "Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole." | 3.71 | Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001) |
| "Elderly men are more likely than elderly women to receive aspirin and ticlopidine and equally like to receive warfarin after a stroke." | 3.70 | Sex differences and similarities in the management and outcome of stroke patients. ( Austin, PC; Holroyd-Leduc, JM; Kapral, MK; Tu, JV, 2000) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 3.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "(1) In the acute phase of ischaemic stroke in patients free of thrombogenic heart disease, combined treatment with aspirin + moderate-dose unfractionated heparin reduces the risk of relapse and death." | 3.70 | Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention. ( , 2000) |
| "(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000) |
| "Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack." | 3.70 | Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. ( Bounameaux, H; Gaspoz, JM; Sarasin, FP, 2000) |
| "(1) Clopidogrel, an antiplatelet drug chemically similar to ticlopidine, is marketed in France for secondary prevention of thrombotic complications in patients with a history of myocardial infarction, ischaemic stroke or peripheral arterial disease." | 3.70 | Clopidogrel: new preparation. An alternative to aspirin. ( , 1999) |
| "(1) The clinical file on ticlopidine is based mainly on a placebo-controlled trial involving patients with lower-limb arterial disease, and two large double-blind trials in the post-stroke period, in which the comparator was a placebo in one and aspirin in the other." | 3.70 | Ticlopidine: a second look. No further use in routine practice. ( , 1999) |
| "The study aimed to investigate the impact of clopidogrel combined with proton pump inhibitors (PPI) pantoprazole treatment on the prognosis of patients with transient ischemic attack (TIA)." | 2.84 | Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack. ( Lu, M, 2017) |
| "Stress hyperglycemia was measured by glucose/glycated albumin (GA) ratio." | 2.84 | Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack: The CHANCE Study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Cai, X; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wei, T; Zhao, X, 2017) |
| "Strokes are infrequent but potentially serious complications following carotid intervention, but antiplatelet therapy can reduce these risks." | 2.82 | Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2. ( Bulbulia, R; Coppi, G; de Borst, GJ; Halliday, A; Huibers, A, 2016) |
| "Patients with API (lacunar infarcts or branch atheromatous disease) admitted within 48 hours after onset were enrolled." | 2.82 | [Argatroban, Aspirin, and Clopidogrel Combination Therapy for Acute Penetrating Artery Infarction: A Pilot Study]. ( Kobayashi, Y; Mano, T; Matsuo, K; Nishi, R, 2016) |
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| "The primary outcome is IS recurrence." | 2.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "The incidences of transient ischemic attack, stroke, or death at up to 30 days after CAS in the high-OTR patients were similar between groups 1 and 2 (P = ." | 2.79 | Antiplatelet effects of clopidogrel dose adjustment (75 mg/d vs 150 mg/d) after carotid stenting. ( Cayuela, A; González, A; Gonzalez-Marcos, JR; Mayol, A; Moniche, F; Montaner, J, 2014) |
| "A cause other than paradoxical embolism was usually apparent in patients with recurrent neurologic events." | 2.77 | Closure or medical therapy for cryptogenic stroke with patent foramen ovale. ( Adams, H; Albers, GW; Felberg, R; Furlan, AJ; Herrmann, H; Kar, S; Landzberg, M; Massaro, J; Mauri, L; Raizner, A; Reisman, M; Wechsler, L, 2012) |
| "The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction and ischemic stroke at 6 months after PCI." | 2.76 | Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-. ( Bae, JH; Bae, JW; Chae, IH; Cho, MC; Kim, HS; Lee, SP; Park, KW; Rha, SW; Suh, JW, 2011) |
| "Fatal bleeding was low and did not differ between groups." | 2.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 2.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "The mechanism of stroke is believed to be thromboembolic in the majority of cases." | 2.73 | Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS). ( , 2007) |
| " The combination of clopidogrel and aspirin is not recommended for long-term use (more than two to three years) because of increased bleeding risk." | 2.55 | Recurrent Ischemic Stroke: Strategies for Prevention. ( Garcellano, M; Oza, R; Rundell, K, 2017) |
| " Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events." | 2.52 | Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015) |
| " Although administration of antiplatelet agents has been confirmed to be one of the major approaches for secondary prevention of noncardioembolic stroke, the short-term or long-term use of aspirin plus clopidogrel for secondary stroke prevention remains to be controversial." | 2.52 | Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention. ( Chen, W; Wang, Y, 2015) |
| "These events, previously called apoplexy, are now called strokes." | 2.50 | Stroke: transient ischemic attack. ( Silver, B; Wulf Silver, R, 2014) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| " The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option." | 2.48 | Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012) |
| "Ischemic stroke is a major cause of death and disability worldwide." | 2.48 | Antiplatelet therapy in stroke prevention. ( Apostolakis, S; Lip, GY; Marín, F, 2012) |
| "Stroke is a leading cause of death worldwide and the first cause of disability in the Western world." | 2.48 | Antiplatelet treatment in primary and secondary stroke prevention in women. ( Acciarresi, M; Caso, V; Paciaroni, M; Pezzella, FR; Santalucia, P, 2012) |
| "Stroke is one of the leading causes of disability; most are due to atherothrombotic mechanisms." | 2.47 | Current status of antiplatelet agents to prevent stroke. ( Benavente, OR; Field, TS, 2011) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| " Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1." | 2.47 | Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011) |
| "Aspirin has been shown to reduce the risk of recurrent strokes, and the combination of aspirin and dipyridamole has repeatedly been shown to outperform aspirin alone." | 2.46 | Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. ( Fung, K; Simmons, BB; Yeo, A, 2010) |
| "Absorption is a critical component of the pharmacokinetics for solid dosage forms administered orally." | 2.46 | Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke. ( Conrado, DJ; Derendorf, H; Gonzalez, D, 2010) |
| "In the past, transient ischemic attack (TIA) was defined as any sudden, focal cerebral ischemic event with neurological deficit lasting <24 hours." | 2.46 | [New clinical concept and therapeutic strategy for TIA]. ( Urabe, T, 2010) |
| "Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone." | 2.45 | Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? ( Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH, 2009) |
| "Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot." | 2.45 | Antiplatelet treatment in ischemic stroke treatment. ( Arnao, V; Di Raimondo, D; Di Sciacca, R; La Placa, S; Licata, G; Miceli, S; Milio, G; Pinto, A; Tuttolomondo, A, 2009) |
| "Stroke is a leading cause of death, disability, and dependence." | 2.44 | The approach to optimizing stroke care. ( Panagos, PD, 2008) |
| "Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States." | 2.44 | Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008) |
| "Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system." | 2.44 | Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| "Heart disease and stroke are leading causes of DALYs lost and deaths worldwide [3]." | 2.44 | Antithrombotic treatment in the prevention of ischemic stroke. ( Emre, U; Rantanen, K; Tatlisumak, T, 2007) |
| "Patients who have transient ischemic attack (TIA) or ischemic stroke are at a high risk of having a first or recurrent stroke." | 2.44 | Antiplatelet agents and randomized trials. ( Diener, HC, 2007) |
| "Aspirin has become the antiplatelet treatment standard against which several other antiplatelet agents have been shown to be more effective." | 2.44 | Antithrombotic and thrombolytic therapy for ischemic stroke. ( Cornett, O; Malhotra, S; Ocava, LC; Rosenbaum, DM; Singh, M, 2008) |
| "The short-term risk of stroke after transient ischemic attack (TIA) is about 10% to 20% in the first 3 months, with much of the risk front-loaded in the first week." | 2.43 | Stroke prevention. MATCHing therapy to the patient with TIA. ( Buchan, AM; Demchuk, AM; Hill, MD; Weir, NU, 2005) |
| " If the international normalized ratio (INR) was kept > 2 for a long period, by means of frequent check-ups and effective dosage adjustment, the chance of death, recurrent myocardial infarction or stroke was 30-50% lower than when acetylsalicylic acid only was used." | 2.43 | [Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. ( Brouwer, A; Verheugt, FW; Waskowsky, WM, 2005) |
| "Aspirin has been shown to be as effective as warfarin in the prevention of noncardioembolic ischaemic stroke, with significantly fewer bleeding complications." | 2.43 | Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. ( Weinberger, J, 2005) |
| "About 80% of strokes have ischemic origin." | 2.43 | [Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005) |
| "However, stroke is a highly preventable disease in the majority of patients." | 2.43 | Strategies for primary and secondary stroke prevention. ( Brass, LM, 2006) |
| "Dipyridamole has been studied as an antiplatelet agent for several decades." | 2.42 | Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. ( Lenz, T; Wilson, A, 2003) |
| "The diagnosis of carotid stenosis is made after occurrence of a cerebral ischemic event or during an angiologic examination, mainly using Doppler/Duplex-sonography." | 2.42 | [Carotid stenosis: diagnosis, patient selection, therapy]. ( Barth, A, 2003) |
| "Aspirin has been studied and used most extensively." | 2.42 | Role of antiplatelet drugs in the prevention of cardiovascular events. ( Tendera, M; Wojakowski, W, 2003) |
| "Aspirin has been the first-line agent for stroke prevention for a long time." | 2.42 | Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke. ( Redman, AR; Ryan, GJ, 2004) |
| "Stroke is the most feared complication of atrial fibrillation, and the risk of stroke increases markedly with age." | 2.42 | Trials of newer approaches to anticoagulation in atrial fibrillation. ( Cooper, HA, 2004) |
| "Stroke is a major cause of morbidity and mortality." | 2.41 | A benefit-risk assessment of agents used in the secondary prevention of stroke. ( MacWalter, RS; Shirley, CP, 2002) |
| "Stroke is the third most common cause of adult mortality in the United States." | 2.41 | Antithrombotic drugs for prevention of recurrent stroke. ( Pettigrew, LC; Williams, SC, 2002) |
| "TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis." | 1.51 | The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019) |
| "Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit." | 1.46 | Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L, 2017) |
| "Hemorrhagic stroke is not the only complication of thrombolysis, ischemic stroke can occur even if it is an extremely rare complication." | 1.46 | Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports. ( Arous, S; Bentaoune, T; El Ghali Benouna, M; Habbal, R; Haboub, M, 2017) |
| "Given the high risk of stroke recurrence, antiplatelets followed by anticoagulation for secondary prevention were initiated." | 1.46 | Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question. ( Abubakar, H; Hassan, AAI; Ibrahim, W; Subahi, A, 2017) |
| "All the patients presented with carotid artery stenosis >70% (North American Symptomatic Carotid Endarterectomy Trial [NASCET] criteria), which was symptomatic in 42 patients (transient ischemic attack, n = 32; minor stroke, n = 10) and asymptomatic in 146." | 1.46 | Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study. ( Calio', FG; Illuminati, G; Masci, F; Pizzardi, G; Ricco, JB; Schneider, F, 2017) |
| "The early recurrence of neurological symptoms (NR) after urgent aggressive best medical therapy (BMT) in symptomatic carotid stenosis is not well documented." | 1.43 | Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy. ( Ellemann, K; Gottschalksen, B; Owen-Falkenberg, A; Shahidi, S, 2016) |
| "Dual treatment with aspirin (5 mg kg(-1) ) and clopidogel (0." | 1.43 | A rabbit model of cerebral microembolic signals for translational research: preclinical validation for aspirin and clopidogrel. ( Chu, L; Desai, K; Gutstein, DE; Kurowski, S; Seiffert, D; Wang, X; Wu, W; Zhou, X, 2016) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 1.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 1.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "Aspirin (53." | 1.43 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016) |
| "Clinical question Following transient ischemic attack or acute minor stroke, does the combination of clopidogrel and aspirin reduce the risk of stroke greater than aspirin alone? Article chosen Wang Y, Wang Y, Zhao X, et al." | 1.42 | Clopidogrel with aspirin versus aspirin alone in prevention of stroke following transient ischemic attack or acute minor stroke. ( Lang, E; Seadon, S, 2015) |
| "CABG had similar rates of cardiac death compared with PCI group (HR=0." | 1.42 | Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication. ( Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jang, WJ; Kim, BS; Kim, WS; Lee, SH; Lee, YT; Song, YB; Yang, JH, 2015) |
| " Long-term use of aspirin plus clopidorel after CAS did not decrease the risk of ischemic stroke, composite vascular events, or death during 6 months of follow-up." | 1.42 | Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial? ( Huang, JY; Jhang, KM; Jian, ZH; Ku, WY; Liaw, YP; Nfor, ON; Tung, YC, 2015) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 1.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "Of a total of 4905 (transient ischemic attack/ischemic stroke, and ocular events) patients, 115 symptomatic patients underwent CEA, 42% within 14 days of the index event and 99% within 14 days of surgical referral." | 1.39 | Urgent best medical therapy may obviate the need for urgent surgery in patients with symptomatic carotid stenosis. ( Ellemann, K; Hjerpsted, U; Owen-Falkenberg, A; Rai, A; Shahidi, S, 2013) |
| "In the Asymptomatic Carotid Artery Stenosis trial (1995), medical management was defined as aspirin in addition to adequate control of comorbidities." | 1.39 | Efficacy of contemporary medical management for asymptomatic carotid artery stenosis. ( Ahn, JE; Chang, J; Chun, L; Landsman, N; Patel, KK; Rhee, K, 2013) |
| "An acute spontaneous spinal epidural hematoma (SSEH) is a rare spinal pathology." | 1.37 | Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel. ( Cho, YR; Hong, BY; Kim, HS; Kim, HW; Ko, YJ; Lee, JI; Lim, SH, 2011) |
| "Cerebral infarction associated with ulcerative colitis is particularly rare, but clinically important because of its high morbidity and mortality." | 1.37 | Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a). ( Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P, 2011) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| "We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)." | 1.36 | Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010) |
| " In these patients, we recommend use of the combination of aspirin and extended-release dipyridamole (25/200 mg bid) over aspirin (Grade 1A) and suggest clopidogrel over aspirin (Grade 2B), and recommend avoiding long-term use of the combination of aspirin and clopidogrel (Grade 1B)." | 1.35 | Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Albers, GW; Amarenco, P; Easton, JD; Sacco, RL; Teal, P, 2008) |
| "Ischemic stroke was reported in 57." | 1.35 | [Secondary prevention with clopidogrel or acetylsalicylic acid after acute cerebrovascular event. Health services research study of private primary care specialists]. ( Diehm, C; Köfüncü, E; Pittrow, D; Sander, D; Schwertfeger, M, 2008) |
| " The ExTRACT-TIMI 25 trial employed a novel dosing regimen for enoxaparin adjusted for age and renal function, which was designed to minimize bleeding risk while maintaining the beneficial effects of enoxaparin." | 1.35 | ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. ( Giugliano, RP; Thomas, D, 2009) |
| "Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury." | 1.34 | TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007) |
| "Embolism is a dreaded complication of infective endocarditis (IE)." | 1.34 | Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. ( Anavekar, NS; Baddour, LM; Chandrasekaran, K; Haddad, C; Khandaker, MH; Mirzoyev, Z; Steckelberg, JM; Tleyjeh, IM; Wilson, WR, 2007) |
| "Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year." | 1.33 | Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? ( Diener, HC, 2006) |
| "The prognosis of traumatic dissection of the internal carotid artery is worse than for spontaneous dissections." | 1.33 | Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections. ( Ben-Hur, T; Cohen, JE; Gomori, JM; Rajz, G; Umansky, F, 2005) |
| "To report procedure-related complications and neurological adverse events of unprotected over-the-wire (OTW) and protected rapid exchange (RX) carotid artery stenting (CAS) in a single-center patient series during an 8-year period." | 1.33 | Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series. ( Ahmadi, A; Amighi, J; Boltuch, J; Dick, P; Minar, E; Mlekusch, W; Sabeti, S; Schillinger, M; Schlager, O, 2005) |
| "Poststroke recurrence rate was low (7." | 1.32 | Ischaemic stroke in young people: a prospective and long-term follow-up study. ( Carerj, S; Di Perri, R; Epifanio, A; Gallitto, G; Gangemi, S; Granata, A; La Spina, P; Leggiadro, N; Manganaro, A; Musolino, R; Tripodi, F, 2003) |
| "Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1." | 1.32 | [Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003) |
| "Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT." | 1.32 | A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. ( Benhameid, O; Endo, M; Shennib, H, 2003) |
| " The lesser long-term pharmacodynamic potency of aspirin relative to clopidogrel raises the prospect of the need for more effective antiplatelet agents or a synergistic combination therapy for stroke prevention in the future." | 1.32 | Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. ( Chang, HW; Chang, YY; Chen, MC; Chen, SS; Chen, WH; Kao, YF; Lai, SL; Lan, MY; Liu, JS; Yip, HK, 2004) |
| "Patients suffering from a transient ischemic attack (TIA) or ischemic stroke are at high risk of a recurrent stroke." | 1.32 | [Secondary prevention of stroke with antiplatelet drugs]. ( Diener, HC, 2004) |
| "Unfortunately, VBA transient ischemic attacks (TIAs) herald a lethal or devastating event within 5 years in 25 to 30% of patients." | 1.31 | Stent-assisted angioplasty of intracranial vertebrobasilar atherosclerosis: an initial experience. ( Barr, JD; Furlan, AJ; Katzan, I; Krieger, D; Markarian, GZ; Masaryk, TJ; Perl, J; Rasmussen, PA; Sila, C, 2000) |
| " It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease." | 1.31 | [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. ( Scheen, AJ, 2001) |
| "Stroke is highly prevalent in long-term care." | 1.31 | Clinical correlates and drug treatment of residents with stroke in long-term care. ( Lapane, KL; Quilliam, BJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (0.66) | 18.2507 |
| 2000's | 335 (36.61) | 29.6817 |
| 2010's | 550 (60.11) | 24.3611 |
| 2020's | 24 (2.62) | 2.80 |
| Authors | Studies |
|---|---|
| Sheng, X | 1 |
| Hua, K | 1 |
| Yang, C | 3 |
| Wang, X | 7 |
| Ji, H | 1 |
| Xu, J | 3 |
| Huang, Z | 2 |
| Zhang, Y | 6 |
| Guo, Y | 1 |
| Zhao, J | 1 |
| Wu, L | 2 |
| Yu, Z | 1 |
| He, D | 1 |
| Huang, H | 2 |
| Qu, W | 1 |
| Luo, X | 1 |
| Xu, X | 1 |
| Wang, H | 2 |
| He, L | 2 |
| Liu, Q | 1 |
| Du, Y | 1 |
| Wang, J | 2 |
| Zhang, S | 2 |
| Zhu, J | 2 |
| Li, H | 14 |
| Li, F | 3 |
| Zhu, B | 1 |
| Li, T | 2 |
| Fang, S | 1 |
| Qin, S | 1 |
| Liu, J | 5 |
| Zhao, Y | 4 |
| Chen, H | 1 |
| Yang, F | 2 |
| Chen, L | 1 |
| Hao, G | 1 |
| Gao, X | 1 |
| Zhou, LW | 1 |
| Kraler, L | 1 |
| de Havenon, A | 1 |
| Lansberg, MG | 1 |
| Hidayat, R | 1 |
| Nabilah, RA | 1 |
| Rasyid, A | 1 |
| Harris, S | 1 |
| Harahap, AR | 1 |
| Herqutanto, H | 1 |
| Louisa, M | 1 |
| Listyaningsih, E | 1 |
| Rambe, AS | 1 |
| Loho, T | 1 |
| Micieli, A | 1 |
| Singh, N | 1 |
| Jahn, B | 1 |
| Siebert, U | 1 |
| Menon, BK | 2 |
| Demchuk, AM | 5 |
| Zhu, Q | 1 |
| Wu, Y | 3 |
| Deng, X | 1 |
| Cheng, J | 1 |
| Zhang, Z | 6 |
| Ma, Y | 1 |
| Shi, T | 1 |
| McDermott, JH | 1 |
| Leach, M | 1 |
| Sen, D | 1 |
| Smith, CJ | 1 |
| Newman, WG | 1 |
| Bath, PM | 12 |
| Moustafa, B | 1 |
| Testai, FD | 1 |
| Liu, H | 2 |
| Shao, T | 1 |
| Yang, T | 1 |
| Li, D | 1 |
| Cheng, Y | 1 |
| Zhang, T | 1 |
| Zhang, J | 4 |
| Deguchi, I | 5 |
| Osada, T | 1 |
| Takahashi, S | 2 |
| Manunga, J | 1 |
| Pedersen, C | 1 |
| Stanberry, L | 1 |
| Pai, A | 1 |
| Skeik, N | 1 |
| Sullivan, TM | 2 |
| Algarni, RA | 1 |
| Althagafi, AA | 1 |
| Alshehri, S | 1 |
| Alshibani, M | 1 |
| Alshargi, O | 1 |
| Pan, YS | 1 |
| Wang, YJ | 2 |
| Hankey, GJ | 19 |
| Kumar, A | 1 |
| Shariff, M | 1 |
| Doshi, R | 1 |
| Chiarito, M | 1 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Cao, D | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Godino, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 1 |
| De Caterina, R | 4 |
| Condorelli, G | 1 |
| Ferrante, G | 1 |
| Stefanini, GG | 1 |
| Tanashyan, MM | 1 |
| Kuznetsova, PI | 1 |
| Raskurazhev, AA | 1 |
| Song, TJ | 1 |
| Kim, J | 1 |
| Han, SW | 2 |
| Kim, YD | 1 |
| Lee, JY | 2 |
| Ahn, SH | 2 |
| Lee, HS | 1 |
| Jung, YH | 1 |
| Lee, KY | 2 |
| Yuan, HW | 1 |
| Lin, YJ | 1 |
| Ji, RJ | 1 |
| Cole, JW | 1 |
| Wong, YS | 1 |
| Tsai, CF | 1 |
| Hsu, YH | 1 |
| Ong, CT | 1 |
| Muthiah, MD | 1 |
| Zheng, H | 3 |
| Chew, NWS | 1 |
| Xiao, J | 1 |
| Lim, LG | 1 |
| Tan, HC | 1 |
| Lee, CH | 1 |
| Low, AF | 1 |
| Foo, LL | 1 |
| Richards, AM | 1 |
| Dan, YY | 1 |
| Ho, KY | 1 |
| Yip, JWL | 1 |
| Chan, MY | 2 |
| Hilkens, NA | 1 |
| Algra, A | 6 |
| Diener, HC | 26 |
| Csiba, L | 3 |
| Hacke, W | 13 |
| Kappelle, LJ | 4 |
| Koudstaal, PJ | 2 |
| Leys, D | 5 |
| Mas, JL | 5 |
| Sacco, RL | 7 |
| Greving, JP | 1 |
| Wang, Y | 51 |
| Lin, Y | 3 |
| Meng, X | 14 |
| Chen, W | 5 |
| Chen, G | 1 |
| Wang, Z | 3 |
| Wu, J | 1 |
| Wang, D | 13 |
| Li, J | 8 |
| Cao, Y | 3 |
| Xu, Y | 4 |
| Zhang, G | 1 |
| Li, X | 5 |
| Pan, Y | 12 |
| Liu, L | 18 |
| Zhao, X | 21 |
| Ghamasaee, P | 1 |
| Carr, K | 1 |
| Johnson, J | 1 |
| Grandhi, R | 1 |
| Melkonian, M | 1 |
| Jarzebowski, W | 1 |
| Pautas, E | 1 |
| Siguret, V | 1 |
| Belmin, J | 1 |
| Lafuente-Lafuente, C | 1 |
| Rao, Z | 2 |
| Wang, F | 2 |
| Wang, A | 10 |
| Dong, K | 3 |
| Jing, J | 6 |
| Johnston, SC | 24 |
| Yan, HB | 1 |
| Song, L | 1 |
| Hua, YH | 1 |
| Zhao, HJ | 2 |
| Liu, C | 1 |
| Zhou, P | 1 |
| Li, JN | 1 |
| Tan, Y | 1 |
| Yang, YM | 1 |
| Fiolaki, A | 1 |
| Katsanos, AH | 1 |
| Kyritsis, AP | 1 |
| Papadaki, S | 1 |
| Kosmidou, M | 1 |
| Moschonas, IC | 1 |
| Tselepis, AD | 3 |
| Giannopoulos, S | 1 |
| Ducrocq, G | 1 |
| Schulte, PJ | 1 |
| Budaj, A | 6 |
| Cornel, JH | 6 |
| Held, C | 7 |
| Himmelmann, A | 3 |
| Husted, S | 9 |
| Storey, RF | 11 |
| Cannon, CP | 10 |
| Becker, RC | 10 |
| James, SK | 9 |
| Katus, HA | 4 |
| Lopes, RD | 8 |
| Sorbets, E | 1 |
| Wallentin, L | 12 |
| Steg, PG | 16 |
| Secemsky, EA | 1 |
| Yeh, RW | 1 |
| Kereiakes, DJ | 2 |
| Cutlip, DE | 1 |
| Massaro, JM | 1 |
| Apruzzese, PK | 1 |
| Mauri, L | 2 |
| Rodés-Cabau, J | 1 |
| Masson, JB | 1 |
| Welsh, RC | 3 |
| Garcia Del Blanco, B | 1 |
| Pelletier, M | 1 |
| Webb, JG | 1 |
| Al-Qoofi, F | 1 |
| Généreux, P | 2 |
| Maluenda, G | 1 |
| Thoenes, M | 1 |
| Paradis, JM | 1 |
| Chamandi, C | 1 |
| Serra, V | 1 |
| Dumont, E | 1 |
| Côté, M | 1 |
| Choi, HI | 1 |
| Ahn, JM | 2 |
| Kang, SH | 2 |
| Lee, PH | 1 |
| Kang, SJ | 3 |
| Lee, SW | 4 |
| Kim, YH | 4 |
| Lee, CW | 3 |
| Park, SW | 3 |
| Park, DW | 3 |
| Park, SJ | 5 |
| Patel, MD | 1 |
| Wu, D | 1 |
| Chase, MR | 1 |
| Mavros, P | 1 |
| Heithoff, K | 1 |
| Hanson, ME | 1 |
| Simpson, RJ | 1 |
| Rosafio, F | 1 |
| Lelli, N | 1 |
| Mimmi, S | 1 |
| Vandelli, L | 1 |
| Bigliardi, G | 1 |
| Dell'Acqua, ML | 1 |
| Picchetto, L | 1 |
| Pentore, R | 1 |
| Ferraro, D | 1 |
| Trenti, T | 1 |
| Nichelli, P | 1 |
| Zini, A | 1 |
| Arous, S | 1 |
| Haboub, M | 1 |
| El Ghali Benouna, M | 1 |
| Bentaoune, T | 1 |
| Habbal, R | 1 |
| Lu, M | 1 |
| Nakamura, M | 2 |
| Iijima, R | 3 |
| Ako, J | 1 |
| Shinke, T | 1 |
| Okada, H | 1 |
| Ito, Y | 1 |
| Ando, K | 1 |
| Anzai, H | 1 |
| Tanaka, H | 1 |
| Ueda, Y | 1 |
| Takiuchi, S | 1 |
| Nishida, Y | 1 |
| Ohira, H | 1 |
| Kawaguchi, K | 1 |
| Kadotani, M | 1 |
| Niinuma, H | 1 |
| Omiya, K | 1 |
| Morita, T | 1 |
| Zen, K | 1 |
| Yasaka, Y | 1 |
| Inoue, K | 1 |
| Ishiwata, S | 1 |
| Ochiai, M | 1 |
| Hamasaki, T | 1 |
| Yokoi, H | 1 |
| Park, SM | 1 |
| Jeong, H | 1 |
| Jung, MH | 1 |
| Hong, KS | 4 |
| Hong, MK | 4 |
| Bang, CS | 1 |
| Kim, CY | 1 |
| Yuan, C | 1 |
| Zhong, L | 1 |
| Huang, RC | 1 |
| Jiang, M | 1 |
| You, JHS | 1 |
| Lee, M | 3 |
| Saver, JL | 3 |
| Rao, NM | 2 |
| Wu, YL | 2 |
| Ovbiagele, B | 7 |
| Milionis, H | 3 |
| Ntaios, G | 1 |
| Papavasileiou, V | 1 |
| Spengos, K | 2 |
| Manios, E | 1 |
| Elisaf, M | 1 |
| Vemmos, K | 2 |
| Sun, H | 1 |
| Ming, T | 1 |
| Liu, X | 7 |
| Cong, Y | 1 |
| Li, Z | 3 |
| Baber, U | 2 |
| Chandrasekhar, J | 1 |
| Sartori, S | 1 |
| Aquino, M | 1 |
| Kini, AS | 1 |
| Kapadia, S | 1 |
| Weintraub, W | 1 |
| Muhlestein, JB | 1 |
| Vogel, B | 1 |
| Faggioni, M | 1 |
| Farhan, S | 1 |
| Weiss, S | 1 |
| Strauss, C | 1 |
| Toma, C | 1 |
| DeFranco, A | 1 |
| Baker, BA | 3 |
| Keller, S | 1 |
| Effron, MB | 4 |
| Henry, TD | 2 |
| Rao, S | 1 |
| Pocock, S | 3 |
| Dangas, G | 1 |
| Mehran, R | 2 |
| Harada, Y | 1 |
| Michel, J | 1 |
| Lohaus, R | 1 |
| Mayer, K | 1 |
| Emmer, R | 1 |
| Lahmann, AL | 1 |
| Colleran, R | 1 |
| Giacoppo, D | 1 |
| Wolk, A | 1 |
| Ten Berg, JM | 4 |
| Neumann, FJ | 4 |
| Han, Y | 5 |
| Adriaenssens, T | 2 |
| Tölg, R | 2 |
| Seyfarth, M | 3 |
| Maeng, M | 2 |
| Zrenner, B | 2 |
| Jacobshagen, C | 3 |
| Wöhrle, J | 2 |
| Kufner, S | 2 |
| Morath, T | 2 |
| Ibrahim, T | 2 |
| Bernlochner, I | 2 |
| Fischer, M | 2 |
| Schunkert, H | 2 |
| Laugwitz, KL | 2 |
| Mehilli, J | 6 |
| Byrne, RA | 3 |
| Kastrati, A | 6 |
| Schulz-Schüpke, S | 2 |
| Baschin, M | 1 |
| Selleng, S | 1 |
| Zeden, JP | 1 |
| Westphal, A | 1 |
| Kohlmann, T | 1 |
| Schroeder, HW | 1 |
| Greinacher, A | 1 |
| Thiele, T | 1 |
| Han, YF | 1 |
| Dai, QL | 1 |
| Chen, XL | 1 |
| Xiong, YY | 1 |
| Yin, Q | 1 |
| Xu, GL | 1 |
| Zhu, WS | 1 |
| Zhang, RL | 1 |
| Ma, MM | 1 |
| Liu, WH | 1 |
| Liu, XF | 1 |
| Hamilos, M | 1 |
| Petousis, S | 1 |
| Xanthopoulou, I | 2 |
| Goudevenos, J | 1 |
| Kanakakis, J | 1 |
| Sitafidis, G | 1 |
| Vavouranakis, M | 1 |
| Skalidis, E | 1 |
| Kochiadakis, G | 1 |
| Lekakis, J | 2 |
| Vardas, PE | 1 |
| Alexopoulos, D | 2 |
| Piccolo, R | 2 |
| Feres, F | 3 |
| Abizaid, A | 3 |
| Gilard, M | 2 |
| Morice, MC | 2 |
| Kim, HS | 9 |
| Colombo, A | 3 |
| Bhatt, DL | 25 |
| Palmerini, T | 3 |
| Stone, GW | 3 |
| Windecker, S | 5 |
| Valgimigli, M | 10 |
| Sibbing, D | 2 |
| Aradi, D | 4 |
| Gross, L | 1 |
| Trenk, D | 1 |
| Geisler, T | 1 |
| Orban, M | 1 |
| Hadamitzky, M | 1 |
| Merkely, B | 2 |
| Kiss, RG | 1 |
| Komócsi, A | 5 |
| Dézsi, CA | 1 |
| Holdt, L | 1 |
| Felix, SB | 1 |
| Parma, R | 1 |
| Klopotowski, M | 1 |
| Schwinger, RHG | 1 |
| Rieber, J | 1 |
| Huber, K | 8 |
| Koltowski, L | 1 |
| Huczek, Z | 1 |
| Massberg, S | 1 |
| D'Ascenzo, F | 1 |
| Benedetto, U | 2 |
| Bianco, M | 1 |
| Conrotto, F | 1 |
| Moretti, C | 2 |
| D'Onofrio, A | 1 |
| Agrifoglio, M | 1 |
| Ribichini, F | 1 |
| Tarantini, G | 1 |
| D'Amico, M | 1 |
| Salizzoni, S | 1 |
| Rinaldi, M | 1 |
| Spence, JD | 1 |
| Reddy C, R | 1 |
| Bompelli, N | 1 |
| Khardenavis, V | 1 |
| Deshpande, A | 1 |
| Subahi, A | 1 |
| Hassan, AAI | 1 |
| Abubakar, H | 1 |
| Ibrahim, W | 1 |
| Cai, X | 1 |
| Wei, T | 1 |
| Oza, R | 1 |
| Rundell, K | 1 |
| Garcellano, M | 1 |
| Bossard, M | 1 |
| Granger, CB | 5 |
| Tanguay, JF | 2 |
| Montalescot, G | 8 |
| Faxon, DP | 1 |
| Jolly, SS | 2 |
| Widimsky, P | 7 |
| Niemela, K | 1 |
| Natarajan, MK | 3 |
| Gao, P | 3 |
| Fox, KAA | 1 |
| Yusuf, S | 20 |
| Mehta, SR | 9 |
| Li, G | 1 |
| Chen, J | 3 |
| Xu, Z | 3 |
| Ding, N | 1 |
| Peng, L | 1 |
| Zhang, C | 2 |
| Shao, Y | 2 |
| Zhong, Z | 1 |
| Hou, J | 1 |
| Zhang, Q | 4 |
| Li, B | 1 |
| Li, C | 4 |
| Liu, Z | 1 |
| Yang, M | 1 |
| Zhong, W | 1 |
| He, X | 1 |
| Wu, H | 1 |
| Zhong, M | 2 |
| Zhao, P | 1 |
| Norgren, L | 2 |
| Patel, MR | 4 |
| Hiatt, WR | 3 |
| Wojdyla, DM | 4 |
| Fowkes, FGR | 1 |
| Baumgartner, I | 2 |
| Mahaffey, KW | 13 |
| Berger, JS | 2 |
| Jones, WS | 2 |
| Katona, BG | 2 |
| Held, P | 2 |
| Blomster, JI | 1 |
| Rockhold, FW | 1 |
| Björck, M | 1 |
| Woodhouse, LJ | 3 |
| Appleton, JP | 2 |
| Beridze, M | 2 |
| Christensen, H | 2 |
| Dineen, RA | 2 |
| Duley, L | 2 |
| England, TJ | 2 |
| Flaherty, K | 2 |
| Havard, D | 1 |
| Heptinstall, S | 3 |
| James, M | 2 |
| Krishnan, K | 2 |
| Markus, HS | 8 |
| Montgomery, AA | 1 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Ranta, A | 2 |
| Robinson, TG | 2 |
| Scutt, P | 2 |
| Venables, GS | 3 |
| Sprigg, N | 4 |
| Ozawa, T | 1 |
| Suda, M | 1 |
| Ikegami, R | 1 |
| Takano, T | 1 |
| Wakasugi, T | 1 |
| Yanagawa, T | 1 |
| Tanaka, K | 1 |
| Ozaki, K | 1 |
| Hirono, S | 1 |
| Minamino, T | 1 |
| Cappellari, M | 1 |
| Turcato, G | 1 |
| Forlivesi, S | 1 |
| Zivelonghi, C | 1 |
| Bovi, P | 1 |
| Bonetti, B | 1 |
| Toni, D | 4 |
| Wu, X | 1 |
| Lin, A | 1 |
| Cai, B | 1 |
| Nagao, T | 1 |
| Toyoda, K | 3 |
| Kitagawa, K | 1 |
| Kitazono, T | 2 |
| Yamagami, H | 1 |
| Uchiyama, S | 7 |
| Tanahashi, N | 6 |
| Matsumoto, M | 2 |
| Minematsu, K | 4 |
| Nagata, I | 2 |
| Nishikawa, M | 2 |
| Nanto, S | 1 |
| Abe, K | 3 |
| Ikeda, Y | 3 |
| Ogawa, A | 2 |
| Nam, YH | 1 |
| Brensinger, CM | 2 |
| Bilker, WB | 2 |
| Leonard, CE | 2 |
| Kasner, SE | 2 |
| Grosser, T | 2 |
| Hennessy, S | 2 |
| Pitts-Tucker, T | 1 |
| Small, J | 1 |
| Duerschmied, D | 1 |
| Brachmann, J | 1 |
| Darius, H | 1 |
| Frey, N | 1 |
| Rottbauer, W | 1 |
| Schäfer, A | 1 |
| Thiele, H | 1 |
| Bode, C | 1 |
| Zeymer, U | 4 |
| Davda, N | 1 |
| Osman, C | 1 |
| Easton, JD | 11 |
| Farrant, M | 2 |
| Barsan, W | 2 |
| Conwit, RA | 1 |
| Elm, JJ | 1 |
| Kim, AS | 2 |
| Lindblad, AS | 1 |
| Palesch, YY | 1 |
| Lim, HH | 1 |
| Li, S | 1 |
| An, GD | 1 |
| Woo, KS | 1 |
| Kim, KH | 1 |
| Kim, JM | 1 |
| Kim, MH | 1 |
| Han, JY | 1 |
| Lin, J | 14 |
| Han, Z | 4 |
| Wang, C | 23 |
| Yi, X | 11 |
| Chai, Z | 2 |
| Zhou, Q | 7 |
| Huang, R | 1 |
| Ding, L | 2 |
| Peng, B | 1 |
| Yao, JC | 1 |
| Cui, M | 1 |
| Pan, MM | 1 |
| Gu, ZC | 1 |
| Li, WY | 1 |
| Kleiman, NS | 1 |
| Rath, CL | 1 |
| Jørgensen, NR | 1 |
| Wienecke, T | 1 |
| Mazlan-Kepli, W | 1 |
| Dawson, J | 1 |
| Berry, C | 1 |
| Walters, M | 1 |
| Donadini, MP | 1 |
| Bellesini, M | 1 |
| Squizzato, A | 2 |
| Yoshiba, S | 1 |
| Wu, Z | 1 |
| Liu, AF | 1 |
| Zhou, J | 1 |
| Wang, K | 3 |
| Qiu, H | 1 |
| Jiang, WJ | 1 |
| Wernly, B | 1 |
| Lichtenauer, M | 1 |
| Hoppe, UC | 1 |
| Lauten, A | 1 |
| Navarese, EP | 1 |
| Jung, C | 1 |
| Ross, S | 1 |
| Paré, G | 2 |
| Sherban, A | 1 |
| Armon, C | 1 |
| Rapoport, M | 1 |
| Chen, ZW | 1 |
| Wu, CK | 1 |
| Yang, YH | 1 |
| Huang, JW | 1 |
| Wu, VC | 1 |
| Lee, JK | 2 |
| Chen, PC | 1 |
| Lin, YH | 1 |
| Lin, LY | 1 |
| Sychev, DA | 1 |
| Shprakh, VV | 1 |
| Kitaeva, EY | 1 |
| Mirzaev, KB | 1 |
| Mickhalevich, IM | 1 |
| Wiśniewski, A | 1 |
| Sikora, J | 1 |
| Filipska, K | 1 |
| Kozera, G | 1 |
| Chi, NF | 1 |
| Wang, SJ | 1 |
| Nietlispach, F | 1 |
| Gloekler, S | 1 |
| Krause, R | 1 |
| Shakir, S | 1 |
| Schmid, M | 1 |
| Khattab, AA | 1 |
| Wenaweser, P | 1 |
| Meier, B | 2 |
| Yu, X | 1 |
| Chen, F | 1 |
| He, J | 2 |
| Gao, Y | 1 |
| Wu, C | 1 |
| Luo, Y | 1 |
| Zhang, X | 1 |
| Ren, X | 1 |
| Lv, S | 1 |
| Helft, G | 1 |
| Le Feuvre, C | 1 |
| Georges, JL | 1 |
| Carrie, D | 1 |
| Leclercq, F | 1 |
| Eltchaninoff, H | 2 |
| Furber, A | 1 |
| Prunier, F | 1 |
| Sebagh, L | 1 |
| Cattan, S | 1 |
| Cayla, G | 1 |
| Vicaut, E | 1 |
| Metzger, JP | 1 |
| Lee, WH | 1 |
| Chu, CY | 1 |
| Hsu, PC | 1 |
| Su, HM | 1 |
| Lin, TH | 1 |
| Voon, WC | 1 |
| Lai, WT | 3 |
| Sheu, SH | 1 |
| Lau, AY | 2 |
| Chen, C | 7 |
| Leung, TW | 6 |
| Fu, J | 3 |
| Huang, Y | 3 |
| Suwanwela, NC | 2 |
| Tan, KS | 2 |
| Ratanakorn, D | 3 |
| Wong, KS | 8 |
| Thapar, A | 1 |
| Jenkins, IH | 1 |
| Mehta, A | 1 |
| Davies, AH | 1 |
| Dunn, SP | 1 |
| Steinhubl, SR | 8 |
| Bauer, D | 1 |
| Charnigo, RJ | 1 |
| Berger, PB | 8 |
| Topol, EJ | 14 |
| Lundström, A | 2 |
| Laska, AC | 2 |
| Von Arbin, M | 2 |
| Jörneskog, G | 2 |
| Wallén, H | 2 |
| Leung, LY | 1 |
| Albright, KC | 1 |
| Boehme, AK | 1 |
| Tarsia, J | 1 |
| Shah, KR | 1 |
| Siegler, JE | 1 |
| Jones, EM | 1 |
| Pletsch, GR | 1 |
| Beasley, TM | 1 |
| Martin-Schild, S | 1 |
| Yang, J | 4 |
| Zhao, HD | 2 |
| Tan, J | 2 |
| Ding, YL | 1 |
| Gu, ZQ | 1 |
| Zou, JJ | 4 |
| Pieper, KS | 3 |
| Harrington, RA | 9 |
| Bennett, D | 1 |
| Yan, B | 1 |
| Jia, DM | 1 |
| Chen, ZB | 1 |
| Zhang, MJ | 1 |
| Yang, WJ | 1 |
| Jin, JL | 1 |
| Xia, YQ | 1 |
| Zhang, CL | 1 |
| Palacio, S | 1 |
| Hart, RG | 12 |
| Pearce, LA | 3 |
| Anderson, DC | 2 |
| Sharma, M | 2 |
| Birnbaum, LA | 1 |
| Benavente, OR | 6 |
| Saia, F | 2 |
| Marino, M | 2 |
| Campo, G | 4 |
| Guastaroba, P | 1 |
| Taglieri, N | 2 |
| Tondi, S | 2 |
| Manari, A | 1 |
| Guiducci, V | 1 |
| Sangiorgio, P | 1 |
| Varani, E | 1 |
| Magnavacchi, P | 1 |
| De Palma, R | 1 |
| Marzocchi, A | 2 |
| Apostolakis, S | 2 |
| Lip, GY | 8 |
| Shantsila, E | 1 |
| Shahidi, S | 2 |
| Owen-Falkenberg, A | 2 |
| Hjerpsted, U | 1 |
| Rai, A | 1 |
| Ellemann, K | 2 |
| Naylor, AR | 1 |
| Sayers, RD | 1 |
| McCarthy, MJ | 1 |
| Bown, MJ | 1 |
| Nasim, A | 1 |
| Dennis, MJ | 1 |
| London, NJ | 1 |
| Bell, PR | 1 |
| Seivani, Y | 1 |
| Abdel-Wahab, M | 2 |
| Geist, V | 1 |
| Richardt, G | 1 |
| Sulimov, DS | 1 |
| El-Mawardy, M | 1 |
| Toelg, R | 1 |
| Akin, I | 1 |
| Zuurbier, SM | 1 |
| Vermeer, SE | 1 |
| Hilkens, PH | 1 |
| Roos, YB | 1 |
| Rongen, GA | 1 |
| Sorkin, GC | 1 |
| Dumont, TM | 1 |
| Wach, MM | 1 |
| Eller, JL | 1 |
| Mokin, M | 1 |
| Natarajan, SK | 2 |
| Baxter, MS | 1 |
| Snyder, KV | 2 |
| Levy, EI | 4 |
| Hopkins, LN | 2 |
| Siddiqui, AH | 2 |
| Cui, L | 1 |
| Jia, J | 1 |
| Dong, Q | 5 |
| Xu, A | 3 |
| Zeng, J | 1 |
| Li, Y | 9 |
| Xia, H | 1 |
| Weimar, C | 6 |
| Cotton, D | 5 |
| Sha, N | 1 |
| Weber, R | 5 |
| Li, M | 4 |
| Li, JY | 1 |
| Xia, YP | 1 |
| Mao, L | 1 |
| Hu, B | 2 |
| Bagoly, Z | 1 |
| Sarkady, F | 1 |
| Magyar, T | 1 |
| Kappelmayer, J | 1 |
| Pongrácz, E | 1 |
| Muszbek, L | 1 |
| Spokoyny, I | 1 |
| Barazangi, N | 1 |
| Jaramillo, V | 1 |
| Rose, J | 1 |
| Wong, C | 1 |
| Tong, D | 1 |
| Cano, P | 1 |
| Consuegra-Sánchez, L | 1 |
| Conesa, P | 1 |
| Torres-Moreno, D | 1 |
| Jaulent, L | 1 |
| Dau, D | 1 |
| Picó, F | 1 |
| Villegas, M | 1 |
| McCormack, T | 1 |
| Liang, ZY | 1 |
| Han, YL | 1 |
| Zhang, XL | 1 |
| Yan, CH | 1 |
| Kang, J | 2 |
| Battenhouse, H | 1 |
| Conwit, R | 3 |
| Dillon, C | 1 |
| Elm, J | 1 |
| Lindblad, A | 1 |
| Morgenstern, L | 1 |
| Poisson, SN | 1 |
| Palesch, Y | 4 |
| Zhang, M | 3 |
| Dong, Y | 1 |
| Cheng, X | 2 |
| Amaro, S | 1 |
| Llull, L | 1 |
| Urra, X | 1 |
| Obach, V | 1 |
| Cervera, Á | 1 |
| Chamorro, Á | 1 |
| Wiviott, SD | 6 |
| White, HD | 11 |
| Ohman, EM | 7 |
| Fox, KA | 23 |
| Armstrong, PW | 11 |
| Prabhakaran, D | 8 |
| Hafley, G | 3 |
| Lokhnygina, Y | 4 |
| Boden, WE | 7 |
| Hamm, C | 2 |
| Clemmensen, P | 3 |
| Nicolau, JC | 6 |
| Menozzi, A | 1 |
| Ruzyllo, W | 3 |
| Oto, A | 3 |
| Leiva-Pons, J | 1 |
| Pavlides, G | 2 |
| Winters, KJ | 6 |
| Roe, MT | 9 |
| Suh, SY | 1 |
| Kang, WC | 1 |
| Oh, PC | 1 |
| Choi, H | 1 |
| Moon, CI | 1 |
| Lee, K | 2 |
| Han, SH | 1 |
| Ahn, T | 1 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Bell, AD | 1 |
| Ackman, ML | 1 |
| Bauer, RD | 1 |
| Cartier, R | 1 |
| Chan, WS | 1 |
| Douketis, J | 1 |
| Roussin, A | 1 |
| Schnell, G | 1 |
| Verma, S | 2 |
| Wong, G | 1 |
| Wu, B | 2 |
| Kun, L | 1 |
| He, B | 1 |
| Park, KW | 7 |
| Park, JJ | 2 |
| Yang, HM | 2 |
| Kang, HJ | 3 |
| Koo, BK | 4 |
| Park, BE | 1 |
| Cha, KS | 1 |
| Rhew, JY | 1 |
| Jeon, HK | 1 |
| Shin, ES | 2 |
| Oh, JH | 2 |
| Jeong, MH | 3 |
| Kim, S | 1 |
| Hwang, KK | 1 |
| Yoon, JH | 1 |
| Lee, SY | 1 |
| Park, TH | 2 |
| Moon, KW | 1 |
| Kwon, HM | 1 |
| Chae, IH | 3 |
| Gorelick, PB | 3 |
| Farooq, MU | 1 |
| Jastrzębska, M | 1 |
| Chełstowski, K | 1 |
| Wódecka, A | 1 |
| Siennicka, A | 1 |
| Clark, J | 1 |
| Nowacki, P | 1 |
| Darweesh, SK | 1 |
| Leening, MJ | 1 |
| Akoudad, S | 1 |
| Loth, DW | 1 |
| Hofman, A | 1 |
| Ikram, MA | 1 |
| Vernooij, MW | 1 |
| Stricker, BH | 1 |
| Chiang, FT | 1 |
| Shyu, KG | 1 |
| Wu, CJ | 1 |
| Mar, GY | 1 |
| Hou, CJ | 1 |
| Li, AH | 1 |
| Wen, MS | 1 |
| Lin, SJ | 1 |
| Kuo, CT | 1 |
| Kuo, C | 1 |
| Li, YH | 1 |
| Hwang, JJ | 1 |
| Kakkos, SK | 1 |
| Tsolakis, IA | 1 |
| Khandelwal, P | 1 |
| Jeong, YH | 1 |
| Pearson-Fuhrhop, KM | 1 |
| Cramer, SC | 1 |
| Turan, TN | 5 |
| Smock, A | 1 |
| Chimowitz, MI | 5 |
| Varenhorst, C | 2 |
| Jensevik, K | 2 |
| Jernberg, T | 2 |
| Sundström, A | 1 |
| Hasvold, P | 1 |
| Lagerqvist, B | 2 |
| James, S | 4 |
| Hill, MD | 5 |
| Stevens, SR | 2 |
| Nessel, CC | 1 |
| Goodman, SG | 6 |
| Piccini, JP | 4 |
| Halperin, JL | 4 |
| Singer, DE | 3 |
| Califf, RM | 1 |
| Breithardt, G | 1 |
| Zhou, BR | 1 |
| Shi, HT | 1 |
| Wang, R | 1 |
| Guan, HT | 1 |
| Liu, ZF | 1 |
| Deng, YH | 1 |
| Malloy, RJ | 1 |
| Kanaan, AO | 1 |
| Silva, MA | 2 |
| Donovan, JL | 2 |
| Bansilal, S | 2 |
| Bonaca, MP | 1 |
| Sabatine, MS | 3 |
| Chang, J | 1 |
| Ahn, JE | 1 |
| Landsman, N | 1 |
| Rhee, K | 1 |
| Chun, L | 1 |
| Patel, KK | 1 |
| Tebaldi, M | 4 |
| Vranckx, P | 6 |
| Biscaglia, S | 2 |
| Tumscitz, C | 2 |
| Ferrari, R | 3 |
| Derdeyn, CP | 4 |
| Lynn, MJ | 4 |
| Fiorella, D | 4 |
| Janis, LS | 3 |
| Montgomery, J | 2 |
| Nizam, A | 1 |
| Lane, BF | 3 |
| Lutsep, HL | 4 |
| Barnwell, SL | 2 |
| Waters, MF | 3 |
| Hoh, BL | 3 |
| Hourihane, JM | 2 |
| Alexandrov, AV | 3 |
| Harrigan, MR | 2 |
| Chiu, D | 2 |
| Klucznik, RP | 2 |
| Clark, JM | 2 |
| McDougall, CG | 2 |
| Johnson, MD | 2 |
| Pride, GL | 2 |
| Lynch, JR | 1 |
| Zaidat, OO | 2 |
| Rumboldt, Z | 2 |
| Cloft, HJ | 2 |
| Costa, RA | 1 |
| Leon, MB | 1 |
| Marin-Neto, JA | 1 |
| Botelho, RV | 1 |
| King, SB | 1 |
| Negoita, M | 1 |
| Liu, M | 3 |
| de Paula, JE | 1 |
| Mangione, JA | 1 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 1 |
| Devito, FS | 1 |
| Labrunie, A | 1 |
| Salvadori, D | 1 |
| Gusmão, M | 1 |
| Staico, R | 1 |
| Costa, JR | 1 |
| de Castro, JP | 1 |
| Abizaid, AS | 1 |
| Ojeifo, O | 1 |
| Antman, EM | 4 |
| Murphy, SA | 4 |
| Udell, JA | 1 |
| Bates, ER | 1 |
| Mega, JL | 1 |
| O'Donoghue, ML | 1 |
| Mansoor, AH | 1 |
| Mujtaba, MT | 1 |
| Silver, B | 2 |
| Zhao, R | 1 |
| Feng, XY | 1 |
| Shen, XL | 1 |
| Su, JJ | 1 |
| Liu, JR | 1 |
| Enomoto, Y | 1 |
| Tokue, M | 1 |
| Ito, N | 1 |
| Nagashima, Y | 1 |
| Araki, T | 1 |
| Yamazaki, K | 1 |
| Utsunomiya, M | 1 |
| Hori, M | 1 |
| Itaya, H | 1 |
| Shiba, M | 1 |
| Hara, H | 1 |
| Sugi, K | 1 |
| Gouya, G | 1 |
| Arrich, J | 1 |
| Wolzt, M | 1 |
| Verheugt, FW | 8 |
| Gurbel, PA | 6 |
| Pirker-Kees, A | 1 |
| Siller-Matula, JM | 1 |
| Omote, Y | 1 |
| Deguchi, K | 1 |
| Kono, S | 1 |
| Liu, N | 1 |
| Liu, W | 2 |
| Kurata, T | 1 |
| Yamashita, T | 1 |
| Gremmel, T | 1 |
| Koppensteiner, R | 1 |
| Ay, C | 1 |
| Panzer, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Meves, SH | 2 |
| Schröder, KD | 1 |
| Endres, HG | 2 |
| Krogias, C | 2 |
| Krüger, JC | 1 |
| Neubauer, H | 2 |
| Tai, WA | 1 |
| Albers, GW | 8 |
| Lamberts, M | 2 |
| Gislason, GH | 3 |
| Lassen, JF | 1 |
| Olesen, JB | 3 |
| Mikkelsen, AP | 1 |
| Sørensen, R | 2 |
| Køber, L | 3 |
| Torp-Pedersen, C | 4 |
| Hansen, ML | 3 |
| Füessl, HS | 1 |
| Castilla-Guerra, L | 1 |
| Fernandez-Moreno, Mdel C | 1 |
| Navas-Alcantara, MS | 1 |
| Jimenez-Gonzalo, F | 1 |
| Tornyos, A | 1 |
| Pintér, T | 3 |
| Vorobcsuk, A | 3 |
| Kónyi, A | 2 |
| Faluközy, J | 1 |
| Veress, G | 1 |
| Magyari, B | 2 |
| Horváth, IG | 3 |
| Alcocer, F | 1 |
| Novak, Z | 1 |
| Combs, BR | 1 |
| Lowman, B | 1 |
| Passman, MA | 1 |
| Mujib, M | 1 |
| Jordan, WD | 1 |
| Maruyama, H | 5 |
| Fukuoka, T | 4 |
| Ohe, Y | 2 |
| Kato, Y | 4 |
| Horiuchi, Y | 4 |
| Hayashi, T | 2 |
| Nagamine, Y | 2 |
| Sano, H | 2 |
| Ice, DS | 1 |
| Shapiro, TA | 1 |
| Gnall, EM | 1 |
| Kowey, PR | 1 |
| Tang, XF | 1 |
| Fan, JY | 1 |
| Meng, J | 1 |
| Jin, C | 1 |
| Yuan, JQ | 1 |
| Yang, YJ | 1 |
| Cotsonis, G | 1 |
| Wooley, RH | 1 |
| Swanson, S | 1 |
| Williams, JE | 1 |
| Stern, BJ | 1 |
| Kohriyama, T | 1 |
| Mihara, C | 1 |
| Yokoyama, T | 1 |
| Torii, T | 1 |
| Yamada, A | 1 |
| Takamatsu, K | 1 |
| Ota, T | 1 |
| Noda, K | 1 |
| Kataoka, S | 1 |
| Ito, H | 1 |
| Nomura, E | 1 |
| Ohtsuki, T | 1 |
| Aoki, S | 1 |
| Nezu, T | 1 |
| Takeda, I | 1 |
| Mukai, T | 1 |
| Hosomi, N | 1 |
| Chen, CY | 1 |
| Lee, KT | 1 |
| Lee, CT | 1 |
| Huang, YB | 1 |
| González, A | 1 |
| Moniche, F | 1 |
| Cayuela, A | 1 |
| Gonzalez-Marcos, JR | 1 |
| Mayol, A | 1 |
| Montaner, J | 2 |
| Sandercock, PA | 1 |
| Counsell, C | 1 |
| Tseng, MC | 1 |
| Cecconi, E | 1 |
| Song, PS | 1 |
| Song, YB | 2 |
| Yang, JH | 2 |
| Hahn, JY | 2 |
| Choi, SH | 2 |
| Choi, JH | 2 |
| Lee, SH | 4 |
| Jang, Y | 3 |
| Seung, KB | 2 |
| Gwon, HC | 2 |
| Bach, RG | 1 |
| Heras, M | 1 |
| Horrow, J | 6 |
| Lassila, R | 2 |
| Morais, J | 4 |
| Wojdyla, D | 1 |
| Amarenco, P | 6 |
| Davis, S | 1 |
| Jones, EF | 1 |
| Cohen, AA | 1 |
| Heiss, WD | 1 |
| Kaste, M | 6 |
| Laouénan, C | 1 |
| Young, D | 1 |
| Macleod, M | 1 |
| Donnan, GA | 8 |
| George, PM | 1 |
| Jover, E | 1 |
| Rodríguez, JM | 1 |
| Bernal, A | 1 |
| Arroyo, AB | 1 |
| Iniesta, JA | 1 |
| Guiú, IS | 1 |
| Martínez, C | 2 |
| Vicente, V | 1 |
| Lozano, ML | 1 |
| Rivera, J | 1 |
| Motovska, Z | 2 |
| Ondrakova, M | 1 |
| Doktorova, M | 1 |
| Zhang, B | 2 |
| Chi, W | 1 |
| Tobin, WO | 4 |
| Kinsella, JA | 4 |
| Kavanagh, GF | 2 |
| O'Donnell, JS | 2 |
| McGrath, RT | 1 |
| Coughlan, T | 4 |
| Collins, DR | 3 |
| O'Neill, D | 4 |
| Egan, B | 3 |
| Tierney, S | 3 |
| Feeley, TM | 3 |
| Murphy, RP | 4 |
| McCabe, DJ | 6 |
| Reilly, CR | 1 |
| Cuesta-Fernandez, A | 1 |
| Kayaleh, OR | 1 |
| Wulf Silver, R | 1 |
| Emanuelsson, H | 3 |
| Bacchi Reggiani, ML | 1 |
| Ghetti, G | 1 |
| Gallo, P | 1 |
| Dall'Ara, G | 1 |
| Marrozzini, C | 1 |
| Rapezzi, C | 1 |
| Meng, H | 1 |
| Xu, L | 1 |
| Kong, D | 1 |
| Chen, P | 1 |
| Gong, X | 1 |
| Bai, J | 1 |
| Zou, F | 1 |
| Yang, Z | 2 |
| Eikelboom, JW | 7 |
| Censori, B | 1 |
| Liu, G | 1 |
| Zhao, K | 1 |
| Hwang, G | 1 |
| Kim, JG | 1 |
| Song, KS | 1 |
| Lee, YJ | 1 |
| Villavicencio, JB | 1 |
| Suroto, NS | 1 |
| Park, NM | 1 |
| Jeong, EA | 1 |
| Kwon, OK | 1 |
| Legrand, V | 1 |
| Cuisset, T | 2 |
| Chenu, P | 1 |
| Vrolix, M | 1 |
| Dens, J | 1 |
| Gach, O | 1 |
| Boland, J | 1 |
| Claeys, MJ | 1 |
| Magne, J | 1 |
| Barbato, E | 1 |
| Wijns, W | 1 |
| Frank, B | 1 |
| Hajjar, K | 1 |
| Bakal, JA | 1 |
| Zheng, Y | 2 |
| Westerhout, CM | 1 |
| Hochman, JS | 2 |
| Brown, EB | 2 |
| Wilcox, R | 1 |
| Iqbal, K | 1 |
| Costigan, T | 1 |
| Lopez-Sendon, J | 3 |
| Ramos, Y | 1 |
| Bae, JP | 1 |
| Faries, DE | 2 |
| Ernst, FR | 1 |
| Lipkin, C | 1 |
| Zhao, Z | 1 |
| Moretz, C | 1 |
| Lieu, HD | 1 |
| Di Minno, G | 2 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 1 |
| Chen, S | 1 |
| Shen, Q | 1 |
| Tang, Y | 1 |
| Peng, Y | 1 |
| Köklü, E | 1 |
| Arslan, Ş | 1 |
| Yüksel, İÖ | 1 |
| Bayar, N | 1 |
| Koç, P | 1 |
| Lei, H | 1 |
| Jiang, W | 2 |
| Han, J | 1 |
| Zhao, G | 1 |
| Sun, W | 1 |
| Zhu, W | 1 |
| Cai, Q | 1 |
| Cao, L | 1 |
| Bai, W | 1 |
| Fan, X | 1 |
| Ma, M | 1 |
| Guo, R | 2 |
| Xu, G | 1 |
| He, F | 1 |
| Xia, C | 1 |
| Zhang, JH | 1 |
| Li, XQ | 1 |
| Zhou, ZH | 1 |
| Li, FP | 1 |
| Li, W | 4 |
| Lv, Y | 1 |
| Chen, HS | 1 |
| Thompson, PL | 1 |
| Aryal, MR | 1 |
| Karmacharya, P | 1 |
| Pandit, A | 1 |
| Hakim, F | 1 |
| Pathak, R | 1 |
| Mainali, NR | 1 |
| Ukaigwe, A | 1 |
| Mahmood, M | 1 |
| Badal, M | 1 |
| Fortuin, FD | 1 |
| Silber, T | 1 |
| Ziemann, U | 1 |
| Ernemann, U | 1 |
| Bischof, F | 1 |
| Liao, D | 1 |
| Chi, L | 3 |
| Verma, A | 1 |
| Cairns, JA | 1 |
| Mitchell, LB | 1 |
| Macle, L | 1 |
| Stiell, IG | 1 |
| Gladstone, D | 1 |
| McMurtry, MS | 1 |
| Connolly, S | 2 |
| Cox, JL | 1 |
| Dorian, P | 2 |
| Ivers, N | 1 |
| Leblanc, K | 1 |
| Nattel, S | 1 |
| Healey, JS | 4 |
| Sehara, Y | 1 |
| Lai, X | 1 |
| Xiong, Z | 1 |
| Huang, L | 2 |
| Tricoci, P | 1 |
| Van de Werf, F | 1 |
| Chen, E | 1 |
| Aylward, PE | 2 |
| Moliterno, DJ | 1 |
| Jennings, LK | 1 |
| Strony, J | 1 |
| Geersing, GJ | 1 |
| Hoshino, H | 1 |
| Kimura, K | 1 |
| Origasa, H | 1 |
| Naritomi, H | 1 |
| Yamaguchi, T | 2 |
| Qiu, LN | 2 |
| Sun, Y | 1 |
| Wang, L | 3 |
| Han, RF | 2 |
| Xia, XS | 2 |
| Sáez, ME | 1 |
| González-Pérez, A | 1 |
| Johansson, S | 1 |
| Nagy, P | 1 |
| Rodríguez, LA | 1 |
| Jeong, TD | 1 |
| Kim, SM | 1 |
| Kim, HJ | 2 |
| Lee, W | 1 |
| Kwon, SU | 2 |
| Min, WK | 1 |
| Kang, DW | 2 |
| Chun, S | 1 |
| Dzeshka, MS | 1 |
| Brown, RA | 1 |
| Zheng, M | 1 |
| Zhang, L | 1 |
| Shang, X | 1 |
| Yan, C | 1 |
| Szapáry, L | 2 |
| Koltai, K | 1 |
| Tibold, A | 1 |
| Fehér, A | 1 |
| Harang, G | 1 |
| Pusch, G | 1 |
| Fehér, G | 1 |
| Mudra, H | 1 |
| von Hodenberg, E | 1 |
| Angiolillo, DJ | 7 |
| von Merzljak, B | 1 |
| Rifatov, N | 1 |
| Feuchtenberger, A | 1 |
| Janssen, PW | 1 |
| Valina, C | 1 |
| Desmet, W | 1 |
| Tiroch, K | 1 |
| Hengstenberg, C | 1 |
| Schömig, A | 4 |
| Sandhu, RK | 1 |
| Hohnloser, SH | 5 |
| Pfeffer, MA | 3 |
| Yuan, F | 1 |
| Connolly, SJ | 9 |
| McAlister, FA | 1 |
| Robson, K | 1 |
| Dineen, R | 1 |
| Flockhart, DA | 1 |
| Freeman, CP | 1 |
| Kimmel, SE | 1 |
| Costa, F | 1 |
| Leonardi, S | 2 |
| Moscarella, E | 1 |
| Ando, G | 1 |
| Calabro, P | 1 |
| Oreto, G | 1 |
| Zijlstra, F | 1 |
| Jickling, GC | 1 |
| Ntalas, IV | 2 |
| Kalantzi, KI | 2 |
| Tsoumani, ME | 2 |
| Vakalis, JN | 1 |
| Vasilakopoulos, V | 2 |
| Vardakis, K | 2 |
| Vemmos, KN | 1 |
| Voukelatou, M | 2 |
| Giannakoulas, G | 2 |
| Giatrakos, I | 2 |
| Giogiakas, V | 2 |
| Goumas, G | 2 |
| Dimoulis, N | 2 |
| Draganigos, A | 2 |
| Efthimiadis, I | 2 |
| Thoma, M | 2 |
| Kazakos, E | 2 |
| Kipouridis, N | 2 |
| Konstantinou, S | 2 |
| Bourdakis, A | 2 |
| Nikolopoulos, D | 2 |
| Peltekis, L | 2 |
| Prokopakis, N | 2 |
| Sinteles, I | 2 |
| Stroumbis, CS | 1 |
| Terzoudi, K | 2 |
| Tsilias, K | 2 |
| Xaraktsis, I | 2 |
| Charmpas, C | 2 |
| Hatziathanasiou, G | 2 |
| Christogiannis, Z | 2 |
| Panagiotakos, DB | 2 |
| Goudevenos, JA | 2 |
| Horie, N | 1 |
| Kaminogo, M | 1 |
| Izumo, T | 1 |
| Hayashi, K | 1 |
| Tsujino, A | 1 |
| Angoulvant, D | 1 |
| Villejoubert, O | 1 |
| Bejan-Angoulvant, T | 1 |
| Ivanes, F | 1 |
| Saint Etienne, C | 1 |
| Lip, GYH | 3 |
| Fauchier, L | 1 |
| Liu, F | 2 |
| Tantry, US | 3 |
| Jia, M | 1 |
| Chu, H | 1 |
| Li, L | 3 |
| Chen, K | 1 |
| Gandhi, S | 1 |
| Schwalm, JD | 2 |
| Velianou, JL | 1 |
| Farkouh, ME | 2 |
| Hassell, ME | 1 |
| Hildick-Smith, D | 1 |
| Durand, E | 1 |
| Kikkert, WJ | 1 |
| Wiegerinck, EM | 1 |
| Stabile, E | 1 |
| Ussia, GP | 1 |
| Sharma, S | 1 |
| Baan, J | 1 |
| Rubino, P | 1 |
| Barbanti, M | 1 |
| Tamburino, C | 2 |
| Poliacikova, P | 1 |
| Blanchard, D | 1 |
| Piek, JJ | 1 |
| Delewi, R | 1 |
| Gross, BA | 1 |
| Albuquerque, FC | 1 |
| Zhou, JS | 3 |
| Zhang, YD | 2 |
| Tian, YY | 1 |
| Ben, H | 1 |
| Zhong, H | 1 |
| Zhao, YX | 1 |
| Yang, ZH | 1 |
| McDonough, CW | 2 |
| McClure, LA | 5 |
| Mitchell, BD | 1 |
| Gong, Y | 2 |
| Horenstein, RB | 1 |
| Lewis, JP | 1 |
| Field, TS | 2 |
| Talbert, RL | 1 |
| Johnson, JA | 2 |
| Shuldiner, AR | 1 |
| Seadon, S | 1 |
| Lang, E | 1 |
| Blann, AD | 1 |
| Skjøth, F | 1 |
| Rasmussen, LH | 2 |
| Larsen, TB | 1 |
| Kim, BS | 2 |
| Jang, WJ | 1 |
| Kim, WS | 1 |
| Lee, YT | 1 |
| Su, Y | 1 |
| Lv, HH | 2 |
| Yang, XL | 2 |
| Li, SX | 2 |
| Wu, S | 2 |
| Jiang, JM | 2 |
| Luo, Z | 2 |
| Zhu, DS | 1 |
| Guan, YT | 2 |
| Xu, JF | 3 |
| Alderazi, YJ | 1 |
| Melloni, C | 1 |
| Neely, ML | 4 |
| Zamoryakhin, D | 1 |
| Dias, A | 1 |
| Franco, E | 1 |
| Koshkelashvili, N | 1 |
| Bhalla, V | 1 |
| Pressman, GS | 1 |
| Hebert, K | 1 |
| Figueredo, VM | 1 |
| Tan, S | 1 |
| Xiao, X | 1 |
| Ma, H | 1 |
| Yu, S | 3 |
| Xu, R | 1 |
| Yang, S | 1 |
| Huang, X | 2 |
| Hong, H | 1 |
| Khatri, S | 1 |
| Pierce, T | 1 |
| Rothlisberger, JM | 1 |
| Xian, Y | 2 |
| Fang, J | 1 |
| Bartels, A | 1 |
| Sarpong, Y | 1 |
| Coberly, J | 1 |
| Hughes, N | 1 |
| Litt, J | 1 |
| Quick, J | 1 |
| Kessel, J | 1 |
| Nelson, C | 1 |
| Coughenour, J | 1 |
| Barnes, SL | 1 |
| Litofsky, NS | 1 |
| Hammer, RD | 1 |
| Ahmad, S | 1 |
| Gigante, B | 1 |
| Höeg Dembrower, K | 1 |
| Laurencikas, E | 1 |
| Leng, X | 2 |
| Pu, Y | 1 |
| Zou, X | 1 |
| Soo, Y | 1 |
| Coignion, C | 1 |
| Poli, M | 1 |
| Sagnier, S | 1 |
| Freyburger, G | 1 |
| Renou, P | 2 |
| Debruxelles, S | 1 |
| Rouanet, F | 1 |
| Sibon, I | 2 |
| Goto, S | 2 |
| Huang, CH | 2 |
| Kimura, T | 2 |
| Fabiaña, N | 1 |
| Ramaswami, AP | 1 |
| Ang, ES | 1 |
| De Silva, DA | 1 |
| Cotsonis, GA | 1 |
| Arif, SA | 1 |
| D'Souza, J | 1 |
| Gil, M | 1 |
| Gim, S | 1 |
| Davis, KA | 1 |
| Miyares, MA | 1 |
| Dietrich, E | 2 |
| Xu, C | 1 |
| Wang, P | 1 |
| Xin, H | 1 |
| Gan, XD | 1 |
| Wei, BZ | 1 |
| Fang, D | 1 |
| Fang, Q | 1 |
| Li, KY | 1 |
| Ding, SL | 1 |
| Peng, S | 1 |
| Wan, J | 1 |
| Kang, K | 1 |
| Lee, SJ | 2 |
| Koh, SH | 1 |
| Kim, BK | 3 |
| Asher, E | 2 |
| Fefer, P | 1 |
| Sabbag, A | 2 |
| Herscovici, R | 1 |
| Regev, E | 1 |
| Mazin, I | 2 |
| Shlomo, N | 1 |
| Zahger, D | 2 |
| Atar, S | 2 |
| Hammerman, H | 1 |
| Polak, A | 2 |
| Beigel, R | 2 |
| Matetzky, S | 2 |
| Jhang, KM | 1 |
| Huang, JY | 1 |
| Nfor, ON | 1 |
| Jian, ZH | 1 |
| Tung, YC | 1 |
| Ku, WY | 1 |
| Liaw, YP | 1 |
| Ofosu, FA | 1 |
| Zheng, SL | 1 |
| An, LX | 1 |
| Christiansen, CB | 1 |
| Pallisgaard, J | 1 |
| Gerds, TA | 1 |
| Jørgensen, ME | 1 |
| Numé, AK | 1 |
| Carlson, N | 1 |
| Kristensen, SL | 2 |
| Gislason, G | 1 |
| Sternberg, Z | 2 |
| Chichelli, T | 2 |
| Sternberg, D | 1 |
| Sawyer, R | 1 |
| Ching, M | 2 |
| Janicke, D | 2 |
| Ambrus, JL | 1 |
| Yu, J | 1 |
| Munschauer, F | 1 |
| Royster, AJ | 1 |
| Sheehan, TO | 1 |
| Burkley, B | 1 |
| Langaee, TY | 1 |
| Mocco, J | 1 |
| Zuckerman, SL | 1 |
| Mummareddy, N | 1 |
| Stephens, ML | 1 |
| Ingram, C | 1 |
| Shaffer, CM | 1 |
| Denny, JC | 1 |
| Brilliant, MH | 1 |
| Kitchner, TE | 1 |
| Linneman, JG | 1 |
| Roden, DM | 1 |
| Fang, L | 1 |
| Wang, N | 1 |
| Lin, M | 1 |
| Huibers, A | 1 |
| Halliday, A | 1 |
| Bulbulia, R | 1 |
| Coppi, G | 1 |
| de Borst, GJ | 2 |
| Mizuma, A | 1 |
| Iijima, K | 1 |
| Kohara, S | 1 |
| Shimizu, M | 1 |
| Imazeki, R | 1 |
| Uesugi, T | 1 |
| Ohnuki, Y | 1 |
| Takizawa, S | 1 |
| Fu, A | 1 |
| Singh, K | 1 |
| Abunassar, J | 1 |
| Malhotra, N | 1 |
| Le May, M | 1 |
| Labinaz, M | 1 |
| Glover, C | 1 |
| Marquis, JF | 1 |
| Froeschl, M | 1 |
| Dick, A | 1 |
| Hibbert, B | 1 |
| Chong, AY | 1 |
| So, DY | 1 |
| Gottschalksen, B | 1 |
| Kim, YJ | 1 |
| Seo, WK | 1 |
| Oh, SH | 1 |
| Kim, YN | 1 |
| Tziomalos, K | 1 |
| Giampatzis, V | 1 |
| Bouziana, SD | 1 |
| Spanou, M | 1 |
| Kostaki, S | 1 |
| Papadopoulou, M | 1 |
| Angelopoulou, SM | 1 |
| Tsopozidi, M | 1 |
| Savopoulos, C | 1 |
| Hatzitolios, AI | 1 |
| Lemesle, G | 1 |
| Schurtz, G | 1 |
| Meurice, T | 1 |
| Tricot, O | 1 |
| Lemaire, N | 1 |
| Caudmont, S | 1 |
| Philias, A | 1 |
| Ketelers, R | 1 |
| Lamblin, N | 1 |
| Bauters, C | 1 |
| Rao, M | 1 |
| Simon, DN | 1 |
| Thomas, L | 1 |
| Ansell, J | 1 |
| Fonarow, GC | 4 |
| Gersh, BJ | 4 |
| Go, AS | 3 |
| Hylek, EM | 2 |
| Kowey, P | 1 |
| Chang, P | 1 |
| Peterson, ED | 7 |
| Murphy, SJ | 1 |
| Coughlan, CA | 1 |
| Tobin, O | 1 |
| Kinsella, J | 1 |
| Lonergan, R | 1 |
| Gutkin, M | 1 |
| Dormuth, CR | 1 |
| Filion, KB | 1 |
| Platt, RW | 1 |
| Reddy, VY | 2 |
| Akehurst, RL | 1 |
| Armstrong, SO | 1 |
| Amorosi, SL | 1 |
| Brereton, N | 1 |
| Hertz, DS | 1 |
| Holmes, DR | 1 |
| Qian, J | 1 |
| Tang, X | 3 |
| Hu, Y | 1 |
| Mărginean, A | 1 |
| Bănescu, C | 1 |
| Moldovan, V | 1 |
| Scridon, A | 1 |
| Mărginean, M | 1 |
| Bălaşa, R | 1 |
| Maier, S | 1 |
| Ţăruşi, M | 1 |
| Dobreanu, M | 1 |
| Nishi, R | 1 |
| Mano, T | 1 |
| Kobayashi, Y | 2 |
| Matsuo, K | 1 |
| Chin, CT | 2 |
| Neely, B | 4 |
| Magnus Ohman, E | 2 |
| Corbalán, R | 4 |
| Cheng, W | 5 |
| Jones, DW | 1 |
| Goodney, PP | 1 |
| Conrad, MF | 1 |
| Nolan, BW | 1 |
| Rzucidlo, EM | 1 |
| Powell, RJ | 1 |
| Cronenwett, JL | 1 |
| Stone, DH | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, Y | 2 |
| Yang, X | 2 |
| Li, R | 1 |
| Jing, Q | 1 |
| Wang, Q | 1 |
| Liu, P | 2 |
| Zhang, P | 1 |
| Liu, Y | 4 |
| Vaduganathan, M | 1 |
| Cryer, BL | 1 |
| Hsieh, WH | 1 |
| Doros, G | 1 |
| Cohen, M | 1 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Ge, F | 1 |
| Lin, H | 2 |
| Ruan, Z | 1 |
| Chang, T | 1 |
| Gallego-Fabrega, C | 1 |
| Carrera, C | 1 |
| Reny, JL | 1 |
| Fontana, P | 1 |
| Slowik, A | 1 |
| Pera, J | 1 |
| Pezzini, A | 3 |
| Serrano-Heras, G | 1 |
| Segura, T | 1 |
| Martí-Fàbregas, J | 2 |
| Muiño, E | 1 |
| Cullell, N | 1 |
| Krupinski, J | 1 |
| Fernandez-Cadenas, I | 1 |
| Leiva-Pons, JL | 2 |
| Gottlieb, S | 3 |
| Dalby, AJ | 2 |
| Schiele, F | 1 |
| Stroumbis, C | 1 |
| Vakalis, I | 1 |
| Holzgreve, H | 1 |
| Liu, R | 1 |
| Zhou, ZY | 1 |
| Chen, YB | 1 |
| Li, JL | 1 |
| Yu, WB | 1 |
| Chen, XM | 1 |
| Zhao, M | 1 |
| Zhao, YQ | 1 |
| Cai, YF | 1 |
| Jin, J | 1 |
| Huang, M | 1 |
| Zhu, WY | 1 |
| Zhao, T | 1 |
| Xiong, XY | 1 |
| Zhou, Y | 2 |
| Gong, ZL | 1 |
| Cheng, SY | 1 |
| Shuai, J | 1 |
| Yang, QW | 1 |
| Shiue, HJ | 1 |
| Sands, KA | 1 |
| Davis, K | 1 |
| Hagström, E | 1 |
| Sidhu, MS | 1 |
| Blomster, J | 1 |
| Millegård, M | 1 |
| Heizer, G | 1 |
| Reist, C | 1 |
| Fowkes, FG | 1 |
| Ma, G | 1 |
| Du, M | 3 |
| Zhang, D | 1 |
| Shi, Y | 1 |
| Hong, SJ | 1 |
| Shin, DH | 1 |
| Kim, JS | 1 |
| Ko, YG | 1 |
| Choi, D | 1 |
| Her, AY | 1 |
| Dadjou, Y | 1 |
| Safavi, S | 1 |
| Kojuri, J | 1 |
| Fu, C | 1 |
| Chen, Y | 1 |
| Zhou, X | 1 |
| Kurowski, S | 1 |
| Wu, W | 2 |
| Desai, K | 1 |
| Chu, L | 1 |
| Gutstein, DE | 1 |
| Seiffert, D | 1 |
| Whalen, JD | 1 |
| Davies, G | 2 |
| Oguz, M | 2 |
| Bash, LD | 1 |
| Ozer-Stillman, I | 1 |
| Zhang, W | 2 |
| Tan, L | 1 |
| Nao, J | 1 |
| Hu, H | 1 |
| Kong, Y | 1 |
| Song, Y | 1 |
| Shimada, YJ | 1 |
| Doll, JA | 1 |
| Wang, TY | 4 |
| Choudhry, NK | 2 |
| Cohen, DJ | 5 |
| Bhandary, DD | 1 |
| Khan, N | 1 |
| Davidson-Ray, LD | 1 |
| Anstrom, K | 1 |
| Abu-Much, A | 1 |
| Goldenberg, I | 1 |
| Segev, A | 1 |
| Shlezinger, M | 1 |
| Zhang, YQ | 1 |
| Wei, CL | 1 |
| Hu, YH | 1 |
| Kim, EG | 1 |
| Cho, KH | 1 |
| Chang, DI | 1 |
| Rha, JH | 1 |
| Bae, HJ | 1 |
| Lee, KB | 1 |
| Kim, DE | 1 |
| Park, JM | 1 |
| Kim, HY | 1 |
| Cha, JK | 4 |
| Yu, KH | 1 |
| Lee, YS | 1 |
| Choi, JC | 1 |
| Cho, YJ | 1 |
| Kim, GM | 1 |
| Sohn, SI | 1 |
| Park, KY | 1 |
| Sohn, CH | 1 |
| Lee, J | 2 |
| Yoon, BW | 3 |
| Deng, QQ | 1 |
| Tang, J | 1 |
| Markus, H | 2 |
| Huang, YN | 2 |
| Zhao, H | 1 |
| Fu, JH | 1 |
| Hoshi, T | 1 |
| Sato, A | 1 |
| Nogami, A | 1 |
| Gosho, M | 1 |
| Aonuma, K | 1 |
| Jackson, LR | 2 |
| Cyr, DD | 1 |
| Martinez, F | 2 |
| Lüscher, TF | 2 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 2 |
| Kedhi, E | 1 |
| Verdoia, M | 1 |
| Barbieri, L | 1 |
| Rognoni, A | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Fahed, E | 1 |
| Ghauche, J | 1 |
| Rahme, R | 1 |
| Okais, N | 1 |
| Samaha, E | 1 |
| Nohra, G | 1 |
| Rizk, T | 1 |
| Maarrawi, J | 1 |
| Menassa-Moussa, L | 1 |
| Moussa, R | 1 |
| Gargiulo, G | 1 |
| Ariotti, S | 1 |
| Santucci, A | 1 |
| Baldo, A | 1 |
| Franzone, A | 1 |
| Magnani, G | 1 |
| Esposito, G | 1 |
| Buck, J | 1 |
| Kaboli, P | 1 |
| Gage, BF | 1 |
| Cram, P | 1 |
| Vaughan Sarrazin, MS | 1 |
| Moulias, A | 1 |
| He, Y | 1 |
| Cai, H | 2 |
| Zhou, G | 2 |
| Čulić, V | 1 |
| Landman, GW | 1 |
| Kleefstra, N | 1 |
| Fosbøl, EL | 1 |
| Ju, C | 2 |
| Anstrom, KJ | 1 |
| Zettler, ME | 1 |
| Messenger, JC | 2 |
| Waksman, R | 1 |
| Moris, D | 3 |
| Avgerinos, E | 2 |
| McCoy, LA | 1 |
| Zettler, M | 1 |
| Yang, Q | 1 |
| Wang, G | 1 |
| Ferri, LA | 1 |
| Morici, N | 1 |
| Grosseto, D | 1 |
| Tortorella, G | 1 |
| Bossi, I | 1 |
| Sganzerla, P | 1 |
| Cacucci, M | 1 |
| Sibilio, G | 1 |
| Toso, A | 1 |
| Ferrario, M | 1 |
| Gandolfo, N | 1 |
| Ravera, A | 1 |
| Mariani, M | 1 |
| Corrada, E | 1 |
| Di Ascenzo, L | 1 |
| Petronio, AS | 1 |
| Cavallini, C | 1 |
| Moffa, N | 1 |
| De Servi, S | 2 |
| Savonitto, S | 1 |
| Bakoyiannis, C | 2 |
| Karaolanis, G | 1 |
| Georgopoulos, S | 1 |
| Wändell, P | 1 |
| Carlsson, AC | 1 |
| Holzmann, M | 1 |
| Ärnlöv, J | 1 |
| Johansson, SE | 1 |
| Sundquist, J | 1 |
| Sundquist, K | 1 |
| Carrero, JJ | 1 |
| Szummer, K | 1 |
| Evans, M | 1 |
| Spaak, J | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Bretz, F | 1 |
| D'Agostino, RB | 1 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Dangas, GD | 1 |
| Bykov, K | 1 |
| Schneeweiss, S | 1 |
| Donneyong, MM | 1 |
| Dong, YH | 1 |
| Gagne, JJ | 1 |
| Simon, T | 2 |
| Danchin, N | 2 |
| Sawlani, NN | 1 |
| Gibson, CM | 3 |
| Hamm, CW | 3 |
| Price, MJ | 1 |
| Prats, J | 1 |
| Deliargyris, EN | 1 |
| Xu, H | 1 |
| Ping, Y | 1 |
| He, P | 1 |
| Dai, H | 1 |
| Jalal, Z | 1 |
| Dinet, ML | 1 |
| Combes, N | 1 |
| Pillois, X | 1 |
| Iriart, X | 1 |
| Thambo, JB | 1 |
| Zuo, FT | 1 |
| Wu, HJ | 1 |
| Su, N | 1 |
| Liu, JQ | 1 |
| Dong, AQ | 1 |
| van Diepen, S | 1 |
| Fuster, V | 1 |
| Hamza, TH | 1 |
| Siami, FS | 1 |
| Della Riva, D | 1 |
| Bacchi Reggiani, L | 1 |
| Chieffo, A | 1 |
| Sangiorgi, D | 1 |
| Biondi-Zoccai, G | 1 |
| Angelini, GD | 2 |
| Pufulete, M | 1 |
| White, J | 1 |
| Song, H | 1 |
| Hou, C | 1 |
| Cao, Q | 1 |
| Feng, W | 1 |
| Wang, M | 1 |
| Ji, X | 1 |
| Illuminati, G | 1 |
| Schneider, F | 1 |
| Pizzardi, G | 1 |
| Masci, F | 1 |
| Calio', FG | 1 |
| Ricco, JB | 1 |
| Chen, YT | 1 |
| Chen, HT | 1 |
| Hsu, CY | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Lee, H | 1 |
| Lim, SW | 1 |
| Rha, SW | 4 |
| Bae, JW | 3 |
| Jeon, DW | 1 |
| Oh, SK | 1 |
| Hur, SH | 2 |
| Lee, JH | 1 |
| Lee, NH | 2 |
| Chase, M | 1 |
| Li, XG | 1 |
| Ma, N | 1 |
| Sun, SS | 1 |
| Miao, ZR | 1 |
| Zhao, ZG | 1 |
| Ou, L | 1 |
| Nakagawa, I | 1 |
| Park, HS | 2 |
| Wada, T | 1 |
| Yokoyama, S | 1 |
| Yamada, S | 1 |
| Motoyama, Y | 1 |
| Kichikawa, K | 1 |
| Nakase, H | 1 |
| Belvís, R | 1 |
| Pagonabarraga, J | 1 |
| Santamaría, A | 1 |
| Kulisevsky, J | 1 |
| Serebruany, VL | 8 |
| Alberts, MJ | 6 |
| Hanley, DF | 2 |
| Sztriha, LK | 1 |
| Vécsei, L | 1 |
| Teal, P | 3 |
| Diener, C | 1 |
| Sarafoff, N | 1 |
| Ndrepepa, G | 2 |
| Dörrler, K | 1 |
| Schulz, S | 2 |
| Byrne, R | 1 |
| Weerakkody, G | 2 |
| Morocutti, G | 1 |
| McCabe, CH | 3 |
| Braunwald, E | 4 |
| Gray, LJ | 1 |
| England, T | 1 |
| Willmot, MR | 1 |
| Zhao, L | 3 |
| Sare, GM | 1 |
| Chaturvedi, S | 2 |
| Anderson, CS | 1 |
| Kent, DM | 1 |
| Thaler, DE | 1 |
| Ounpuu, S | 2 |
| Lawton, WA | 2 |
| Martin, RH | 4 |
| Bath, P | 3 |
| Bornstein, N | 2 |
| Chan, BP | 2 |
| Chen, ST | 2 |
| Cunha, L | 2 |
| Dahlöf, B | 2 |
| De Keyser, J | 2 |
| Estol, C | 3 |
| Gorelick, P | 4 |
| Gu, V | 2 |
| Hermansson, K | 3 |
| Hilbrich, L | 2 |
| Lu, C | 2 |
| Machnig, T | 2 |
| Pais, P | 3 |
| Roberts, R | 3 |
| Skvortsova, V | 2 |
| Vandermaelen, C | 2 |
| Voigt, T | 2 |
| Weber, M | 2 |
| Zimmermann, N | 1 |
| Hohlfeld, T | 2 |
| Sander, D | 1 |
| Schwertfeger, M | 1 |
| Köfüncü, E | 1 |
| Diehm, C | 1 |
| Pittrow, D | 1 |
| Panagos, PD | 1 |
| Pogue, J | 8 |
| Haladyn, K | 1 |
| Peters, RJ | 2 |
| Avezum, A | 1 |
| Rupprecht, HJ | 4 |
| Vande Griend, JP | 1 |
| Saseen, JJ | 1 |
| Suri, MF | 2 |
| Hussein, HM | 1 |
| Abdelmoula, MM | 1 |
| Divani, AA | 1 |
| Qureshi, AI | 3 |
| Thomas, D | 1 |
| Giugliano, RP | 1 |
| Bassand, JP | 4 |
| Chrolavicius, S | 5 |
| Diaz, R | 3 |
| Jolly, S | 2 |
| Lees, KR | 5 |
| Selim, M | 1 |
| Jeon, HW | 1 |
| Kang, MJ | 1 |
| Rossini, R | 1 |
| Musumeci, G | 1 |
| Lettieri, C | 1 |
| Molfese, M | 1 |
| Mihalcsik, L | 1 |
| Mantovani, P | 1 |
| Sirbu, V | 1 |
| Bass, TA | 2 |
| Della Rovere, F | 1 |
| Gavazzi, A | 1 |
| Verstuyft, C | 1 |
| Mary-Krause, M | 1 |
| Quteineh, L | 1 |
| Drouet, E | 1 |
| Méneveau, N | 1 |
| Ferrières, J | 1 |
| Becquemont, L | 1 |
| Minnerup, J | 1 |
| Schäbitz, WR | 1 |
| Yu, SC | 2 |
| Lam, WW | 1 |
| Chan, AY | 1 |
| Wong, LK | 2 |
| Hegge, KA | 1 |
| Fukuuchi, Y | 1 |
| Massie, BM | 1 |
| Collins, JF | 1 |
| Ammon, SE | 1 |
| Cleland, JG | 1 |
| Ezekowitz, M | 1 |
| Jafri, SM | 1 |
| Krol, WF | 1 |
| O'Connor, CM | 1 |
| Schulman, KA | 1 |
| Teo, K | 1 |
| Warren, SR | 1 |
| Furlan, AJ | 3 |
| Jung, JH | 1 |
| Min, PK | 1 |
| Sung, CW | 1 |
| Choi, S | 1 |
| Cho, JR | 1 |
| Lee, N | 1 |
| Byun, KH | 1 |
| Stulman, J | 1 |
| McGinn, T | 1 |
| Korenstein, D | 1 |
| Mak, KH | 5 |
| Shao, M | 1 |
| Pfeffer, M | 3 |
| Balucani, C | 1 |
| Cordonnier, C | 2 |
| Usman, MH | 1 |
| Notaro, LA | 1 |
| Nagarakanti, R | 1 |
| Brahin, E | 1 |
| Dessain, S | 1 |
| Gracely, E | 1 |
| Ezekowitz, MD | 2 |
| Boysen, G | 2 |
| Preobrazhenskiĭ, DV | 3 |
| Beckman, JA | 1 |
| Ionita, CC | 1 |
| O'Donoghue, M | 1 |
| Finkelstein, A | 1 |
| Penny, WF | 1 |
| Fridrich, V | 1 |
| Katus, H | 1 |
| Scirica, BM | 1 |
| Skene, A | 1 |
| Freij, A | 1 |
| Thorsén, M | 1 |
| Bal Dit Sollier, C | 1 |
| Crassard, I | 2 |
| Simoneau, G | 1 |
| Bergmann, JF | 1 |
| Bousser, MG | 2 |
| Drouet, L | 1 |
| Pisters, R | 2 |
| Dinh, T | 1 |
| Crijns, HJ | 2 |
| Chua, D | 1 |
| Legal, M | 1 |
| Shalansky, SJ | 1 |
| Lee, YE | 1 |
| DeZee, KJ | 1 |
| Goldstein, LB | 2 |
| Richard, T | 1 |
| Butaffuoco, F | 1 |
| Vanhaeverbeek, M | 1 |
| Shalimar, S | 1 |
| Pangtey, GS | 1 |
| Singh, KK | 1 |
| Sudlow, CL | 3 |
| Mason, G | 1 |
| Maurice, JB | 1 |
| Wedderburn, CJ | 1 |
| Depta, JP | 2 |
| Peacock, WF | 1 |
| Pinto, A | 1 |
| Di Raimondo, D | 1 |
| Tuttolomondo, A | 1 |
| Di Sciacca, R | 1 |
| Arnao, V | 1 |
| La Placa, S | 1 |
| Milio, G | 1 |
| Miceli, S | 1 |
| Licata, G | 1 |
| Serebruany, V | 4 |
| Rao, SV | 2 |
| Kannan, AO | 1 |
| Makarov, L | 1 |
| Atar, D | 4 |
| Karkos, CD | 1 |
| Karamanos, DG | 1 |
| Papazoglou, KO | 1 |
| Demiropoulos, FP | 1 |
| Papadimitriou, DN | 1 |
| Gerassimidis, TS | 1 |
| Kan, LP | 1 |
| Chu, KM | 1 |
| Lin, GM | 1 |
| Sharma, JC | 3 |
| Vassallo, M | 1 |
| Ross, IN | 1 |
| Meyer, D | 1 |
| Cherala, G | 1 |
| Williams, C | 1 |
| Surigin, S | 1 |
| Booze, C | 1 |
| Kuliczkowski, W | 1 |
| Mahoney, EM | 2 |
| Arnold, SV | 1 |
| Proskorovsky, I | 1 |
| Wiviott, S | 1 |
| Antman, E | 1 |
| Bilodeau, ML | 1 |
| Simon, DI | 2 |
| Dosh, K | 1 |
| Marso, S | 1 |
| van Lente, F | 1 |
| Brennan, DM | 4 |
| Charnigo, R | 1 |
| Steinhubl, S | 2 |
| Cattaneo, M | 1 |
| Diedler, J | 1 |
| Ahmed, N | 2 |
| Sykora, M | 1 |
| Uyttenboogaart, M | 1 |
| Overgaard, K | 2 |
| Luijckx, GJ | 1 |
| Soinne, L | 1 |
| Ford, GA | 2 |
| Wahlgren, N | 2 |
| Ringleb, P | 1 |
| Wait, SD | 1 |
| Abla, AA | 1 |
| Killory, BD | 1 |
| Starke, RM | 1 |
| Spetzler, RF | 1 |
| Nakaji, P | 1 |
| Randall, MS | 1 |
| McKevitt, FM | 1 |
| Kumar, S | 1 |
| Cleveland, TJ | 1 |
| Endean, K | 1 |
| Gaines, PA | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Breet, NJ | 2 |
| van Werkum, JW | 2 |
| Bouman, HJ | 2 |
| Kelder, JC | 2 |
| Ruven, HJ | 1 |
| Bal, ET | 1 |
| Deneer, VH | 1 |
| Harmsze, AM | 2 |
| van der Heyden, JA | 1 |
| Rensing, BJ | 1 |
| Suttorp, MJ | 1 |
| Hackeng, CM | 2 |
| Sacco, R | 2 |
| Burke, JP | 1 |
| Sander, S | 2 |
| Shah, H | 2 |
| Zarotsky, V | 1 |
| Henk, H | 1 |
| Simmons, BB | 2 |
| Yeo, A | 1 |
| Fung, K | 1 |
| Gao, F | 1 |
| Zhou, YJ | 1 |
| Wang, ZJ | 1 |
| Shen, H | 1 |
| Liu, XL | 1 |
| Nie, B | 1 |
| Yan, ZX | 1 |
| Yang, SW | 1 |
| Jia, de A | 1 |
| Yu, M | 1 |
| Giossi, A | 1 |
| Del Zotto, E | 1 |
| Volonghi, I | 1 |
| Costa, P | 1 |
| Ferrari, D | 1 |
| Padovani, A | 1 |
| Han, KH | 1 |
| Yun, SC | 2 |
| Lee, SG | 1 |
| Seong, IW | 1 |
| Yoon, J | 1 |
| Yang, JY | 1 |
| Lee, BK | 1 |
| Choi, YJ | 1 |
| Chung, WS | 1 |
| Lim, DS | 1 |
| Cheong, SS | 1 |
| Kim, KS | 1 |
| Chae, JK | 1 |
| Nah, DY | 1 |
| Jeon, DS | 1 |
| Jang, JS | 1 |
| Maegdefessel, L | 1 |
| Azuma, J | 1 |
| Tsao, PS | 1 |
| Geraghty, OC | 2 |
| Kennedy, J | 2 |
| Chandratheva, A | 2 |
| Marquardt, L | 1 |
| Buchan, AM | 3 |
| Rothwell, PM | 3 |
| Chang, HM | 2 |
| Chollate, P | 1 |
| Koh, A | 1 |
| Hao, Q | 2 |
| Scacciatella, P | 1 |
| Butera, G | 1 |
| Amato, G | 1 |
| Tomassini, F | 1 |
| Giorgi, M | 1 |
| Marra, S | 1 |
| Polydorou, AD | 1 |
| Megaloikonomos, P | 1 |
| Moutiris, JA | 1 |
| Polydorou, V | 1 |
| Antypa, E | 1 |
| Testembasi, E | 1 |
| Tziakouri, CH | 1 |
| Palatianos, G | 1 |
| Nikas, D | 1 |
| Bolos, K | 1 |
| Polydorou, A | 1 |
| Paul, NL | 1 |
| Birkmeier, KA | 1 |
| Moshage, W | 1 |
| Dotzer, F | 1 |
| Dirschinger, J | 1 |
| Frankel, MR | 1 |
| Liang, L | 1 |
| Labresh, KA | 1 |
| Ellrodt, G | 1 |
| Hernandez, AF | 1 |
| Schwamm, LH | 2 |
| Smith, EE | 1 |
| Pakhomov, IaM | 1 |
| Okura, H | 1 |
| Renda, G | 1 |
| Fischer, D | 1 |
| Haentjes, J | 1 |
| Klein, G | 1 |
| Schieffer, B | 1 |
| Drexler, H | 1 |
| Meyer, GP | 1 |
| Schaefer, A | 1 |
| Lee, SP | 2 |
| Suh, JW | 2 |
| Lee, HY | 2 |
| Choi, DJ | 1 |
| Cho, MC | 2 |
| Kwon, TG | 1 |
| Bae, JH | 2 |
| Joyner, CD | 1 |
| Afzal, R | 1 |
| Tiroch, KA | 1 |
| Koch, W | 1 |
| Roosen-Runge, T | 1 |
| Memtsoudis, SG | 1 |
| Sharrock, NE | 1 |
| Knosalla, C | 1 |
| Dandel, M | 1 |
| Hetzer, R | 1 |
| Sidorenko, BA | 1 |
| Fettser, DV | 1 |
| Batyraliev, TA | 1 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Clausen, MT | 1 |
| Fog-Petersen, ML | 1 |
| Raunsø, J | 1 |
| Gadsbøll, N | 1 |
| Folke, F | 1 |
| Andersen, SS | 1 |
| Schramm, TK | 1 |
| Abildstrøm, SZ | 1 |
| Poulsen, HE | 1 |
| Jin, B | 1 |
| Ni, HC | 1 |
| Shen, W | 1 |
| Shi, HM | 1 |
| Ibrahim, MM | 1 |
| Sebastian, J | 1 |
| Hussain, M | 1 |
| Al-Hussain, F | 1 |
| Uchino, K | 1 |
| Molina, C | 1 |
| Khan, K | 1 |
| Saqqur, M | 1 |
| Feldman, DN | 1 |
| Minutello, RM | 1 |
| Bergman, G | 1 |
| Moussa, I | 1 |
| Wong, SC | 1 |
| Gilchrist, IC | 1 |
| Rosenbaum, A | 1 |
| Rizvi, AZ | 1 |
| Alden, PB | 1 |
| Tretinyak, AS | 1 |
| Graber, JN | 1 |
| Goldman, JA | 1 |
| Schlitt, A | 1 |
| Greer, DM | 1 |
| Tran, M | 1 |
| Tafreshi, J | 1 |
| Pai, RG | 1 |
| Hanna, EB | 2 |
| Abu-Fadel, MS | 1 |
| Conrado, DJ | 1 |
| Gonzalez, D | 1 |
| Derendorf, H | 1 |
| Donohue, MM | 1 |
| Tirschwell, DL | 1 |
| Kral, M | 1 |
| Herzig, R | 1 |
| Sanak, D | 1 |
| Skoloudik, D | 1 |
| Vlachova, I | 1 |
| Bartkova, A | 1 |
| Hlustik, P | 1 |
| Kovacik, M | 1 |
| Kanovsky, P | 1 |
| Maron, BA | 1 |
| Shekar, PS | 1 |
| Goldhaber, SZ | 1 |
| De Rango, P | 1 |
| Parlani, G | 1 |
| Romano, L | 1 |
| Verzini, F | 1 |
| Giordano, G | 1 |
| Cieri, E | 1 |
| Barbante, M | 1 |
| Cao, P | 1 |
| Sakata, T | 1 |
| Kario, K | 1 |
| Gentilomo, C | 1 |
| Huang, YS | 1 |
| Raffini, L | 1 |
| Juurlink, DN | 1 |
| Gomes, T | 1 |
| Mamdani, MM | 1 |
| Gladstone, DJ | 1 |
| Kapral, MK | 2 |
| Muñoz-Torrero, JF | 1 |
| Escudero, D | 1 |
| Suárez, C | 1 |
| Sanclemente, C | 1 |
| Pascual, MT | 1 |
| Zamorano, J | 1 |
| Trujillo-Santos, J | 1 |
| Monreal, M | 1 |
| Lazzaro, MA | 1 |
| Malhotra, K | 1 |
| Mohammad, YM | 1 |
| Fedorov, A | 1 |
| Chibisova, Y | 1 |
| Szymaszek, A | 1 |
| Alexandrov, M | 1 |
| Gall, C | 1 |
| Sabel, BA | 1 |
| Furuya, D | 1 |
| Takeda, H | 2 |
| Dembo, T | 2 |
| Nagoya, H | 2 |
| King, A | 1 |
| Cay, S | 1 |
| Cagirci, G | 1 |
| Aydogdu, S | 1 |
| Balbay, Y | 1 |
| Sen, N | 1 |
| Maden, O | 1 |
| Demir, AD | 1 |
| Erbay, AR | 1 |
| Tapp, LD | 1 |
| Lane, DA | 2 |
| Zheng, ZT | 1 |
| Wang, ZH | 1 |
| Li, SH | 1 |
| Topçuoglu, MA | 1 |
| Arsava, EM | 1 |
| Ay, H | 1 |
| Savage, EB | 1 |
| White, CL | 2 |
| Pearce, L | 1 |
| Pergola, P | 1 |
| Roldan, A | 2 |
| Benavente, MF | 2 |
| Coffey, C | 1 |
| Szychowski, JM | 3 |
| Heberling, PA | 1 |
| Howard, G | 2 |
| Bazan, C | 1 |
| Vidal-Pergola, G | 1 |
| Talbert, R | 1 |
| Khan, M | 5 |
| Kamal, AK | 6 |
| Lim, SH | 1 |
| Hong, BY | 1 |
| Cho, YR | 1 |
| Lee, JI | 1 |
| Kim, HW | 1 |
| Ko, YJ | 1 |
| Sharma, N | 1 |
| Meyers, JL | 1 |
| Davis, KL | 1 |
| Yu, YF | 1 |
| Röther, J | 2 |
| Guthrie, R | 1 |
| Gaillard, R | 1 |
| Mir, O | 1 |
| Gonzenbach, RR | 1 |
| Taegtmeyer, AB | 1 |
| Luft, A | 1 |
| Russmann, S | 1 |
| Nijjer, SS | 1 |
| Watson, G | 1 |
| Athanasiou, T | 1 |
| Malik, IS | 1 |
| Hwang, Y | 1 |
| Kang, W | 1 |
| Seong, SJ | 1 |
| Lim, MS | 1 |
| Lee, HW | 1 |
| Yim, DS | 1 |
| Sohn, DR | 1 |
| Han, S | 1 |
| Yoon, YR | 1 |
| Garg, N | 1 |
| Rajpurohit, N | 1 |
| Flaker, G | 2 |
| Calabrò, RS | 1 |
| Gervasi, G | 1 |
| Pollicino, P | 1 |
| Bramanti, P | 1 |
| Vidal-Jordana, A | 1 |
| Barroeta-Espar, I | 1 |
| Sáinz Pelayo, MP | 1 |
| Mateo, J | 1 |
| Delgado-Mederos, R | 1 |
| Baracchini, C | 1 |
| Gruppo, M | 1 |
| Mazzalai, F | 1 |
| Lorenzetti, R | 1 |
| Meneghetti, G | 1 |
| Ballotta, E | 1 |
| Carroll, K | 1 |
| Mono, ML | 1 |
| Geister, L | 1 |
| Galimanis, A | 1 |
| Jung, S | 1 |
| Praz, F | 1 |
| Arnold, M | 2 |
| Fischer, U | 1 |
| Wolff, S | 1 |
| Findling, O | 1 |
| Wahl, A | 1 |
| Mattle, HP | 3 |
| Nedeltchev, K | 2 |
| Romualdi, E | 1 |
| Dentali, F | 1 |
| Ageno, W | 1 |
| Awad, HH | 1 |
| Zubaid, M | 1 |
| Alsheikh-Ali, AA | 1 |
| Al Suwaidi, J | 1 |
| Anderson, FA | 1 |
| Gore, JM | 2 |
| Goldberg, RJ | 1 |
| Bhattacharya, P | 1 |
| Chen, M | 1 |
| Wei, JF | 1 |
| Xu, YN | 1 |
| Liu, XJ | 1 |
| Huang, DJ | 1 |
| Torbey, MT | 1 |
| Rideg, O | 1 |
| Magyarlaki, T | 1 |
| Shah, BR | 1 |
| Olson, DM | 1 |
| Pan, W | 1 |
| Bushnell, CD | 1 |
| Urabe, T | 1 |
| Chiu, FC | 1 |
| Wang, TD | 1 |
| Shih, FY | 1 |
| Lin, JW | 1 |
| Chen, WJ | 1 |
| Chen, MF | 1 |
| Joerg, L | 1 |
| Bridgman, C | 1 |
| Selvanayagam, JB | 1 |
| Parodi, G | 1 |
| Marcucci, R | 1 |
| Valenti, R | 1 |
| Gori, AM | 1 |
| Migliorini, A | 1 |
| Giusti, B | 1 |
| Buonamici, P | 1 |
| Gensini, GF | 1 |
| Abbate, R | 1 |
| Antoniucci, D | 1 |
| Rodríguez-Yáñez, M | 1 |
| Arias-Rivas, S | 1 |
| Fernández-Ferro, J | 1 |
| Leira, R | 1 |
| Castillo, J | 1 |
| Blanco, M | 1 |
| Ng, J | 1 |
| Hirsh, J | 1 |
| Hohnloser, S | 3 |
| Fang, MC | 2 |
| Rahme, RJ | 1 |
| Aoun, SG | 1 |
| Batjer, HH | 1 |
| Bendok, BR | 1 |
| Vinisko, R | 1 |
| French, J | 1 |
| Rosenberg, K | 1 |
| Aw, D | 1 |
| Chitose, T | 1 |
| Hokimoto, S | 1 |
| Oshima, S | 1 |
| Nakao, K | 1 |
| Fujimoto, K | 1 |
| Miyao, Y | 1 |
| Shimomura, H | 1 |
| Tsunoda, R | 1 |
| Hirose, T | 1 |
| Yamamoto, K | 1 |
| Mizobe, M | 1 |
| Kaikita, K | 1 |
| Nakamura, S | 1 |
| Ogawa, H | 1 |
| Comin, J | 1 |
| Kallmes, D | 1 |
| Overbeck, U | 1 |
| Morange, PE | 1 |
| Alessi, MC | 1 |
| Krings, T | 1 |
| Sawyer, RN | 1 |
| Radovic, V | 1 |
| Mehta, B | 1 |
| Farooq, O | 1 |
| Munschauer, FE | 1 |
| Coleman, CI | 1 |
| Straznitskas, AD | 1 |
| Sobieraj, DM | 1 |
| Kluger, J | 1 |
| Anglade, MW | 1 |
| Capodanno, D | 1 |
| Calvi, V | 1 |
| Clare, R | 1 |
| Cantor, WJ | 1 |
| Kilhamn, J | 1 |
| Wanke, I | 1 |
| Möller-Hartmann, C | 1 |
| Gizewski, ER | 1 |
| Blatchford, J | 1 |
| Forsting, M | 1 |
| Warach, S | 1 |
| Diehl, A | 1 |
| Acelajado, MC | 1 |
| Oparil, S | 1 |
| Benavente, O | 2 |
| Geeganage, CM | 1 |
| Dengler, R | 1 |
| Bath, MW | 1 |
| You, JJ | 1 |
| Howard, PA | 1 |
| Eckman, MH | 1 |
| Schulman, S | 1 |
| Hughes, M | 1 |
| Spencer, FA | 2 |
| Manning, WJ | 1 |
| Zhou, YH | 1 |
| Wei, X | 1 |
| Lu, J | 1 |
| Ye, XF | 1 |
| Wu, MJ | 1 |
| Qin, YY | 1 |
| Reisman, M | 1 |
| Massaro, J | 1 |
| Adams, H | 1 |
| Felberg, R | 1 |
| Herrmann, H | 1 |
| Kar, S | 1 |
| Landzberg, M | 1 |
| Raizner, A | 1 |
| Wechsler, L | 2 |
| Nyírő, G | 1 |
| Inczédy-Farkas, G | 1 |
| Reményi, V | 1 |
| Gál, A | 1 |
| Pál, Z | 1 |
| Molnár, MJ | 1 |
| Monti, M | 1 |
| Percoco, G | 1 |
| Castriota, F | 1 |
| Colombo, F | 1 |
| Fucà, G | 1 |
| Kubbajeh, M | 1 |
| Cangiano, E | 1 |
| Minarelli, M | 1 |
| Scalone, A | 1 |
| Cavazza, C | 1 |
| Frangione, A | 1 |
| Borghesi, M | 2 |
| Marchesini, J | 1 |
| Parrinello, G | 2 |
| Mazya, M | 1 |
| Egido, JA | 1 |
| Mikulik, R | 1 |
| Agarwal, S | 1 |
| Hachamovitch, R | 1 |
| Menon, V | 1 |
| Simonsen, KL | 1 |
| Emison, ES | 1 |
| Bhakta, N | 1 |
| Flather, MD | 4 |
| Cacoub, P | 3 |
| Creager, MA | 3 |
| Murugesan, G | 1 |
| Kottke-Marchant, K | 2 |
| Lincoff, AM | 1 |
| Pretell, EJ | 1 |
| Del Brutto, OH | 1 |
| Kase, CS | 1 |
| Arauz, A | 1 |
| Meyer, BC | 1 |
| Meissner, I | 1 |
| Demaerschalk, BM | 1 |
| Coffey, CS | 3 |
| Irby, LH | 1 |
| Peri, K | 1 |
| Pergola, PE | 1 |
| Soo, YO | 1 |
| Siu, DY | 1 |
| Abrigo, J | 1 |
| Ng, N | 1 |
| Ahuja, AT | 1 |
| Khurmi, NS | 1 |
| Keltai, M | 1 |
| Maya, J | 1 |
| Raev, D | 1 |
| Lopez-Sendon, JL | 1 |
| Chechik, O | 1 |
| Goldstein, Y | 1 |
| Behrbalk, E | 1 |
| Kaufman, E | 1 |
| Rabinovich, Y | 1 |
| Varughese, CJ | 1 |
| Tada, T | 1 |
| Natsuaki, M | 1 |
| Morimoto, T | 1 |
| Furukawa, Y | 1 |
| Nakagawa, Y | 1 |
| Kadota, K | 1 |
| Iwabuchi, M | 1 |
| Shizuta, S | 1 |
| Tazaki, J | 1 |
| Shiomi, H | 1 |
| Abe, M | 1 |
| Ehara, N | 1 |
| Mizoguchi, T | 1 |
| Mitsuoka, H | 1 |
| Inada, T | 1 |
| Araki, M | 1 |
| Kaburagi, S | 1 |
| Taniguchi, R | 1 |
| Eizawa, H | 1 |
| Nakano, A | 1 |
| Suwa, S | 1 |
| Takizawa, A | 1 |
| Nohara, R | 1 |
| Fujiwara, H | 1 |
| Mitsudo, K | 1 |
| Nobuyoshi, M | 1 |
| Kita, T | 1 |
| Thompson, VP | 1 |
| Kochman, J | 1 |
| McClure, MW | 1 |
| Gretler, DD | 1 |
| Berdan, LG | 1 |
| Paynter, G | 1 |
| Madan, M | 1 |
| French, WJ | 1 |
| Petrie, C | 1 |
| Fowler, J | 1 |
| Novak, E | 1 |
| Katzan, I | 3 |
| Bakdash, S | 1 |
| Nikolic, E | 1 |
| Janzon, M | 1 |
| Hauch, O | 1 |
| Henriksson, M | 1 |
| Dewilde, S | 1 |
| Hawkins, N | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Foody, JM | 1 |
| Funk, M | 2 |
| Alexander, KP | 2 |
| Nolin, TD | 1 |
| Geng, DF | 1 |
| Jin, DM | 1 |
| Deng, J | 1 |
| Wang, JF | 1 |
| Shevelev, VI | 2 |
| Kanorskiĭ, SG | 1 |
| Burton, TM | 1 |
| Lacey, M | 1 |
| Yu, Y | 1 |
| Monsalvo, ML | 1 |
| Lang, K | 1 |
| Rose, DZ | 1 |
| Koch, S | 1 |
| Reyes-Iglesias, Y | 1 |
| Yavagal, DR | 1 |
| Ruwald, MH | 1 |
| Hansen, CM | 1 |
| Karasoy, D | 1 |
| Lin, WH | 1 |
| Zhao, YD | 1 |
| Chen, XY | 1 |
| Marín, F | 1 |
| Ten Cate, H | 1 |
| Brenck, J | 1 |
| Meade, T | 1 |
| Ardissino, D | 3 |
| McGuire, DK | 1 |
| Parkhomenko, A | 1 |
| Topacio, GO | 1 |
| Goudev, AR | 1 |
| Tseng, CD | 1 |
| Gasparovic, V | 1 |
| Cinteză, M | 1 |
| McLendon, RC | 1 |
| Caso, V | 1 |
| Santalucia, P | 1 |
| Acciarresi, M | 1 |
| Pezzella, FR | 1 |
| Paciaroni, M | 2 |
| Rossen, JD | 1 |
| Chalouhi, N | 1 |
| Wassef, SN | 1 |
| Thomas, J | 1 |
| Abel, TJ | 1 |
| Jabbour, PM | 1 |
| Kung, DK | 1 |
| Hasan, DM | 1 |
| Fort, JG | 1 |
| Plachetka, JR | 1 |
| Cox, D | 1 |
| Collins, R | 1 |
| Vanstreels, L | 1 |
| Molenberghs, G | 1 |
| Voigt, JU | 1 |
| Coppens, M | 1 |
| Shestakovska, O | 1 |
| Paulu, P | 1 |
| Osmancik, P | 1 |
| Tousek, P | 1 |
| Minarik, M | 1 |
| Benesova, L | 1 |
| Bednar, F | 1 |
| Kocka, V | 1 |
| McGrath, RA | 1 |
| Hess, CN | 1 |
| Broderick, S | 1 |
| Newby, LK | 1 |
| Shaw, LK | 1 |
| Alexander, JH | 1 |
| Erlinge, D | 1 |
| Neely, M | 1 |
| Brown, E | 1 |
| Zhou, C | 1 |
| Jakubowski, JA | 1 |
| Wadiwala, MF | 1 |
| Salisbury, AC | 1 |
| Jones, PG | 1 |
| Spertus, JA | 1 |
| Fries, S | 1 |
| Lawson, JA | 1 |
| Kapoor, SC | 1 |
| Grant, GR | 1 |
| FitzGerald, GA | 1 |
| Song, HG | 1 |
| Kim, WJ | 1 |
| Simonsen, CZ | 1 |
| Yoo, AJ | 1 |
| Kohli, P | 1 |
| Reyes, E | 1 |
| Maurer, G | 1 |
| Kanorsky, SG | 1 |
| Michel, P | 3 |
| Bellemain-Appaix, A | 1 |
| O'Connor, SA | 1 |
| Silvain, J | 1 |
| Cucherat, M | 1 |
| Beygui, F | 1 |
| Barthélémy, O | 1 |
| Collet, JP | 1 |
| Jacq, L | 1 |
| Bernasconi, F | 1 |
| Wordsworth, DR | 1 |
| Halsey, T | 1 |
| Griffiths, R | 1 |
| Parker, MJ | 1 |
| Thomson, RM | 1 |
| Doshi, SK | 1 |
| Sievert, H | 1 |
| Buchbinder, M | 1 |
| Neuzil, P | 1 |
| Holmes, D | 1 |
| He, BS | 1 |
| Mahabaleshwarkar, RK | 1 |
| Datar, MV | 1 |
| Bentley, JP | 1 |
| Strum, MW | 1 |
| Banahan, BF | 1 |
| Null, KD | 1 |
| Warlow, C | 1 |
| Davis, SM | 3 |
| MacWalter, RS | 1 |
| Shirley, CP | 1 |
| Mann, JT | 1 |
| Fry, ET | 1 |
| DeLago, A | 1 |
| Wilmer, C | 1 |
| Ono, A | 1 |
| Fujita, T | 1 |
| Musolino, R | 1 |
| La Spina, P | 1 |
| Granata, A | 1 |
| Gallitto, G | 1 |
| Leggiadro, N | 1 |
| Carerj, S | 1 |
| Manganaro, A | 1 |
| Tripodi, F | 1 |
| Epifanio, A | 1 |
| Gangemi, S | 1 |
| Di Perri, R | 1 |
| Pollack, CV | 1 |
| Zhao, F | 3 |
| Commerford, PJ | 2 |
| Blumenthal, M | 1 |
| Wittlinger, T | 1 |
| Ornato, JP | 1 |
| Grau, AJ | 2 |
| Reiners, S | 1 |
| Lichy, C | 2 |
| Buggle, F | 2 |
| Ruf, A | 1 |
| Meyer, BJ | 1 |
| Dörffler-Melly, J | 1 |
| Schmidli, J | 1 |
| Mahler, F | 1 |
| Dogra, S | 1 |
| Kanwar, AJ | 1 |
| Gerschutz, GP | 1 |
| Jilma, B | 2 |
| Hamann, GF | 1 |
| Glahn, J | 1 |
| Busse, O | 2 |
| Lee, KM | 1 |
| Bae, HR | 2 |
| Lim, YJ | 1 |
| Cheon, SM | 1 |
| Sivenius, J | 1 |
| Ziegler, BK | 1 |
| Kristensen, SD | 1 |
| Hildebrandt, PR | 1 |
| Nielsen, HK | 1 |
| Husted, SE | 2 |
| Richardson, D | 1 |
| Kelly, M | 1 |
| Ruland, S | 2 |
| Hung, E | 1 |
| Harris, Y | 1 |
| Kittner, S | 1 |
| Leurgans, S | 1 |
| Lenz, T | 1 |
| Wilson, A | 1 |
| Wienbergen, H | 2 |
| Gitt, AK | 2 |
| Schiele, R | 1 |
| Juenger, C | 1 |
| Heer, T | 3 |
| Meisenzahl, C | 1 |
| Limbourg, P | 1 |
| Bossaller, C | 1 |
| Senges, J | 3 |
| Saw, J | 1 |
| Brennan, D | 1 |
| Shalaev, SV | 1 |
| Lewis, BS | 1 |
| Kopecky, SL | 1 |
| Valentin, V | 1 |
| Ito, E | 1 |
| Takahashi, A | 1 |
| Yamamoto, H | 1 |
| Kuzuhara, S | 1 |
| Nakajima, M | 1 |
| Christian, JB | 1 |
| Lapane, KL | 2 |
| Toppa, RS | 1 |
| Georgiadis, D | 1 |
| Bogousslavsky, J | 5 |
| Baumgartner, RW | 1 |
| Barth, A | 1 |
| van Gijn, J | 2 |
| Tendera, M | 1 |
| Wojakowski, W | 1 |
| Yamazaki, M | 2 |
| Redman, AR | 1 |
| Ryan, GJ | 1 |
| Shennib, H | 1 |
| Endo, M | 1 |
| Benhameid, O | 1 |
| Teal, PA | 1 |
| Ringleb, PA | 4 |
| Hirsch, AT | 1 |
| Cooper, HA | 1 |
| Elkind, MS | 1 |
| Brass, LM | 4 |
| Cimminiello, C | 1 |
| Matias-Guiu, J | 1 |
| Jo, WS | 1 |
| Shin, HC | 1 |
| Ho, JM | 1 |
| Kim, JW | 1 |
| Von Scheidt, W | 1 |
| Haerten, K | 1 |
| Krabbe, C | 1 |
| Raiber, M | 1 |
| Boddy, AW | 1 |
| Dukovic, DA | 1 |
| Brandt, T | 1 |
| Moonis, M | 1 |
| Fisher, M | 1 |
| Tan, KT | 1 |
| Yip, HK | 1 |
| Chen, SS | 1 |
| Liu, JS | 1 |
| Chang, HW | 1 |
| Kao, YF | 1 |
| Lan, MY | 1 |
| Chang, YY | 1 |
| Lai, SL | 1 |
| Chen, WH | 1 |
| Chen, MC | 1 |
| Schellinger, PD | 3 |
| Schwark, C | 2 |
| Helø, OH | 1 |
| Madsen, JK | 1 |
| Kastrup, J | 1 |
| Herbert, JM | 2 |
| Savi, P | 2 |
| Boucher, M | 1 |
| Pharand, C | 1 |
| Skidmore, B | 1 |
| Peters, R | 1 |
| Lakkis, N | 1 |
| Frey, JL | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Nicholls, C | 1 |
| Sani, M | 1 |
| Raman, S | 1 |
| Waldo, AL | 1 |
| Weir, NU | 1 |
| Waskowsky, WM | 1 |
| Brouwer, A | 1 |
| Eriksson, P | 2 |
| Schleinitz, MD | 1 |
| Heidenreich, PA | 1 |
| Nagy, V | 1 |
| Fehér, J | 1 |
| Lim, MJ | 1 |
| Dabbous, OH | 1 |
| Agnelli, G | 1 |
| Kline-Rogers, EM | 1 |
| Dibenedetto, D | 1 |
| Eagle, KA | 1 |
| Mehta, RH | 1 |
| Weinberger, J | 2 |
| Fletcher, S | 1 |
| Weaver, C | 1 |
| Leonardi-Bee, J | 2 |
| May, J | 1 |
| Fox, S | 1 |
| Willmot, M | 1 |
| Heptinstal, S | 1 |
| Cohen, JE | 1 |
| Ben-Hur, T | 1 |
| Rajz, G | 1 |
| Umansky, F | 1 |
| Gomori, JM | 1 |
| Schwaninger, M | 1 |
| Ascione, R | 1 |
| Ghosh, A | 1 |
| Rogers, CA | 1 |
| Cohen, A | 2 |
| Monk, C | 1 |
| Pettersen, AA | 1 |
| Seljeflot, I | 1 |
| Abdelnoor, M | 1 |
| Arnesen, H | 1 |
| Sherif, C | 1 |
| Dick, P | 2 |
| Sabeti, S | 3 |
| Mlekusch, W | 3 |
| Amighi, J | 3 |
| Ahmadi, R | 1 |
| Lalouschek, W | 2 |
| Minar, E | 3 |
| Schillinger, M | 3 |
| Droste, DW | 1 |
| Kaps, M | 1 |
| Larrue, V | 1 |
| Siebler, M | 2 |
| Ringelstein, EB | 1 |
| Morton, JA | 1 |
| Newton, J | 1 |
| Gray, CS | 1 |
| Ziegler, S | 1 |
| Felber, K | 1 |
| Exner, M | 1 |
| Brunner, M | 1 |
| Müller, M | 1 |
| Mannhalter, C | 1 |
| Hansen, DB | 2 |
| van der Meijden, PE | 1 |
| Feijge, MA | 1 |
| Giesen, PL | 1 |
| Huijberts, M | 1 |
| van Raak, LP | 1 |
| Heemskerk, JW | 1 |
| Schaerlig, E | 1 |
| Veloso, HH | 1 |
| de Paola, AA | 1 |
| Larroche, C | 1 |
| Chadenat, ML | 1 |
| Chaunu, MP | 1 |
| Abad, S | 1 |
| Casassus, P | 1 |
| Dhôte, R | 1 |
| Luk, HH | 1 |
| Pang, J | 1 |
| Li, LS | 1 |
| Ng, M | 1 |
| Biondi, A | 1 |
| Katz, JM | 1 |
| Vallabh, J | 1 |
| Segal, AZ | 1 |
| Gobin, YP | 1 |
| Gebel, JM | 1 |
| Beinart, SC | 1 |
| Kolm, P | 1 |
| Veledar, E | 1 |
| Bouin, O | 1 |
| Gabriel, S | 2 |
| Jackson, J | 1 |
| Chen, R | 1 |
| Caro, J | 1 |
| Topol, E | 1 |
| Weintraub, WS | 1 |
| Malinin, AI | 2 |
| Ziai, W | 1 |
| Pokov, AN | 1 |
| Fahey, CD | 1 |
| Bernstein, RA | 1 |
| Rothberg, M | 1 |
| Jamieson, DG | 2 |
| Parekh, A | 1 |
| Nitschmann, S | 1 |
| Hartung, HP | 1 |
| Ouriel, K | 1 |
| Wholey, MH | 1 |
| Fayad, P | 1 |
| Katzen, BT | 1 |
| Whitlow, P | 1 |
| Frentzko, M | 1 |
| Kuntz, RE | 1 |
| Hopkins, N | 1 |
| Satler, L | 1 |
| Mishkel, G | 1 |
| Yadav, JS | 3 |
| Boltuch, J | 1 |
| Schlager, O | 1 |
| Ahmadi, A | 1 |
| Blann, A | 1 |
| Ringborg, A | 1 |
| Lindgren, P | 1 |
| Jönsson, B | 1 |
| Ederhy, S | 1 |
| Meuleman, C | 1 |
| Hammoudi, N | 1 |
| Janower, S | 1 |
| Boccara, F | 1 |
| Bezerra, DC | 1 |
| Gray, L | 1 |
| Weaver, CS | 1 |
| Esagunde, RU | 1 |
| Lee, MP | 1 |
| Gan, HY | 1 |
| Wong, MC | 1 |
| Chen, CL | 1 |
| Tsivgoulis, G | 1 |
| Toulas, P | 1 |
| Sameli, S | 1 |
| Vassilopoulou, S | 1 |
| Zakopoulos, N | 1 |
| Sfagos, K | 1 |
| Hill, SL | 1 |
| Brozyna, W | 1 |
| Caplan, LR | 1 |
| Nakamura, T | 1 |
| Kimura, Y | 1 |
| Iwata, M | 1 |
| Soman, T | 1 |
| Rafay, MF | 1 |
| Hune, S | 1 |
| Allen, A | 1 |
| MacGregor, D | 1 |
| deVeber, G | 1 |
| Black, HR | 2 |
| Cohen, EA | 2 |
| Haffner, SM | 1 |
| Pearson, TA | 3 |
| Weber, MA | 2 |
| Fabry-Ribaudo, L | 2 |
| Booth, J | 1 |
| Kirmani, JF | 1 |
| Safdar, A | 1 |
| Ahmed, S | 1 |
| Sayed, MA | 1 |
| Pande, RU | 1 |
| Ferguson, R | 1 |
| Hershey, LA | 1 |
| Qazi, KJ | 1 |
| Ikeda, U | 1 |
| Calvet, D | 1 |
| Touzé, E | 1 |
| Brinker, AD | 1 |
| Swartz, L | 1 |
| Casella, G | 1 |
| Greco, C | 1 |
| Perugini, E | 1 |
| Pallotti, MG | 1 |
| Pavesi, PC | 1 |
| Di Pasquale, G | 1 |
| Hart, R | 1 |
| Assadian, A | 1 |
| Eidher, U | 1 |
| Senekowitsch, C | 1 |
| Rotter, R | 1 |
| Löchli, S | 1 |
| Hagmüller, GW | 1 |
| Knöbl, P | 1 |
| Habib, GB | 1 |
| Wallaschofski, H | 1 |
| Lohmann, T | 1 |
| Hild, E | 1 |
| Kobsar, A | 1 |
| Siegemund, A | 1 |
| Spilcke-Liss, E | 1 |
| Hentschel, B | 1 |
| Stumpf, C | 1 |
| Daniel, WG | 1 |
| Garlichs, CD | 1 |
| Eigenthaler, M | 1 |
| Walker, NE | 1 |
| Fasano, MB | 1 |
| Horwitz, PA | 1 |
| Roffi, M | 2 |
| Rabinstein, AA | 1 |
| Kamalesh, M | 1 |
| Heeg, B | 1 |
| van Gestel, A | 1 |
| Hout, Bv | 1 |
| Olsen, J | 1 |
| Haghfelt, TH | 1 |
| Lee, MS | 1 |
| Smith, SD | 1 |
| Galor, A | 1 |
| Hoffman, GS | 1 |
| Kjaer, J | 1 |
| Larsen, CH | 1 |
| Poulsen, TS | 2 |
| Møller, JE | 1 |
| Mickley, H | 1 |
| Grond, M | 1 |
| Karabatsou, K | 1 |
| Sinha, A | 1 |
| Das, K | 1 |
| Rainov, NG | 1 |
| Kramer, J | 1 |
| Abraham, J | 1 |
| Teven, CM | 1 |
| Jones, PA | 1 |
| Okada, Y | 1 |
| Ibayashi, S | 1 |
| Inoue, T | 1 |
| Yasumori, K | 1 |
| Fukui, D | 1 |
| Uwatoko, T | 1 |
| Makihara, N | 1 |
| Karpha, M | 1 |
| Krakauer, JW | 1 |
| Sechenova, O | 1 |
| Hennekens, CH | 1 |
| Cheng, Hy | 1 |
| Pamukcu, B | 1 |
| Oflaz, H | 1 |
| Onur, I | 1 |
| Oncul, A | 1 |
| Ozcan, M | 1 |
| Umman, B | 1 |
| Mercanoglu, F | 1 |
| Meric, M | 1 |
| Nisanci, Y | 1 |
| Dániel, A | 1 |
| Sacco, S | 1 |
| Carolei, A | 1 |
| Al-Bahrani, A | 1 |
| Taha, S | 1 |
| Shaath, H | 1 |
| Bakhiet, M | 1 |
| Sylaja, PN | 1 |
| Liao, JK | 1 |
| Anavekar, NS | 2 |
| Tleyjeh, IM | 1 |
| Mirzoyev, Z | 1 |
| Steckelberg, JM | 1 |
| Haddad, C | 1 |
| Khandaker, MH | 1 |
| Wilson, WR | 1 |
| Chandrasekaran, K | 1 |
| Baddour, LM | 1 |
| Aronow, WS | 1 |
| Spiesser, J | 1 |
| Hakimi, Z | 1 |
| Bego, G | 1 |
| Carita, P | 1 |
| Hu, T | 2 |
| Kikano, GE | 1 |
| Brown, MT | 1 |
| Hilgevoord, AA | 1 |
| de Vries, JP | 1 |
| van der Mee, M | 1 |
| Moll, FL | 1 |
| van de Pavoordt, HD | 1 |
| Ackerstaff, RG | 1 |
| Macdonald, S | 1 |
| Badimon, JJ | 1 |
| Emre, U | 1 |
| Rantanen, K | 1 |
| Tatlisumak, T | 1 |
| Wang, TH | 1 |
| Helton, TJ | 1 |
| Bavry, AA | 1 |
| Kumbhani, DJ | 1 |
| Duggal, S | 1 |
| Roukoz, H | 1 |
| Fintel, DJ | 1 |
| Kirshner, HS | 1 |
| Zahn, R | 2 |
| Jünger, C | 2 |
| Bauer, T | 2 |
| Köth, O | 1 |
| Gottwik, M | 2 |
| Ryckborst, KJ | 1 |
| Eliasziw, M | 1 |
| Bernardo, E | 1 |
| Sabaté, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Costa, MA | 1 |
| Palazuelos, J | 1 |
| Hernández-Antolin, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Guzman, LA | 1 |
| Macaya, C | 1 |
| Fernandez-Ortiz, A | 1 |
| Schmaier, AH | 1 |
| Hassan, AE | 1 |
| Zacharatos, H | 1 |
| Riesmeyer, J | 1 |
| Pajitnev, D | 1 |
| Salzman, BE | 1 |
| Gitt, A | 1 |
| Koeth, O | 1 |
| Mark, B | 1 |
| Müller-Schunk, S | 1 |
| Linn, J | 1 |
| Peters, N | 1 |
| Spannagl, M | 1 |
| Deisenberg, M | 1 |
| Brückmann, H | 1 |
| Mayer, TE | 1 |
| Gengo, FM | 1 |
| Rainka, M | 1 |
| Robson, M | 1 |
| Gengo, MF | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Bates, V | 1 |
| Ryding, AD | 1 |
| Banning, AP | 1 |
| Reaume, KT | 1 |
| Regal, RE | 1 |
| Dorsch, MP | 1 |
| Adams, RJ | 1 |
| Albers, G | 1 |
| Furie, K | 1 |
| Halperin, J | 1 |
| Harbaugh, R | 1 |
| Kelly-Hayes, M | 1 |
| Kenton, EJ | 1 |
| Marks, M | 1 |
| Hills, NK | 1 |
| Helgason, CM | 1 |
| Grossi, E | 1 |
| Pandey, D | 1 |
| Valika, A | 1 |
| Cursio, J | 1 |
| Brace, LD | 1 |
| Schwartz, NE | 1 |
| Cornett, O | 1 |
| Ocava, LC | 1 |
| Singh, M | 1 |
| Malhotra, S | 1 |
| Rosenbaum, DM | 1 |
| Alvarez, W | 1 |
| Akyuz, A | 1 |
| Bolayir, E | 1 |
| Dener, S | 1 |
| Topalkara, K | 1 |
| Topaktas, S | 1 |
| Harker, LA | 1 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Gent, M | 1 |
| Bennett, CL | 1 |
| Davidson, CJ | 1 |
| Raisch, DW | 1 |
| Weinberg, PD | 1 |
| Bennett, RH | 1 |
| Feldman, MD | 1 |
| Stam, J | 1 |
| Vermeulen, M | 1 |
| Overell, JR | 1 |
| Weir, CJ | 1 |
| Walker, A | 1 |
| Niclot, P | 1 |
| Rasmussen, PA | 1 |
| Perl, J | 1 |
| Barr, JD | 1 |
| Markarian, GZ | 1 |
| Sila, C | 1 |
| Krieger, D | 1 |
| Masaryk, TJ | 1 |
| Dunbabin, DW | 2 |
| Holroyd-Leduc, JM | 1 |
| Austin, PC | 1 |
| Tu, JV | 1 |
| Gondek, K | 1 |
| Sarasin, FP | 1 |
| Gaspoz, JM | 1 |
| Bounameaux, H | 1 |
| Niessen, LW | 1 |
| Dippel, DW | 1 |
| Limburg, M | 1 |
| Gallai, V | 1 |
| Brown, MM | 1 |
| Devuyst, G | 1 |
| Weksler, BB | 1 |
| Tsai, MH | 1 |
| Tsai, SL | 1 |
| Chen, TC | 1 |
| Liaw, YF | 1 |
| Mitka, M | 1 |
| Scheen, AJ | 1 |
| Ernst, ME | 1 |
| Zauner, C | 1 |
| Funk, GC | 1 |
| Birnbacher, R | 1 |
| Quilliam, BJ | 1 |
| Nair, GV | 1 |
| Davis, CJ | 1 |
| McKenzie, ME | 1 |
| Lowry, DR | 1 |
| Olson, J | 1 |
| Huntington, J | 1 |
| Majid, A | 1 |
| Delanty, N | 1 |
| Kantor, J | 1 |
| Kapadia, SR | 1 |
| Bajzer, CT | 1 |
| Chew, DP | 1 |
| Ziada, KM | 1 |
| Mukherjee, D | 1 |
| Lang, W | 1 |
| Müllner, M | 1 |
| Borrás-Blasco, J | 1 |
| Navarro-Ruiz, A | 1 |
| Gutiérrez-Casbas, A | 1 |
| Matarredona-Catalá, J | 1 |
| González-Delgado, M | 1 |
| Tufano, A | 1 |
| Cerbone, AM | 1 |
| Doggrell, SA | 1 |
| Undas, A | 1 |
| Bazan-Socha, S | 1 |
| Swadzba, J | 1 |
| Musial, J | 1 |
| Pettigrew, LC | 1 |
| Williams, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke.[NCT02506140] | Phase 2/Phase 3 | 675 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227] | Phase 4 | 3,773 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Comparison of Efficacy and Safety Between Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk[NCT02960126] | Phase 3 | 1,500 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI[NCT01959451] | Phase 4 | 2,600 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052] | Phase 4 | 634 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease[NCT01732822] | Phase 3 | 13,885 participants (Actual) | Interventional | 2012-12-04 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889] | Phase 3 | 516 participants (Anticipated) | Interventional | 2023-11-09 | Recruiting | ||
| Comparison of Clinical Outcomes After Left Atrial Appendage Closure or Oral Anticoagulation in Patients With Atrial Fibrillation: A Retrospective Propensity Matched Study[NCT02787525] | 1,000 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536] | Phase 4 | 1,798 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| China Registry of Non-disabling Ischemic Cerebrovascular Events: A Prospective Multi-center, National Registry Trail[NCT03079674] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2017-06-01 | Not yet recruiting | |||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study[NCT05644314] | 144 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Randomised Controlled Prospective Trial of Early Administration of Aspirin After Systemic Thrombolysis in Acute Ischemic Stroke[NCT02921360] | 120 participants (Anticipated) | Interventional | 2016-08-31 | Active, not recruiting | |||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke[NCT05369533] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2022-08-01 | Active, not recruiting | ||
| A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700] | 78,000 participants (Actual) | Observational | 2006-01-31 | Active, not recruiting | |||
| The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry[NCT02521038] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-07-31 | Recruiting | |||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis[NCT00576693] | Phase 3 | 451 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Stroke Imaging Package Study of Intracranial Atherosclerosis[NCT03719820] | 550 participants (Anticipated) | Observational [Patient Registry] | 2018-11-14 | Recruiting | |||
| Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging[NCT05907629] | 300 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| Evolocumab Added to Statin Therapy in Patients With Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)---a Pilot Study[NCT05741086] | Phase 3 | 80 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | ||
| China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China[NCT01763320] | Phase 3 | 380 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery[NCT00235248] | Phase 3 | 350 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry[NCT02264912] | 2,016 participants (Actual) | Observational [Patient Registry] | 2008-07-31 | Completed | |||
| Comparison of Dual-Antiplatelet and Triple-Antiplatelet Preparation Using P2Y12 Assay in Patients With High On-Treatment Platelet Reactivity Undergoing Stent-Assisted Coil Embolization for An Unruptured Intracranial Aneurysm[NCT03581409] | Phase 4 | 198 participants (Actual) | Interventional | 2018-10-24 | Completed | ||
| Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling of Unruptured Intracranial Aneurysms: A Prospective Randomized Multicenter Trial[NCT05257824] | Phase 4 | 528 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | ||
| Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709] | Phase 4 | 7 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236] | 150 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00661206] | Phase 4 | 4,005 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| An Open-label, Randomized, Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes[NCT02944123] | Phase 3 | 120 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Prospective, Randomized, Open-Label, Multicenter Study Assessing Efficacy and Safety of Ticagrelor De-escalation Strategy in East Asian Acute Myocardial Infarction With Coronary Intervention: EASTYLE Trial[NCT04755387] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2021-02-15 | Recruiting | ||
| MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting[NCT05566301] | 1,140 participants (Anticipated) | Observational | 2021-09-02 | Recruiting | |||
| Carotid Stenosis Management During COVID-19 Era - Best Medical Intervention Alone (CASCOM Pilot Study): A Prospective Observational Study[NCT04947046] | 120 participants (Anticipated) | Observational | 2020-03-11 | Recruiting | |||
| Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping[NCT01174693] | Phase 4 | 795 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281] | 1,079 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial[NCT00814268] | Phase 4 | 358 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome[NCT01088503] | 12,227 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890] | Phase 4 | 510 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)[NCT00086450] | Phase 3 | 1,900 participants (Actual) | Interventional | 2004-04-30 | Active, not recruiting | ||
| The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance[NCT01925872] | 2,000 participants (Anticipated) | Observational | 2013-05-31 | Enrolling by invitation | |||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Stent For Life Observatory[NCT01251198] | 460 participants (Actual) | Observational | 2010-11-30 | Completed | |||
| French Registry of Acute Coronary Syndrome With or Without ST Elevation[NCT00673036] | 3,750 participants (Actual) | Observational | 2005-10-31 | Active, not recruiting | |||
| Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome[NCT01994941] | Phase 4 | 133 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| French Cohort of Myocardial Infarction Evaluation[NCT04050956] | 15,000 participants (Anticipated) | Observational | 2019-03-11 | Recruiting | |||
| French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010[NCT01237418] | 3,700 participants (Anticipated) | Observational | 2010-10-31 | Active, not recruiting | |||
| Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients[NCT02707445] | 5,000 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514] | 4,471 participants (Actual) | Observational | 2009-10-31 | Terminated (stopped due to Administrative reasons) | |||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.[NCT01611545] | 130 participants (Actual) | Observational | 2012-06-30 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)[NCT00007683] | Phase 3 | 1,587 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873] | Phase 3 | 7,554 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease[NCT02110303] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes - the TC4 Comparative Effectiveness Study[NCT04057300] | Phase 4 | 1,038 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| CARDIOBASE Bern PCI Registry[NCT02241291] | 10,000 participants (Anticipated) | Observational | 2009-03-31 | Recruiting | |||
| A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow[NCT03654157] | 1,576 participants (Actual) | Observational | 2018-03-25 | Completed | |||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention[NCT04999293] | 1,505 participants (Actual) | Observational | 2021-07-20 | Completed | |||
| A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients[NCT02430493] | 1,066 participants (Actual) | Observational [Patient Registry] | 2015-05-28 | Completed | |||
| Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome[NCT04937699] | Phase 4 | 2,690 participants (Anticipated) | Interventional | 2023-03-28 | Recruiting | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Follow up of Ticagrelor Treatment Patterns in Chinese Acute Coronary Syndromes Patients- A Database Retrospective Study[NCT04861363] | 20,000 participants (Anticipated) | Observational | 2019-06-19 | Enrolling by invitation | |||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events[NCT02291419] | Phase 4 | 6 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Enrollment expectations were not met) | ||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study[NCT01660373] | Phase 3 | 100 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events[NCT00484926] | Phase 4 | 2,000 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events[NCT00590174] | Phase 4 | 1,175 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250] | Phase 4 | 800 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574] | 84 participants (Actual) | Observational | 2019-02-26 | Completed | |||
| TEC4Home Stroke - Assessing the Feasibility of Home Telemonitoring Technology in Managing Hypertension Among Stroke/TIA Patients. Pilot Study at Vancouver Stroke Program in Collaboration With TEC4Home Heart Failure Team[NCT03712033] | 50 participants (Actual) | Observational | 2018-03-01 | Completed | |||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Intracranial Stenting in Non-acute Symptomatic Ischemic Stroke: an Open-label, Randomised Controlled Trial[NCT05063630] | 300 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | |||
| Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial[NCT01994161] | 840 participants (Anticipated) | Observational [Patient Registry] | 2012-12-31 | Recruiting | |||
| Wingspan One Year Vascular Imaging Events and Neurologic Outcomes (WOVEN)[NCT04221984] | 129 participants (Actual) | Observational [Patient Registry] | 2019-11-12 | Completed | |||
| Registry of Emergent Large veSsel oCclUsion duE to IntraCranial AtherosclerosiS[NCT05403593] | 600 participants (Anticipated) | Observational [Patient Registry] | 2021-12-15 | Recruiting | |||
| A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Maurora® Sirolimus-Eluting Stent Versus the Apollo Stent in Intracranial Atherosclerotic Stenosis(Maurora ICAS Trial)[NCT05719883] | 156 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | |||
| Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)[NCT00004732] | 2,502 participants (Actual) | Interventional | 2000-12-31 | Completed | |||
| Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)[NCT04948749] | 792 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | |||
| The Effect of Early Administration of PCSK9 Inhibitor, Alirocumab to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile, a Single Center Study, Registry Based, Pragmatic, Prospective Trial[NCT06083961] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | ||
| 150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention[NCT00638326] | Phase 3 | 500 participants (Anticipated) | Interventional | 2008-03-31 | Terminated (stopped due to Greater differences between randomized patients than previously anticipated) | ||
| REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry[NCT01231035] | 1,789 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.[NCT02380391] | 260 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.[NCT01843361] | 159 participants (Actual) | Observational | 2010-07-31 | Completed | |||
| Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744] | 3,400 participants (Anticipated) | Interventional | 2018-01-31 | Not yet recruiting | |||
| Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777] | 4,162 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838] | 1,200 participants (Anticipated) | Observational | 2023-08-09 | Recruiting | |||
| A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism [NCT00201461] | Phase 2/Phase 3 | 900 participants (Anticipated) | Interventional | 2003-06-30 | Active, not recruiting | ||
| Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594] | 100 participants (Anticipated) | Observational | 2020-10-01 | Recruiting | |||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.[NCT02084615] | 300 participants (Anticipated) | Interventional | 2014-08-31 | Enrolling by invitation | |||
| A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI[NCT00751231] | Phase 2 | 652 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Mechanism Based Resistance to Aspirin[NCT00948987] | Phase 1 | 400 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| [NCT02937025] | Phase 1/Phase 2 | 154 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)[NCT00129545] | Phase 2/Phase 3 | 800 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212] | 2,931 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-10-13 | Completed | ||
| Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794] | 300 participants (Actual) | Observational [Patient Registry] | 2018-03-14 | Completed | |||
| Feasibility and Prognostic Role of Percutaneous Left Atrial Appendage Closure in Patients With Heart Failure and Atrial Fibrillation at High Risk for Cerebrovascular Events[NCT04472871] | 300 participants (Anticipated) | Observational | 2020-07-20 | Not yet recruiting | |||
| Influence of the Compression Method After Transradial Catheterization in Radial Artery[NCT02697526] | 274 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Platelet Function in Resuscitated Patients[NCT02914795] | 99 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups[NCT01645306] | Phase 2 | 158 participants (Actual) | Interventional | 2013-03-08 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00243178] | Phase 3 | 6,706 participants (Actual) | Interventional | 2003-07-31 | Terminated | ||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)[NCT00109382] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2003-05-31 | Completed | ||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 117 |
| Clopidogrel 75 mg od | 115 |
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 628 |
| Clopidogrel 75 mg od | 635 |
Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 179 |
| Clopidogrel 75 mg od | 208 |
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1211 |
| Clopidogrel 75 mg od | 1250 |
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg bd | 751 |
| Clopidogrel 75 mg od | 740 |
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 766 |
| Clopidogrel 75 mg od | 759 |
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 839 |
| Clopidogrel 75 mg od | 833 |
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 363 |
| Clopidogrel 75 mg od | 343 |
Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1312 |
| Clopidogrel 75 mg od | 1314 |
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 846 |
| Clopidogrel 75 mg od | 892 |
Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 100 |
| Clopidogrel 75 mg od | 116 |
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 349 |
| Clopidogrel 75 mg od | 334 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1119 |
| Clopidogrel 75 mg od | 1140 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1183 |
| Clopidogrel 75 mg od | 1199 |
Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 983 |
| Clopidogrel 75 mg od | 992 |
Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 789 |
| Clopidogrel 75 mg od | 786 |
Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 250 |
| Clopidogrel 75 mg od | 272 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 206 |
| Clopidogrel 75 mg od | 188 |
Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 168 |
| Clopidogrel 75 mg od | 112 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 113 |
| Clopidogrel 75 mg od | 109 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 193 |
| Clopidogrel 75 mg od | 175 |
"Change in ankle brachial index (ABI) / toe brachial index (TBI).~Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD):~Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: <0.4~Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used:~Normal: >0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: <0.35 and toe pressure 40 mmHg Severe: <0.35 and toe pressure < 30 mmHg" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Change in ABI/TBI (Mean) | |||
|---|---|---|---|---|
| ABI - 6 months N = 6184(Tica), 6319(Clopi) | ABI - End of treatment N = 4951(Tica), 5073(Clopi) | TBI - 6 months N = 55(Tica), 48(Clopi) | TBI - End of treatment N = 36(Tica), 21(Clopi) | |
| Clopidogrel 75 mg od | 0.011 | 0.016 | 0.036 | -0.065 |
| Ticagrelor 90 mg bd | 0.016 | 0.022 | 0.050 | 0.059 |
"Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage.~Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | |||||
|---|---|---|---|---|---|---|
| Stage I - End of treatment | Stage IIa - End of treatment | Stage IIb - End of treatment | Stage III - End of treatment | Stage IV - End of treatment | Missing - End of treatment | |
| Clopidogrel - Stage I | 743 | 230 | 56 | 9 | 4 | 250 |
| Clopidogrel - Stage IIa | 723 | 1956 | 311 | 15 | 7 | 724 |
| Clopidogrel - Stage IIb | 198 | 557 | 450 | 23 | 10 | 370 |
| Clopidogrel - Stage III | 33 | 33 | 38 | 23 | 5 | 60 |
| Clopidogrel - Stage IV | 19 | 21 | 15 | 12 | 13 | 45 |
| Ticagrelor - Stage I | 775 | 227 | 45 | 7 | 7 | 248 |
| Ticagrelor - Stage IIa | 683 | 1948 | 269 | 24 | 7 | 743 |
| Ticagrelor - Stage IIb | 171 | 560 | 469 | 12 | 5 | 403 |
| Ticagrelor - Stage III | 15 | 41 | 39 | 31 | 1 | 59 |
| Ticagrelor - Stage IV | 26 | 28 | 19 | 7 | 13 | 47 |
"Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification.~Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.~Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Category 0 - End of treatment | Category 1/2 - End of treatment | Category 3 - End of treatment | Category 4 - End of treatment | Category 5 - End of treatment | Category 6 - End of treatment | Missing - End of treatment | |
| Clopidogrel - Cat 0 | 743 | 230 | 56 | 9 | 2 | 2 | 250 |
| Clopidogrel - Cat 1/2 | 723 | 1956 | 311 | 15 | 6 | 1 | 724 |
| Clopidogrel - Cat 3 | 198 | 557 | 450 | 23 | 6 | 4 | 370 |
| Clopidogrel - Cat 4 | 33 | 33 | 38 | 23 | 4 | 1 | 60 |
| Clopidogrel - Cat 5 | 13 | 18 | 12 | 11 | 12 | 0 | 34 |
| Clopidogrel - Cat 6 | 6 | 3 | 3 | 1 | 1 | 0 | 11 |
| Ticagrelor - Cat 0 | 775 | 227 | 45 | 7 | 5 | 2 | 248 |
| Ticagrelor - Cat 3 | 171 | 560 | 469 | 12 | 3 | 2 | 403 |
| Ticagrelor - Cat 4 | 15 | 41 | 39 | 31 | 1 | 0 | 59 |
| Ticagrelor - Cat 5 | 23 | 23 | 13 | 4 | 11 | 0 | 33 |
| Ticagrelor - Cat 6 | 3 | 5 | 6 | 3 | 0 | 2 | 14 |
| Ticagrelor - Stage II | 683 | 1948 | 269 | 24 | 4 | 3 | 743 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
Any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days after enrollment OR any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, OR an ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up. (NCT00576693)
Timeframe: Mean length of follow-up was 2.4 years
| Intervention | participants (Number) |
|---|---|
| Intensive Medical Management Plus Stenting | 52 |
| Intensive Medical Management Alone | 34 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
The Duke CAD Index is a validated composite measure of angiographic burden, which assigns prognostic weights 1 through 100. Higher scores indicate greater angiographic burden and are associated with poorer prognosis. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | units on a scale (Mean) |
|---|---|
| Prasugrel | 40.36 |
| Other | 41.87 |
(NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | grams/deciliter (g/dL) (Mean) |
|---|---|
| Prasugrel | 14.59 |
| Other | 14 |
Academic Research Consortium (ARC) criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least 1 of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with ST events are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a definite or probable ST event. (NCT01088503)
Timeframe: Baseline through 15 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 1.35 |
| Clopidogrel | 1.79 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participant = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 12.67 |
| Clopidogrel | 15.89 |
MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events in 12 months/ number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 13.14 |
| Clopidogrel | 17.12 |
Factors are drug-eluting stent (DES) vs. bare metal stent (BMS) placement, other (no stent) vs. BMS, STEMI, other race, cardiogenic shock occurred within 24 hours, male, European Quality of Life Questionnaire-5 Dimension Health State Score (EQ-5D) - United States (US) Index =1 vs. <1, married, diabetes, and other vs. BMS placement. The EQ-5D US index is a participant-rated, health-related, quality-of-life instrument based on US population. Scores range from -0.11 to 1.0 with 1.0 = perfect health. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Received DES | Received only BMS | STEMI | Other Race (Non-Caucasian) | Cardiogenic Shock on Presentation | Male Participants | EQ-5D US index = 1 vs. <1 | Married Participants | Participant has Diabetes | No BMS or DES | |
| Other | 6282 | 2491 | 4508 | 1049 | 176 | 6342 | 3873 | 5601 | 2472 | 331 |
| Prasugrel | 2365 | 672 | 1831 | 365 | 79 | 2451 | 1516 | 2044 | 767 | 86 |
Bleeding events were collected utilizing the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition of bleeding. Non-coronary artery bypass grafting (CABG)-related GUSTO severe or life-threatening bleeding is any intracranial hemorrhage (ICH) OR any bleeding event resulting in substantial hemodynamic compromise requiring treatment. Non-CABG-related GUSTO moderate bleeding is any bleeding event resulting in the need for transfusion that is not considered a GUSTO severe or life-threatening bleed. Additional bleeding events are fatal bleeding or ICH, or any non -fatal surgical-related bleeding events leading to ≥4 units of red cell transfusion. Observed (unadjusted) percentages of participants with bleeding events, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline, 1, 6, 12 and 15 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline | 1 month | 6 months | 12 months | 15 months | |
| Clopidogrel | 0.45 | 1.62 | 2.77 | 3.86 | 4.21 |
| Prasugrel | 0.54 | 1.22 | 1.93 | 2.72 | 3.10 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a MACE event. (NCT01088503)
Timeframe: Baseline through 1, 6 and 15 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 1 month | 6 months | 15 months | |
| Clopidogrel | 5.40 | 12.04 | 19.13 |
| Prasugrel | 4.63 | 9.64 | 14.26 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
median 3.8 years of follow-up (NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 26.6 |
| Coronary Artery Bypass Graft | 18.7 |
(NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.3 |
| Coronary Artery Bypass Graft | 10.9 |
(NCT00086450)
Timeframe: Measured at Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.8 |
| Coronary Artery Bypass Graft | 11.8 |
Major adverse cardiovascular and cerebrovascular events (NCT00086450)
Timeframe: Measured at Day 30
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 4.8 |
| Coronary Artery Bypass Graft | 5.2 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 251 |
| Placebo + ASA | 162 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 825 |
| Placebo + ASA | 841 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 296 |
| Placebo + ASA | 408 |
"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Non-CNS systemic embolism | - Vascular death | |
| Clopidogrel + ASA | 832 | 84 | 285 | 50 | 413 |
| Placebo + ASA | 924 | 105 | 391 | 48 | 380 |
Time to first occurence of All-cause death. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of Cardiovascular death. The number of patients with events was reported. (NCT02291419)
Timeframe: Up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of the composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Coronary Revascularization or Non-fatal Stroke. The number of patients with events is reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of Non-fatal myocardial infarction or coronary revascularization. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of Non-fatal stroke. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
(NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
The primary aim of CREST is to assess if the efficacy of CAS differs from that of CEA in preventing stroke, myocardial infarction and death during a 30-day peri-procedural period, or ipsilateral stroke over the follow-up period in patients with symptomatic (>=50%) or asymptomatic (>=60%) extracranial carotid stenosis. Four-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 30 days and 4 years
| Intervention | Percentage (Mean) |
|---|---|
| Carotid-Artery Stenting | 7.2 |
| Carotid Endarterectomy | 6.8 |
4-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 4 years
| Intervention | Percentage (Mean) | |
|---|---|---|
| Men | Women | |
| Carotid Endarterectomy | 6.8 | 6.7 |
| Carotid-Artery Stenting | 6.2 | 8.9 |
A Bayesian model allowed for sequential evaluation of the primary endpoints, event rates reported per 100 patient-years (calculated as 100*N events/Total patient-years) (NCT00129545)
Timeframe: 5 years
| Intervention | events per 100 pt yrs (Number) |
|---|---|
| Implantable Device | 2.2 |
| Warfarin Control | 3.7 |
Implant procedure success is defined as the delivery and release of a WATCHMAN Device into the LAA. (NCT00129545)
Timeframe: Initial implant procedure
| Intervention | percentage of implant attempts (Number) |
|---|---|
| WATCHMAN | 90.9 |
Serious bleeding events evaluated by the Clinical Events Committee included pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion, and any bleeding related to the device or procedure that necessitates an operation. (NCT00129545)
Timeframe: 5 years
| Intervention | Events per 100 pt-yrs (Number) |
|---|---|
| Implantable Device | 3.5 |
| Warfarin Control | 3.2 |
(NCT02914795)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Non-resuscitated Myocardial Infarction | 0 |
| Resuscitated Myocardial Infarction | 3 |
Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3
| Intervention | AU*min (Median) |
|---|---|
| Non-resuscitated Myocardial Infarction | 109 |
| Resuscitated Myocardial Infarction | 253.8 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
"Anti-drug antibodies were measured at baseline and 3 month after IMP application.~Number of patients with positive anti-drug antibodies compared to baseline are counted." (NCT01645306)
Timeframe: 3 month (+/- 1 month) after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| 40 mg Revacept | 0 |
| 120 mg Revacept | 0 |
patients with any stroke & TIA, myocardial infarction & percutaneous coronary intervention (PCI), death or bleeding within one year (365 days) after IMP application. (NCT01645306)
Timeframe: 365 days after IMP application
| Intervention | Number of Events (Number) |
|---|---|
| Placebo | 19 |
| 40 mg Revacept | 15 |
| 120 mg Revacept | 10 |
patients with major bleedings occuring within 90 days after IMP application (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
The number of new diffusion weighted imaging (DWI) lesion(s) reported. (1 day after intervention compared to baseline). (NCT01645306)
Timeframe: 1 day post intervention
| Intervention | Number of new lesions (Mean) |
|---|---|
| Placebo | 1.2 |
| 40 mg Revacept | 1.0 |
| 120 mg Revacept | 0.6 |
patients with any stroke or TIA occuring within 90 days after IMP application. (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 6 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
All adverse events were assessed during complete study period (~ 1 year after IMP application). (NCT01645306)
Timeframe: ~ 365 days after IMP application (whole study period)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| patients with adverse events | patients with drug related AEs | patients with serious AEs | patients with drug related serious AEs | patients with AE with fatal outcome events | |
| 120 mg Revacept | 32 | 2 | 15 | 0 | 1 |
| 40 mg Revacept | 41 | 10 | 17 | 4 | 0 |
| Placebo | 35 | 4 | 17 | 1 | 0 |
209 reviews available for ticlopidine and Apoplexy
| Article | Year |
|---|---|
The role of
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Ischemic Attack, Transient; Ischemic Stroke | 2022 |
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggre | 2022 |
[Optimal antiplatelet strategy in patients with high-risk transient ischemic attack and minor ischemic stroke].
Topics: Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticlopi | 2019 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients.
Topics: Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Ethnicity; Humans; Myocardia | 2021 |
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis.
Topics: Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation | 2017 |
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2017 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Plat | 2017 |
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; | 2017 |
Recurrent Ischemic Stroke: Strategies for Prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; P | 2017 |
Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Administration Schedule | 2018 |
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; | 2018 |
Triple therapy: worth the risk?
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitor | 2018 |
Pharmacogenetics of Stroke.
Topics: Anticoagulants; Drug Therapy, Combination; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors | 2018 |
[TREATMENT WITH DUAL ANTIPLATELET THERAPY FOR SECONDARY PREVENTION OF STROKE - PROS AND CONS].
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; S | 2018 |
Diagnosis and management of carotid atherosclerosis.
Topics: Carotid Artery Diseases; Carotid Artery, Common; Clopidogrel; Endarterectomy, Carotid; Female; Human | 2013 |
Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Cytochrom | 2013 |
Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Dr | 2013 |
Effect of addition of clopidogrel to aspirin on stroke incidence: Meta-analysis of randomized trials.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; | 2015 |
Pharmacokinetic considerations for antithrombotic therapies in stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor | 2013 |
Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy.
Topics: Angioscopy; Aspirin; Carotid Artery Diseases; Clinical Protocols; Clopidogrel; Drug Therapy, Combina | 2013 |
[Secondary prevention with clopidogrel after TIA or stroke].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; N | 2013 |
The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review.
Topics: Aspirin; Bleeding Time; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human | 2013 |
The challenge of stroke prevention with intracranial arterial stenosis.
Topics: Aspirin; Carotid Artery, Common; Carotid Stenosis; Clopidogrel; Constriction, Pathologic; Drug Thera | 2013 |
Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Mal | 2013 |
Ticagrelor for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Human | 2013 |
Antiplatelet therapy to prevent recurrent stroke: Three good options.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Secon | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studie | 2014 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dru | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coro | 2014 |
Oral antiplatelet therapy for acute ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlle | 2014 |
Successful gestation and delivery using clopidogrel for secondary stroke prophylaxis: a case report and literature review.
Topics: Adult; Clopidogrel; Delivery, Obstetric; Female; Humans; Infant, Newborn; Ischemic Attack, Transient | 2014 |
Stroke: transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Clopidogrel; Diffusion Magnetic Resonance I | 2014 |
Risk of stroke in patients with high on-clopidogrel platelet reactivity to adenosine diphosphate after percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Global Health | 2014 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.
Topics: Animals; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticlopid | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Safety; Strok | 2014 |
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2014 |
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarc | 2015 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2014 |
Patients with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and concerns: part I.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; He | 2015 |
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2015 |
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre | 2015 |
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Evidence-Based Medicine; Hemorrhage; Hum | 2015 |
Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Fem | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheteriz | 2015 |
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug | 2015 |
Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications.
Topics: Antiplatyhelmintic Agents; Aspirin; Brain Ischemia; Clopidogrel; Evidence-Based Medicine; Humans; St | 2015 |
Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Stroke; Ticlopidine | 2015 |
Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Humans; Platel | 2015 |
Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Gastrointestinal Hemorrhag | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic | 2015 |
Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Corona | 2015 |
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At | 2015 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2016 |
[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation].
Topics: Administration, Oral; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Hemorrhage; Humans; | 2016 |
Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hy | 2016 |
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Databases, Factual; Genotype; Humans; Ischemic Attac | 2017 |
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Databases, Factual; Genotype; Humans; Ischemic Attac | 2017 |
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Databases, Factual; Genotype; Humans; Ischemic Attac | 2017 |
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Databases, Factual; Genotype; Humans; Ischemic Attac | 2017 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Clopidogrel in secondary ischemic stroke prevention.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Evidence- | 2008 |
Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2008 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance; | 2008 |
The approach to optimizing stroke care.
Topics: Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Emergenc | 2008 |
Combination antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat | 2008 |
Digestion of the antiplatelets comparison of PRoFESS: 18-7=1?
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Mi | 2009 |
Multifunctional actions of approved and candidate stroke drugs.
Topics: Albumins; Animals; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Cytidine Diphospha | 2009 |
What's new in stroke? The top 10 studies of 2006-2008. Part I.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
Antiplatelet agents for prevention of recurrent ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practic | 2009 |
Antiplatelet drugs for ischemic stroke prevention.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; | 2009 |
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
Topics: Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Com | 2009 |
Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, | 2009 |
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I | 2009 |
Antiplatelet treatment in ischemic stroke treatment.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2009 |
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Cost- | 2010 |
Antiplatelets and stroke outcomes: state of the science.
Topics: Arachidonic Acid; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Clopidogrel; Dipy | 2009 |
Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Topics: American Heart Association; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; I | 2010 |
Advances in antiplatelet therapy for stroke prevention: the new P2Y12 antagonists.
Topics: Animals; Clopidogrel; Drug Delivery Systems; Drug Design; Drug Resistance; Humans; Platelet Aggregat | 2010 |
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.
Topics: Age Factors; Atrial Fibrillation; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregatio | 2010 |
Economy class syndrome complicated by stroke: a rare condition due to paradoxical embolism--a case report and review of the literature.
Topics: Aircraft; Anticoagulants; Aspirin; Clopidogrel; Echocardiography; Embolism, Paradoxical; Foramen Ova | 2011 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Human | 2011 |
[New aspects on "triple therapy" after coronary stent implantation].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; | 2010 |
Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Second | 2010 |
Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Cytoc | 2010 |
Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke.
Topics: Administration, Oral; Anticoagulants; Clopidogrel; Dipyridamole; Humans; Intestinal Absorption; Plat | 2010 |
Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.
Topics: Anticoagulants; Clopidogrel; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse R | 2011 |
Oral antiplatelet therapy in stroke prevention. Minireview.
Topics: Administration, Oral; Aspirin; Clopidogrel; Dipyridamole; Drug Combinations; Humans; Ischemic Attack | 2010 |
Current status of antiplatelet agents to prevent stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2011 |
The role of antithrombotics in secondary stroke prevention.
Topics: Anticoagulants; Clopidogrel; Cyclooxygenase Inhibitors; Fibrinolytic Agents; Humans; Phosphodiestera | 2010 |
"Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Heart Disease | 2011 |
Antiplatelet resistance in stroke.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Resistance; Humans; P | 2011 |
Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Aspirin; Chronic Disease; Clopidogrel; Delayed-Act | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clop | 2011 |
Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies.
Topics: Acute Coronary Syndrome; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Critical Care; Fema | 2011 |
Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Clinical Trials as Topic; Clopidogrel; Humans; Male; M | 2012 |
Clopidogrel hydrogen sulphate for atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platel | 2011 |
Statins for acute ischemic stroke.
Topics: Atorvastatin; Cause of Death; Clopidogrel; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reduct | 2011 |
New insights in antiplatelet therapy for patients with ischemic stroke.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; I | 2011 |
A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Data Interpretation, Statistical; Drug Interactions; Endpoint | 2012 |
[New clinical concept and therapeutic strategy for TIA].
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diffusion Magnetic Resonance Imaging; Humans; Ischemic Attac | 2010 |
[Clopidogrel and stroke].
Topics: Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Inflamm | 2011 |
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregati | 2012 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab | 2012 |
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2012 |
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Brain Ischemia; Clopidogrel; | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr | 2012 |
Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Dipyridamole; Drug Therapy, Combination; H | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Antiplatelet therapy in stroke prevention.
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Randomized Contro | 2012 |
Challenges in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, C | 2012 |
Antiplatelet therapy in cerebrovascular disorders.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Humans; Platelet Aggr | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia | 2012 |
Antiplatelet treatment in primary and secondary stroke prevention in women.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; Naphthalenes; Platele | 2012 |
Stroke genetics: prospects for personalized medicine.
Topics: Anticoagulants; Clopidogrel; Genetic Variation; Humans; Pharmacogenetics; Precision Medicine; Risk A | 2012 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracra | 2013 |
Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Life S | 2013 |
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; H | 2012 |
Aspirin and clopidogrel for prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platel | 2013 |
A benefit-risk assessment of agents used in the secondary prevention of stroke.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Aspirin; Clinical | 2002 |
Utility of platelet adp receptor antagonism in the emergency department: a review.
Topics: Aspirin; California; Clopidogrel; Coronary Disease; Critical Care; Drug Utilization; Emergency Servi | 2003 |
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Dipyridamole; | 2003 |
Evidence with antiplatelet therapy and ADP-receptor antagonists.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic | 2003 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Clopidogrel; Dipyridamole | 2003 |
Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Evidence-Based Medicine; Humans; Plate | 2003 |
[Antiplatelet drugs in prevention of complications of arteriosclerotic diseases: it is necessary to move beyond aspirin].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Therapy, Combination; Hu | 2003 |
[Treatment of acute stroke -- an overview].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Brain Edema; Case-Control Studies; Cereb | 2003 |
[Carotid stenosis: diagnosis, patient selection, therapy].
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Carotid St | 2003 |
Aspirin and stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Platelet Aggregation I | 2003 |
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; | 2003 |
Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Delayed-Action | 2004 |
Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Pla | 2004 |
Trials of newer approaches to anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Interna | 2004 |
The role of warfarin and aspirin in secondary prevention of stroke.
Topics: Anticoagulants; Aspirin; Clopidogrel; Heart Septal Defects, Atrial; Humans; Ischemic Attack, Transie | 2004 |
Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Human | 2003 |
Atrial fibrillation: should we target platelets or the coagulation pathway?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Assessment; | 2003 |
Clopidogrel in the management of cerebrovascular events.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet Aggr | 2004 |
[Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Myoc | 2004 |
P2Y12, a new platelet ADP receptor, target of clopidogrel.
Topics: Adenosine Diphosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Down-Regulation; Hum | 2003 |
The results of MATCH: light or heat?
Topics: Aspirin; Clopidogrel; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Ischem | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Preparing for the post-warfarin generation of antithrombotics.
Topics: Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clopidogrel; Fibrinolytic Agents; Fon | 2004 |
New possibilities in anticoagulant management of atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Oligosa | 2004 |
Stroke: advances in therapy.
Topics: Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Drug Thera | 2005 |
Secondary prevention of recurrent stroke.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetes Complications; Endarterectomy; Endarterecto | 2005 |
Stroke prevention. MATCHing therapy to the patient with TIA.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2005 |
[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coumarins; Death, Sudden, Cardiac; Fibrinolytic Agents; Humans | 2005 |
[Clopidogrel in the prevention of stroke].
Topics: Clinical Trials as Topic; Clopidogrel; Humans; Injections, Intravenous; Platelet Aggregation Inhibit | 2004 |
Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Hu | 2005 |
Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Health Care Costs; Humans | 2005 |
Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Humans; Ischemic At | 2005 |
Clopidogrel for the secondary prevention of stroke.
Topics: Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stroke | 2005 |
Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Recurrence; Salicylates | 2005 |
[Preventing cerebrovascular accidents during atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2005 |
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; | 2005 |
Extensive mobile thrombus of the internal carotid artery: a case report, treatment options, and a review of the literature.
Topics: Anticoagulants; Carotid Artery Thrombosis; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angi | 2005 |
[Anti-platelet drugs (aspirin, ticlopidine, etc)].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Humans; Meta-An | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru | 2006 |
[Atheromatosis of the thoracic aorta and risk of stroke].
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Atherosclerosis; Clopidogrel; Controlled | 2006 |
Prevention of vascular events in patients with cerebrovascular disease: efficacy and appropriate duration of antiplatelet therapy.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Pl | 2006 |
Aortic arch atheroma and the risk of stroke.
Topics: Aorta, Thoracic; Aspirin; Atherosclerosis; Clopidogrel; History, 18th Century; Humans; Risk Factors; | 2006 |
[Platelet-function inhibitors in the secondary prevention of ischemic stroke].
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Middle Aged; Platelet A | 2006 |
Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials.
Topics: Aspirin; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical | 2007 |
Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2006 |
Current management of transient ischemic attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Endarterectomy, Carotid; Humans; Ischemic Attack, T | 2007 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Co | 2007 |
Strategies for primary and secondary stroke prevention.
Topics: Antihypertensive Agents; Clopidogrel; Humans; Losartan; Platelet Aggregation Inhibitors; Randomized | 2006 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
Antithrombotic treatment in the prevention of ischemic stroke.
Topics: Anticoagulants; Blood Coagulation; Brain Ischemia; Clopidogrel; Fibrinolytic Agents; Humans; Platele | 2007 |
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2007 |
[What should be done after the first TIA?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopi | 2007 |
Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' resu
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, C | 2007 |
The PRoFESS trial: future impact on secondary stroke prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2007 |
Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Family P | 2007 |
Drug evaluation of clopidogrel in patients with ischemic stroke.
Topics: Animals; Carotid Artery Thrombosis; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Randomized | 2007 |
Antiplatelet therapy for stroke prevention.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel | 2007 |
Antiplatelet agents and randomized trials.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; P | 2007 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron | 2008 |
Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combi | 2008 |
Antithrombotic and thrombolytic therapy for ischemic stroke.
Topics: Aspirin; Benzenesulfonates; Cardiomyopathies; Clopidogrel; Comorbidity; Drug Therapy, Combination; F | 2008 |
Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial.
Topics: Animals; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Platelet | 2008 |
Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.
Topics: Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic; | 1999 |
[Aspirin and cerebral ischemic accidents].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Infarction; Clinica | 2000 |
Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fibrinolytic Agents; Humans; Platelet Aggregation Inh | 2000 |
Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2000 |
Antiplatelet agents for stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2000 |
Prevention of ischaemic stroke--antiplatelets.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; Pl | 2000 |
Antiplatelet agents in stroke prevention. combination therapy: present and future.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Dipyridamole; Humans; Immunoglobulin Fab Fr | 2000 |
Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Topics: Arteriosclerosis; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggre | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
Regular or "super-aspirins"? A review of thienopyridines or aspirin to prevent stroke.
Topics: Aspirin; Clopidogrel; Drug Combinations; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitor | 2001 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Cor | 2001 |
Antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Humans; Myocard | 2001 |
Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascula patients?
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; | 2001 |
Atherothrombosis--the neurologist's point of view.
Topics: Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Predictive Value | 2001 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
The use of antithrombotic drugs in older people.
Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo | 2002 |
Antithrombotic drugs for prevention of recurrent stroke.
Topics: Adult; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Fibrinolytic Agents; F | 2002 |
198 trials available for ticlopidine and Apoplexy
| Article | Year |
|---|---|
Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design.
Topics: Adenosine; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Hetero | 2017 |
Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE.
Topics: Aspirin; Brain Ischemia; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Fibrino | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Chi-Square Distribution; China; Cl | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Endoscopy, Digestive System; G | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack: The CHANCE Study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events).
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Blood Glucose; Brain Ischemia; Clopidogrel; Double-Bl | 2017 |
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; He | 2017 |
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
Topics: Adenosine; Aged; Clopidogrel; Female; Hospitalization; Humans; Hypertension; Incidence; Ischemia; Ka | 2018 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial.
Topics: Clopidogrel; Double-Blind Method; Humans; Japan; Platelet Aggregation Inhibitors; Prasugrel Hydrochl | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
Topics: Aged; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Hemorr | 2018 |
Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fem | 2018 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D | 2013 |
Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study.
Topics: Adult; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; I | 2014 |
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggrega | 2013 |
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Angiography; Death, Sudden, Cardiac; Electrocar | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
Topics: Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; | 2013 |
Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Double-Blind Method; Drug The | 2013 |
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Fema | 2014 |
Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction.
Topics: Aged; Aged, 80 and over; Cerebral Infarction; Cholesterol; Clopidogrel; Female; Follow-Up Studies; H | 2013 |
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Restenosis; Female; Humans; Italy; Male; Mid | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Inte | 2013 |
Antiplatelet effects of clopidogrel dose adjustment (75 mg/d vs 150 mg/d) after carotid stenting.
Topics: Aged; Angioplasty; Blood Platelets; Carotid Artery Diseases; Clopidogrel; Female; Humans; Ischemic A | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2014 |
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Brain Ischemia; | 2014 |
A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Intra | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma | 2015 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial.
Topics: Aged; Angina, Unstable; Clopidogrel; Endpoint Determination; Humans; Middle Aged; Myocardial Infarct | 2015 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad | 2014 |
Initial 3-weeks' Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) followed by Clopidogrel alone in high-risk patients with Acute Non-Disabling Cerebrovascular Events (ADANCE): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aspirin; Clopidogrel; Double-Blind Method; Drug Administrat | 2014 |
Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; M | 2015 |
Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke.
Topics: Acute Disease; Aged; Aspirin; Atherosclerosis; Clopidogrel; Female; Humans; Male; Nervous System Dis | 2015 |
Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients.
Topics: Adenosine Diphosphate; Aged; Blood Coagulation Tests; Clopidogrel; Drug Resistance; Female; Humans; | 2014 |
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Electrocardi | 2014 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug- | 2015 |
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid | 2015 |
Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Female; Humans; Internation | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Glyc | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggrega | 2015 |
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatinine; Female; Hemorrhage; Humans; Kaplan-Meier Est | 2016 |
Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ischemic | 2015 |
Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE.
Topics: Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Double-Blind Method; Drug Therapy, Combination | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?
Topics: Angioplasty; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Constriction, Patholo | 2015 |
Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds.
Topics: Aged; Aspirin; Cerebral Cortex; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Female; | 2015 |
Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in stroke patients: multicenter, randomized, open-label, phase 4, non-inferiority clinical trial.
Topics: Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Ticlo | 2016 |
Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2.
Topics: Aspirin; Carotid Artery, Common; Carotid Stenosis; Clopidogrel; Dose-Response Relationship, Drug; En | 2016 |
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Topics: Brain Ischemia; Cerebral Hemorrhage; Chemoprevention; Clopidogrel; Cytochrome P-450 CYP2C19; Follow- | 2016 |
[Argatroban, Aspirin, and Clopidogrel Combination Therapy for Acute Penetrating Artery Infarction: A Pilot Study].
Topics: Acute Disease; Aged; Arginine; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Infa | 2016 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Com | 2016 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem | 2016 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middl | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug | 2016 |
Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2016 |
Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Infarction; Cerebrovascular Circulation; China; Clopidogrel; | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
Topics: Adenosine; Clopidogrel; Cost Sharing; Drug Costs; Financial Support; Health Care Costs; Health Expen | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone.
Topics: Aged; Aspirin; Atherosclerosis; Brain; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therap | 2016 |
The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Arterial Diseases; Clopidogrel; Drug Therapy, Co | 2016 |
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin | 2017 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.
Topics: Aged; Aspirin; Blood Glucose; Brain Ischemia; Clopidogrel; Diabetes Complications; Double-Blind Meth | 2016 |
Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male | 2018 |
Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events).
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Comorbidity; Drug Therapy, Combi | 2016 |
Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 2017 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail.
Topics: Arterial Occlusive Diseases; Aspirin; China; Clopidogrel; Dose-Response Relationship, Drug; Drug The | 2017 |
Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA.
Topics: Aged; Aspirin; Brain; Brain Infarction; Brain Ischemia; Clopidogrel; Female; Humans; Image Processin | 2017 |
Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Glycated Serum Al | 2017 |
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combinati | 2017 |
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Doubl | 2008 |
Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; Drug-Elutin | 2008 |
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Huma | 2008 |
A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Drug Tolerance; | 2008 |
Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS).
Topics: Anticoagulants; Aortic Dissection; Aspirin; Clinical Protocols; Clopidogrel; Diagnostic Imaging; Dip | 2007 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F | 2009 |
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle A | 2008 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials.
Topics: Aged; Brain Infarction; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Humans; Inciden | 2009 |
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study.
Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Double-Blind Method; Ethnicity; Female; Follow-U | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
[Clopidogrel in the treatment of atrial fibrillation: benefit from addition to aspirin. The results of ACTIVE A trial].
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Follow-Up S | 2009 |
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combinatio | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug | 2009 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Female; Fibrinolytic Agents; Humans; Kapla | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.
Topics: Adult; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Drug Therapy, Combina | 2010 |
One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Double-Blind M | 2010 |
Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence; Intention to Treat Analy | 2010 |
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolyt | 2010 |
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
The safety of proton pump inhibitors and clopidogrel in patients after stroke.
Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Ontario; Platelet Aggregation Inhibitors | 2011 |
Non-invasive alternating current stimulation induces recovery from stroke.
Topics: Aged; Aphasia; Aspirin; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Electric Stimulation | 2010 |
Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Aspirin; Clopidogrel; Dipyridamole; Double-Blind Method; D | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.
Topics: Aged; Brain Ischemia; Calcium Channel Blockers; Cilostazol; Clopidogrel; Death; Drug Antagonism; Dru | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.
Topics: Aged; Angina, Stable; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relations | 2012 |
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind | 2011 |
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Topics: Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Inf | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
[Branch atheromatous disease: prognosis and management. The SPS3 experience].
Topics: Aspirin; Basilar Artery; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Stroke, Lacun | 2011 |
Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Co | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Topics: Age Factors; Aged; Aspirin; Body Weight; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; F | 2012 |
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genot | 2012 |
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.
Topics: Aged; Antihypertensive Agents; Aspirin; Black or African American; Blood Pressure; Chi-Square Distri | 2013 |
Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; | 2012 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial | 2012 |
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Disease-Free Survival; Do | 2012 |
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life E | 2013 |
The effectiveness of dual antiplatelet treatment in acute ischemic stroke patients with intracranial arterial stenosis: a subgroup analysis of CLAIR study.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination | 2013 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub | 2012 |
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hem | 2012 |
High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Female; Humans; Ischemic Attack, Tr | 2013 |
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogre | 2013 |
Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke.
Topics: Age Factors; Aged; Asian People; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Double- | 2012 |
Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Female; Follow | 2013 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
What is better antiplatelet agent to prevent recurrent stroke?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2012 |
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Mid | 2013 |
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.
Topics: Administration, Oral; Adolescent; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Cyclooxygenase 1; | 2013 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic A | 2013 |
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
Topics: Aged; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Aryldialkylphosphatase; Asian People; Clopidogrel; F | 2012 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
Topics: Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Clopidogrel; Cross-Ove | 2003 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.
Topics: Aged; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Clopidogrel; D | 2002 |
Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial.
Topics: Aged; Aspirin; Black or African American; Double-Blind Method; Female; Humans; Male; Middle Aged; Pl | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2003 |
Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic Attac | 2003 |
Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2004 |
Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100.
Topics: Clopidogrel; Hematologic Tests; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Platel | 2004 |
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Cell Adhesion; Clopidog | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Fem | 2005 |
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.
Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blood Platelets; Bra | 2005 |
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
Topics: Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Femal | 2005 |
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience.
Topics: Adult; Aged; Clopidogrel; Coronary Disease; Desensitization, Immunologic; Dose-Response Relationship | 2006 |
Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Disease; Death; Drug Resistance; Female | 2007 |
Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Be | 2007 |
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Co | 2007 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Ele | 2008 |
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Bipheny | 2008 |
Platelet aggregation and recruitment with aspirin-clopidogrel therapy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Humans; Platelet Ag | 2008 |
The effect of aspirin, ticlopidine and their low-dose combination on platelet aggregability in acute ischemic stroke: a short duration follow-up study.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combin | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage | 2002 |
508 other studies available for ticlopidine and Apoplexy
| Article | Year |
|---|---|
Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents.
Topics: Animals; Antipyrine; Benzofurans; Cell Line; Drug Design; Edaravone; Free Radical Scavengers; Humans | 2015 |
Triglyceride glucose index influences platelet reactivity in acute ischemic stroke patients.
Topics: Brain Ischemia; Glucose; Humans; Ischemic Stroke; Platelet Aggregation; Platelet Aggregation Inhibit | 2021 |
Dual Antiplatelet Therapy Plus Argatroban Prevents Early Neurological Deterioration in Branch Atherosclerosis Disease.
Topics: Arginine; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Humans; Pipecolic Acids; Platelet A | 2022 |
Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Ischemic Stroke; Platelet Aggregation Inhibi | 2022 |
Relationship between recurrent ischemic events in cerebrovascular disease and cytochrome P450 2C19 gene polymorphism on the basis of thrombelastography.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Polymorphism, Geneti | 2022 |
Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Cost-Benefit Analysis; Humans; Markov Chains; Platelet Aggregation | 2022 |
Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia.
Topics: Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Humans; Indonesia; Ischemic Stroke; | 2022 |
Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
Topics: Aspirin; Canada; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Humans; Ischemic Atta | 2023 |
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, T | 2022 |
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic | 2023 |
Efficacy of Treatment with and without Initial Clopidogrel Loading in Branch Atheromatous Disease.
Topics: Cerebral Infarction; Clopidogrel; Humans; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; | 2023 |
Impact of continued clopidogrel use on outcomes of patients undergoing carotid endarterectomy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Female; Humans; Male; Myocard | 2023 |
Comparative effectiveness of dual antiplatelet therapy versus monotherapy in patients with ischemic stroke.
Topics: Aspirin; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Humans; Ischemic Stroke; P | 2023 |
CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Ag | 2020 |
Aspirin plus clopidogrel versus aspirin Mono-Therapy for ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2020 |
[Expanding the possibilities of antithrombotic therapy of cerebrovascular pathology].
Topics: Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Pilot Projects; Platelet Aggreg | 2020 |
Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
Topics: Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Ischemic Stroke; Multicente | 2020 |
Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports.
Topics: Aged; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; | 2020 |
Topics: Clopidogrel; Humans; Ischemic Attack, Transient; Precision Medicine; Stroke; Ticlopidine | 2021 |
Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged | 2020 |
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc | 2021 |
Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™.
Topics: Adenosine; Aged; Aspirin; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embolization, | 2017 |
The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Ischem | 2017 |
[Contemporary use of ticagrelor in patients with acute coronary syndrome after discharge].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Myocardial Infarction; Patient Discharge; Platelet Aggre | 2017 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Huma | 2017 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A | 2017 |
Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database.
Topics: Adolescent; Adult; Aged; Clopidogrel; Databases, Factual; Female; Humans; Male; Medicare; Middle Age | 2017 |
Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Chi-Square Distribution; Clopidog | 2017 |
Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports.
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Ischemic Atta | 2017 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi | 2017 |
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi | 2017 |
Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Diabetes Mel | 2017 |
Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Topics: Alleles; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; F | 2017 |
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thr | 2017 |
Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Decompression, Surgical; Female; Hemorrhage; Humans; In | 2017 |
Emergent loading dose of antiplatelets for stenting after IV rt-PA in acute ischemic stroke: a feasibility study.
Topics: Administration, Intravenous; Aged; Aspirin; Brain Ischemia; Clopidogrel; Computed Tomography Angiogr | 2018 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbi | 2018 |
Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Pla | 2017 |
Response by Lee and Ovbiagele to Letter Regarding Article, "Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis".
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2017 |
Letter by Spence Regarding Article, "Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis".
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2017 |
Scorpion bite-induced ischaemic stroke.
Topics: Animals; Biomarkers; Catecholamines; Cerebral Angiography; Clopidogrel; Fatal Outcome; Female; Heart | 2017 |
Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Humans; Isolated Noncompaction | 2017 |
[Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
Topics: Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Inter | 2017 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Dec | 2018 |
Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Dose-Response Relationshi | 2018 |
STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Fibrinol | 2018 |
Basilar artery fenestration: an unusual possible cause of ischaemic stroke?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ataxia; Basilar Artery; Cerebral Angiograph | 2018 |
Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; | 2018 |
Artery of Percheron: an unusual stroke presentation.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorv | 2018 |
Anterior spinal cord infarct: a rare yet disabling stroke.
Topics: Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Diagnosis, Differential; Humans; Hydroxymethy | 2018 |
Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myoc | 2018 |
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; China; Clinical Decision-Making; Clopidogrel; Cyto | 2018 |
Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Genotype; Humans; Ischemi | 2018 |
Never So Simple: Bedside Measurement of Platelet Reactivity and the Risk of Stroke After Coronary Stenting.
Topics: Blood Platelets; Brain Ischemia; Drug-Eluting Stents; Humans; Stents; Stroke; Ticlopidine; Treatment | 2018 |
Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response.
Topics: Aged; Clopidogrel; Denmark; Drug Resistance; Female; Humans; Ischemic Attack, Transient; Male; Medic | 2018 |
Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; | 2019 |
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2018 |
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag | 2019 |
Aspirin-still the GLOBAL LEADER in antiplatelet therapy.
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2018 |
New opportunities to optimize antithrombotic therapy for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Ischemic Attack, Trans | 2019 |
Prasugrel or clopidogrel for long-term secondary stroke prevention?
Topics: Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Strok | 2019 |
Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis.
Topics: Aspirin; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2019 |
[Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
Topics: Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 Enzyme System; Female; | 2019 |
Assessment of the relationship between platelet reactivity, vascular risk factors and gender in cerebral ischaemia patients.
Topics: Blood Platelets; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibitors; Risk Factors | 2019 |
CYP2C19 loss-of-function alleles: A common but overlooked problem associated with clopidogrel resistance.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Stroke; Tic | 2019 |
Amplatzer left atrial appendage occlusion: single center 10-year experience.
Topics: Aged; Aged, 80 and over; Anesthesia, Local; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac | 2013 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; | 2013 |
Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Cohort Studies; Female; Humans; Longitudinal Studies; Male; | 2013 |
Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA.
Topics: Aged; Blood Glucose; Blood Platelets; Clopidogrel; Female; Glucose Intolerance; Humans; Insulin Resi | 2014 |
Short-term bleeding events observed with clopidogrel loading in acute ischemic stroke patients.
Topics: Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Plat | 2013 |
CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Asian People; China; | 2013 |
CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Case-Control Studies; China; Clopidogrel | 2013 |
Urgent best medical therapy may obviate the need for urgent surgery in patients with symptomatic carotid stenosis.
Topics: Adult; Ambulatory Care; Carotid Stenosis; Clopidogrel; Disease Management; Drug Therapy, Combination | 2013 |
Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dru | 2013 |
[Clopidogrel plus acetylsalicylic acid: a deadly combination].
Topics: Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secondary Preventi | 2013 |
Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Revascularizatio | 2014 |
Dual antiplatelet therapy in acute transient ischemic attack and minor stroke.
Topics: Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stro | 2013 |
Early dual therapy for Chinese adults with TIA.
Topics: Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracranial Hemorrhages; Is | 2013 |
Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Topics: Adenosine Diphosphate; Adult; Aged; Alprostadil; Blood Platelets; Cell Adhesion Molecules; Clinical | 2013 |
Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events.
Topics: Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-450 CYP2C19; Dru | 2014 |
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aryldialkylphosphatase; Biotransformation; | 2014 |
The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2013 |
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subf | 2013 |
Response to letter regarding article, "CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China".
Topics: Aryl Hydrocarbon Hydroxylases; Asian People; Female; Humans; Male; Platelet Aggregation Inhibitors; | 2013 |
Letter by Dong et al regarding article, "CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China".
Topics: Aryl Hydrocarbon Hydroxylases; Asian People; Female; Humans; Male; Platelet Aggregation Inhibitors; | 2013 |
Risks and benefits of early antithrombotic therapy after thrombolytic treatment in patients with acute stroke.
Topics: Administration, Oral; Aged; Aspirin; Brain; Clopidogrel; Female; Fibrinolytic Agents; Heparin; Human | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
Stroke: a new CHANCE for combination antiplatelet therapy?
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therap | 2014 |
Aspirin plus clopidogrel in acute minor ischaemic stroke or transient ischaemic attack is superior to aspirin alone for stroke risk reduction: CHANCE trial.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2014 |
Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study.
Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Cholesterol, HDL; Clopido | 2013 |
Clopidogrel use is associated with an increased prevalence of cerebral microbleeds in a stroke-free population: the Rotterdam study.
Topics: Aged; Aged, 80 and over; Cerebral Hemorrhage; Clopidogrel; Cross-Sectional Studies; Female; Humans; | 2013 |
Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; | 2014 |
Clopidogrel with aspirin in minor stroke or transient ischemic attack.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Clopidogrel with aspirin in minor stroke or transient ischemic attack.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Clopidogrel with aspirin in minor stroke or transient ischemic attack.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Clopidogrel with aspirin in minor stroke or transient ischemic attack.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Pharmacogenetics of neural injury recovery.
Topics: Anticoagulants; Brain Injuries; Clopidogrel; Humans; Pharmacogenetics; Platelet Aggregation Inhibito | 2013 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2014 |
ACP Journal Club. Adding clopidogrel to aspirin after TIA or minor ischemic stroke reduced stroke without increasing bleeding.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Efficacy of contemporary medical management for asymptomatic carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2013 |
Progressive hemorrhagic transformation following dual antiplatelet therapy.
Topics: Angiography, Digital Subtraction; Aspirin; Brain; Cerebral Angiography; Cerebral Hemorrhage; Clopido | 2014 |
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera | 2014 |
Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation.
Topics: Animals; Antigens; Aspirin; Cerebrovascular Circulation; Cilostazol; Clopidogrel; Disease Models, An | 2014 |
Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Blood Platelets; Cardiovascular Diseases; Clopidogrel | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Clopidogrel high-on-treatment platelet reactivity in acute ischemic stroke patients.
Topics: Aged; Blood Platelets; Cardiography, Impedance; Clopidogrel; Female; Humans; Male; Platelet Aggregat | 2014 |
Secondary prevention of atherothrombotic or cryptogenic stroke.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Th | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2014 |
[Not Available].
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Switching from aspirin to clopidogrel in patients with aspirin resistance after an ischemic stroke. Is it a good solution?
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Resistance; Drug Substitution; F | 2014 |
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined | 2014 |
Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
Topics: Aged; Alabama; Angioplasty; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Drug Ther | 2014 |
Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle | 2014 |
Intracranial stenosis: impact of randomized trials on treatment preferences of US neurologists and neurointerventionists.
Topics: Angioplasty; Aspirin; Cerebral Arteries; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combin | 2014 |
Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Substitution; Female; Fibrinolytic Agents | 2014 |
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate | 2014 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2015 |
Aortic arch atheroma: a plaque of a different color or more of the same?
Topics: Anticoagulants; Aortic Diseases; Aspirin; Clopidogrel; Female; Humans; Male; Platelet Aggregation In | 2014 |
High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease: assessment of prevalence and stability over time using four platelet function tests.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Blood Platelets; Cell Adhesion Molecules; Cells, Cul | 2014 |
Severe left ventricular systolic dysfunction is independently associated with high on-clopidogrel platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Humans | 2014 |
Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Enzyme-Linked Immunosorbent Assay; Female; Humans; | 2014 |
Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
Topics: Aspirin; China; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; H | 2014 |
Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle | 2014 |
Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle | 2014 |
Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle | 2014 |
Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle | 2014 |
[New aspects of stroke medicine].
Topics: Anticoagulants; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Pneumatic Compression Devices | 2014 |
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middl | 2014 |
Acute Carotid Artery Stent Thrombosis Due to Dual Antiplatelet Resistance.
Topics: Acute Disease; Aged; Aspirin; Carotid Artery Thrombosis; Carotid Artery, Internal; Clopidogrel; Drug | 2015 |
Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
Topics: Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Humans; Male | 2015 |
Analysis of periinterventional complications of intracranial angioplasty and stenting: a single center experience.
Topics: Aged; Angioplasty; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Diabetes Complication | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Ischemia; Cell Adhesion Molecules; China; Clopidog | 2014 |
Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Huma | 2015 |
Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Foll | 2015 |
CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
Topics: Aged; Asian People; Brain; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Diffusion Magnetic | 2015 |
[Clopidogrel resistance in cerebrovascular disease -- results of one-year follow-up].
Topics: Adult; Aged; Blood Glucose; Blood Pressure; C-Reactive Protein; Clopidogrel; Drug Resistance; Female | 2015 |
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data | 2015 |
Comment: TIA response to antiplatelets stratified by glycated albumin.
Topics: Aspirin; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticlopidine | 2015 |
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Databases, Factual; Female; Fibrinolyti | 2015 |
Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopido | 2015 |
Predictive value of high residual platelet reactivity by flow cytometry for outcomes of ischemic stroke patients on clopidogrel therapy.
Topics: Aged; Aged, 80 and over; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Flow Cytometry; Human | 2015 |
Antiplatelets Versus Anticoagulation for Cervical Arterial Dissection.
Topics: Anticoagulants; Aortic Dissection; Aspirin; Carotid Artery, Internal, Dissection; Cervical Vertebrae | 2015 |
The association of ABCC3 promoter methylation with clopidogrel response in Chinese ischemic stroke patients.
Topics: Aged; Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; DNA Methylation; Female; Heterozygote; Hu | 2014 |
Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cost-Benefit Analysis; Humans; Middle Aged; Pe | 2015 |
ABCB1 hypomethylation is associated with decreased antiplatelet effects of clopidogrel in Chinese ischemic stroke patients.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Asian People; ATP Binding Cassette Transporter, Subf | 2015 |
Clopidogrel with aspirin versus aspirin alone in prevention of stroke following transient ischemic attack or acute minor stroke.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2015 |
Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; | 2015 |
Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
Topics: Aged; Biomarkers, Pharmacological; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Fo | 2015 |
Dual antiplatelet therapy for TIA reduces subsequent disability: A CHANCE to improve outcomes?
Topics: Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Outcome Assessment, Health Care; Platelet | 2015 |
Antiplatelet therapy in Takotsubo cardiomyopathy: does it improve cardiovascular outcomes during index event?
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Heart Failure; Hospital Mortality; Hu | 2016 |
Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardia | 2015 |
Failure of the Platelet Function Assay (PFA)-100 to detect antiplatelet agents.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelet Disorders; Brain Injuries; Clopidogrel; False Negat | 2015 |
Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease.
Topics: Aged; Blood Glucose; Carotid Artery Diseases; Cerebral Small Vessel Diseases; Clopidogrel; Cohort St | 2015 |
Interest of Antiplatelet Drug Testing after an Acute Ischemic Stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation | 2015 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; | 2015 |
Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Comorbidity; Coronary Artery By | 2016 |
Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?
Topics: Aged; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Female; Follow-Up Studies; Humans; M | 2015 |
An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes.
Topics: Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; T | 2015 |
Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China.
Topics: Adenosine Diphosphate; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Platele | 2016 |
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; | 2015 |
Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; CD40 Ligand; Clopidogrel; Femal | 2016 |
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Topics: Aged; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Freq | 2016 |
[Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
Topics: Aged; Alleles; Asian People; Brain Ischemia; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; G | 2015 |
Effect of atorvastatin co-treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Hydroxymethylglu | 2015 |
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination | 2016 |
Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endarterectomy, C | 2016 |
Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Disability E | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F | 2016 |
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; | 2016 |
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr | 2016 |
Likelihood ratio meta-analysis: New motivation and approach for an old method.
Topics: Aspirin; Bayes Theorem; Clopidogrel; Data Interpretation, Statistical; Humans; Hydroxymethylglutaryl | 2016 |
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Surgical Procedures; Clopido | 2016 |
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cardiography, Impedance; Clopidogrel; Cytochrome | 2017 |
Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Male; | 2016 |
Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population.
Topics: Aged; Aged, 80 and over; Asian People; Chi-Square Distribution; China; Clopidogrel; Disability Evalu | 2016 |
Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy.
Topics: Aged; Aspirin; Asymptomatic Diseases; Carotid Artery Diseases; Chi-Square Distribution; Clopidogrel; | 2016 |
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
Topics: Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Humans; Ischemia; Male; | 2016 |
TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; CpG Islands; DNA Methylation; Epigenesis, Gene | 2016 |
The contemporary management of intracranial atherosclerotic disease.
Topics: Angioplasty; Aspirin; Clopidogrel; Fibrinolytic Agents; Humans; Intracranial Arteriosclerosis; Strok | 2016 |
[After the first stroke, acetylsalicylic acid is no longer enough].
Topics: Aged; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Humans; Recurrence; Stroke | 2016 |
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
Topics: Aged; Asian People; Case-Control Studies; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CY | 2016 |
Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia.
Topics: Aged; Alleles; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male | 2016 |
Extended use of clopidogrel and aspirin after ischemic stroke.
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Humans; Platelet Aggregation Inhibitors; Post-Ex | 2016 |
Extended use of clopidogrel and aspirin after ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Humans; Platelet Aggregation Inh | 2016 |
Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Humans; I | 2017 |
Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population.
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; M | 2016 |
A rabbit model of cerebral microembolic signals for translational research: preclinical validation for aspirin and clopidogrel.
Topics: Animals; Aspirin; Carotid Artery Thrombosis; Chlorides; Clopidogrel; Disease Models, Animal; Drug Ev | 2016 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Isr | 2016 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial.
Topics: Aged; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence | 2016 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra | 2016 |
Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Topics: Aged; Aged, 80 and over; Brain Ischemia; China; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P- | 2016 |
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran | 2016 |
Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
Topics: Aged; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Genotype; Hu | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longi
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Drug Costs; Female; Health | 2016 |
Letter by Moris and Avgerinos Regarding Article, "Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone".
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ti | 2016 |
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu
Topics: Acute Coronary Syndrome; Aftercare; Aged; Cardiovascular Diseases; Clopidogrel; Comparative Effectiv | 2016 |
Response to the letter by Dr. Demetrios Moris "Reply to Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel".
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Platelet Aggregation Inhibitors; Polymorphi | 2017 |
Reply to effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with Clopidogrel.
Topics: Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Stro | 2017 |
Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co | 2017 |
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
Topics: Aspirin; Clopidogrel; Data Interpretation, Statistical; Humans; Models, Statistical; Myocardial Infa | 2017 |
Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors.
Topics: Aged; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19 Inhibitors; Databas | 2017 |
Clinical Impact of Pharmacogenomics of Clopidogrel in Stroke.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Pharmacogenetics; Platelet Aggregation; Pla | 2017 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery | 2017 |
Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Foll | 2017 |
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl | 2017 |
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug The | 2017 |
Effect of Clopidogrel by Smoking Status on Secondary Stroke Prevention.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Datasets as Topic; Drug Therapy, Combination; Humans | 2017 |
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2017 |
Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogr | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)".
Topics: Adenosine; Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Tic | 2017 |
Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcom
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregat | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction | 2017 |
Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Brain Ischemia; Clopidogrel; Female; Genetic Varia | 2017 |
Current practice of antithrombotic treatment in ischemic stroke: a survey among Hungarian neurologists.
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Prescriptions; | 2008 |
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
[Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Germany; Humans; Multicenter Studies | 2008 |
The PRoFESS trial results: what went wrong?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlled T | 2008 |
CHARISMA revisited: is the glass half full or just empty?
Topics: Aspirin; Clopidogrel; Coronary Disease; Disease Progression; Humans; Platelet Aggregation Inhibitors | 2008 |
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combi | 2006 |
Stroke prevention--insights from incoherence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridam | 2008 |
[Secondary prevention with clopidogrel or acetylsalicylic acid after acute cerebrovascular event. Health services research study of private primary care specialists].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Comorbidity; Cross-Sectional Studies; Female; | 2008 |
[Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Aspirin; Benzimida | 2008 |
ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
Topics: Aged; Anticoagulants; Clopidogrel; Combined Modality Therapy; Comorbidity; Disease-Free Survival; Dr | 2009 |
PRoFESS.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Clopido | 2009 |
Antiplatelets for stroke prevention: implications of the PRoFESS trial.
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, | 2009 |
ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Dr | 2008 |
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; D | 2008 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2009 |
Would self-expanding stent occlude middle cerebral artery perforators?
Topics: Adult; Aged; Angioplasty; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Infarction, Middl | 2009 |
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? Yes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combi | 2009 |
Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg).
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Sche | 2009 |
Clopidogrel for preventing cardiovascular events.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; | 2009 |
The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I | 2009 |
ACTIVE A: balancing the benefits and risks of clopidogrel and aspirin.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracra | 2009 |
[Clopidogrel in the treatment of atrial fibrillation: comparison with warfarin. The results of ACTIVE W trial].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dose-Response Relationship, Drug; Follow-Up | 2009 |
Prevention of stroke in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; | 2009 |
Aspirin for heart attack, stroke prevention. When benefits outweigh risks: four new studies help clarify who should--and who shouldn't--take the drug.
Topics: Aspirin; Clopidogrel; Contraindications; Drug Interactions; Drug Therapy, Combination; Female; Gastr | 2009 |
Safety and effectiveness of endovascular therapy after 8 hours of acute ischemic stroke onset and wake-up strokes.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Cerebral Arteries; Clopidogrel; Fema | 2009 |
Who is ineligible for warfarin in atrial fibrillation?
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Contraindications; Drug Therapy, Combinat | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet A | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Pla | 2009 |
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atri | 2009 |
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications.
Topics: Aged; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Mal | 2010 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Thirty-day outcome following carotid artery stenting: a 10-year experience from a single center.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiography; Carotid Stenosis; Clopidogrel; Co | 2010 |
Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
ProFESS trial: any lessons to learn for future anti-platelet trials?
Topics: Aged; Aspirin; Brain; Cerebral Arteries; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Femal | 2009 |
Aspirin gets a backup against atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I | 2009 |
Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance".
Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female | 2009 |
The PLATO trial: do you believe in magic?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intrac | 2010 |
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cos | 2010 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
Clopidogrel for the hot patient.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Drug Therapy, | 2009 |
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Double-B | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocard | 2009 |
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh | 2010 |
Safety of carotid endarterectomy while on clopidogrel (Plavix). Clinical article.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Cohort Studies; Edema; E | 2010 |
Long-term results of carotid artery stents to manage symptomatic carotid artery stenosis and factors that affect outcome.
Topics: Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Carotid Stenosis; Chemotherapy | 2010 |
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; | 2010 |
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema | 2010 |
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2010 |
Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fol | 2010 |
Time matters for reducing risk of stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Risk; Stroke; T | 2010 |
If I take the blood thinner Plavix, should I avoid using Prilosec or other heartburn medications?
Topics: Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Health Knowledge, Atti | 2010 |
Carotid angioplasty in asymptomatic patients undergoing CABG surgery.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Carotid Stenosis; Clopidogrel; Coronary Angiography; Cor | 2010 |
Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic A | 2010 |
Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; P | 2010 |
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhag | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Echocardiography, Transesophageal; Embolism, Paradoxi | 2011 |
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
Topics: Aged; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Biotransformation; Car | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronary Disease; Drug Administr | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, C | 2010 |
Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antithrombins; Chi | 2010 |
It is standard practice, but is it really best practice or clinical biocreep?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Coronary Angiog | 2010 |
Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Endar | 2011 |
Management of severe bilateral carotid artery stenosis concomitant to severely symptomatic coronary arterial disease requiring coronary artery bypass grafting: a case-based review.
Topics: Carotid Artery Diseases; Carotid Stenosis; Clopidogrel; Coronary Artery Bypass; Endarterectomy, Caro | 2010 |
Paradoxical embolism.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Dyspnea; Echocardiography, Transesophageal; Embolism, Para | 2010 |
Second-generation thienopyridine use is not associated with better early perioperative outcome during carotid stenting.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty; Asymptomatic Diseases; Carotid Stenosis; | 2011 |
Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Down-Reg | 2011 |
Ischaemic stroke--prevention is better than cure.
Topics: Adult; Age Factors; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Blo | 2010 |
Significant increase in clopidogrel use across U.S. children's hospitals.
Topics: Adolescent; Child; Child, Preschool; Clopidogrel; Coronary Thrombosis; Databases, Factual; Drug Ther | 2011 |
Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry.
Topics: Aged; Cerebrovascular Disorders; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Inter | 2011 |
What you need to know about Clopidogrel. This drug helps to prevent the blood clots that can cause heart attacks and stroke.
Topics: Clopidogrel; Health Knowledge, Attitudes, Practice; Heart Diseases; Humans; Myocardial Infarction; P | 2009 |
Evaluation of clopidogrel resistance in ischemic stroke patients.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Resistance; Female | 2011 |
Optimal antithrombotic therapy in patients receiving long-term oral anticoagulation requiring percutaneous coronary intervention: "triple therapy" or "triple threat".
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Heart Disease | 2011 |
Did clopidogrel confound the results?
Topics: Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Platelet Aggregation Inhibitors; Postoperativ | 2011 |
What is the best antiplatelet agent for prevention of recurrent stroke in Pakistani patients? Do combinations offer significant advantages in the South Asian context?
Topics: Asian People; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medicine | 2010 |
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B | 2010 |
Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Hematoma, Epidural, Spinal; Humans; Magnetic Resonance Imaging; Male; Middle A | 2011 |
Significance of cardiocoronary pathology in acute stroke.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2011 |
Stroke and transient ischemic attack in the long-term care setting: patient characteristics, medication treatment, and length of stay.
Topics: Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Databases, Factual; Drug Administration Schedu | 2011 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Biphenyl Compounds; Cl | 2011 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay.
Topics: Aged; Blood Coagulation Tests; Blood Platelets; Carotid Artery Diseases; Cilostazol; Clopidogrel; Dr | 2011 |
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
Fluoxetine and motor recovery after ischaemic stroke.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2011 |
Fluoxetine and motor recovery after ischaemic stroke.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2011 |
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid St | 2011 |
[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?].
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Female; Follow-Up Studies; Humans; | 2012 |
Predictors of neck bleeding after eversion carotid endarterectomy.
Topics: Adult; Aged; Aged, 80 and over; Carotid Artery Diseases; Chi-Square Distribution; Clopidogrel; Drug | 2011 |
Have medical therapy and stenting been fairly compared? A repercussion upon termination of recruitment in the SAMMPRIS trial.
Topics: Angioplasty; Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Humans; National Inst | 2011 |
Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Foramen Ovale, Patent; | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri | 2011 |
Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Femal | 2011 |
Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug T | 2011 |
Imaging cardio-vascular anatomy and function in D-Transposition of the great arteries after mustard procedure.
Topics: Adult; Clopidogrel; Heart Arrest; Humans; Magnetic Resonance Angiography; Male; Platelet Aggregation | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
Selecting the optimal stroke prevention therapy in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 2011 |
SAMMPRIS: end of intracranial stenting for atherosclerosis or back to the drawing board?
Topics: Cerebral Angiography; Clopidogrel; Female; Humans; Intracranial Arteriosclerosis; Male; Platelet Agg | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Medical management trumps stenting for intracranial arterial stenosis.
Topics: Angioplasty; Aspirin; Cerebral Arteries; Clopidogrel; Combined Modality Therapy; Constriction, Patho | 2011 |
Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronar | 2012 |
Clopidogrel (plavix).
Topics: Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2011 |
Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Brain Ischemia; Clopidogrel; Dose-Response | 2012 |
High residual platelet reactivity and thrombotic events.
Topics: Acute Coronary Syndrome; Female; Humans; Male; Myocardial Infarction; Platelet Adhesiveness; Platele | 2011 |
Editorial - do not throw the baby out with the bathwater….
Topics: Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Humans; Multicenter Studies as Topic; National | 2011 |
My patient just had a transient ischaemic attack. Can I predict his risk for stroke? Is stroke inevitable or preventable?
Topics: Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Middle Aged; Plat | 2011 |
Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Re | 2013 |
Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Cohort St | 2012 |
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopid | 2012 |
Antiplatelet therapy for transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
The effect of the CYP 2C19*2 polymorphism on stroke care.
Topics: Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19 | 2012 |
Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; S | 2012 |
Blood loss and complications following carotid endarterectomy in patients treated with clopidogrel.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Artery Diseases; Clopidogrel; Drug T | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; | 2012 |
Clopidogrel in atrial fibrillation: is there any justification now in the era of new anticoagulants?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Practice Guideli | 2012 |
Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Fem | 2012 |
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Topics: Aged; Amlodipine; Angioplasty, Balloon, Coronary; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interact | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2012 |
Clopidogrel efficacy and cigarette smoking status.
Topics: Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP1A2; Humans; Myocardial Infarction; Platel | 2012 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response | 2012 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo | 2012 |
One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.
Topics: Adolescent; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Delayed-Action Preparations; Drug Therap | 2012 |
Obesity and intracranial in-stent thrombosis.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Aspirin; Body Mass Index; Brain Ischemia; C | 2013 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi | 2012 |
Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combina | 2012 |
Letter by Fort and Plachetka regarding article, "association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO".
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump | 2012 |
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br | 2013 |
Secondary stroke prevention: misguided by guidelines?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Pla | 2012 |
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Longitu | 2013 |
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2012 |
Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.
Topics: Aged; Belgium; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Emer | 2013 |
Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization.
Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Peripheral Arterial Disease; Plat | 2012 |
Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hemo | 2013 |
Antiplatelet therapy in ischemic stroke: does one size fit all?
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2012 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz | 2012 |
Clopidogrel has no effect on mortality from hip fracture.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Aspirin; Bl | 2013 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; | 2013 |
[Platelet antiaggregation treatment in the aftermath of GUSTO IV, TARGET, TACTICS, and CURE trials].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coro | 2002 |
Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Platelet Aggregation I | 2002 |
Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug | 2002 |
Aspirin therapy should be first line: probably, but watch this space.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Synergism; Humans; Myocardial Isc | 2002 |
Clopidogrel plus aspirin for stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Follow- | 2002 |
Stroke prevention in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Female; F | 2003 |
Ischaemic stroke in young people: a prospective and long-term follow-up study.
Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Aspirin; Brain Ischemia; Disability Evaluation; Ec | 2003 |
I'm a 65-year-old man with high blood pressure and a family history of stroke. Which stroke-prevention medication would be better for me--aspirin or clopidogrel (Plavix)?
Topics: Aged; Aspirin; Clopidogrel; Family Health; Humans; Hypertension; Life Style; Male; Platelet Aggregat | 2003 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo | 2003 |
[Anticoagulation and antiaggregation in neurological patients].
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopid | 2003 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
Clopidogrel bisulphate-induced photosensitive lichenoid eruption: first report.
Topics: Clopidogrel; Female; Humans; Lichenoid Eruptions; Middle Aged; Photosensitivity Disorders; Platelet | 2003 |
Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Activation; Platelet Aggregation I | 2003 |
Adherence to secondary stroke prevention strategies--results from the German Stroke Data Bank.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Databases as Topic; Female; Follow-Up St | 2003 |
[Clearly superior in acute coronary syndrome. Helps aggressive platelet inhibition even after stroke?].
Topics: Acute Disease; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; My | 2003 |
Antiplatelet agents. European perspective.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Europe; Hum | 2003 |
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.
Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Dr | 2003 |
[Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; H | 2003 |
[Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidaz | 2003 |
Racial disparities in receipt of secondary stroke prevention agents among US nursing home residents.
Topics: Aged; Anticoagulants; Aspirin; Databases, Factual; Dipyridamole; Drug Therapy, Combination; Drug Uti | 2003 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimida | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
Topics: Antigens, CD; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Cross-Over Studies; | 2003 |
A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Feasibility | 2003 |
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz | 2004 |
Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia; | 2004 |
[Interaction of statins with clopidogrel].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Biotransformation; Cause of Death; Clinica | 2004 |
[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Arteries; Clopidogrel; Drug The | 2004 |
"Super aspirin" cuts risks after multiple cardiac events.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prev | 2004 |
Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; P-Se | 2004 |
A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes.
Topics: Aspirin; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Randomized Controlled Tri | 2004 |
[Clopidogrel protection is not increased further by ASS!].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2004 |
[Clopidogrel as basic therapy in high-risk stroke patients].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Hemo | 2004 |
Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Tic | 2004 |
[Secondary prevention of stroke with antiplatelet drugs].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, | 2004 |
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; C | 2004 |
Antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Humans; Myocardial Infarction; Patient | 2004 |
Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Peripheral Vascular | 2005 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; | 2005 |
Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections.
Topics: Adult; Angiography; Angioplasty; Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis I | 2005 |
In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Female; Heparin; Hospital | 2005 |
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; | 2004 |
Who needs Plavix? This super aspirin is meant mainly for people at high risk of having a heart attack or stroke.
Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Stroke | 2005 |
Neurological outcome of conservative versus endovascular treatment of patients with asymptomatic high-grade carotid artery stenosis: a propensity score-adjusted analysis.
Topics: Aged; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Disease-Free Survival; Female; Follow-Up | 2005 |
Counting the true cost of antiplatelet therapy for stroke prevention.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Dipyridam | 2005 |
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex | 2005 |
Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: Yes.
Topics: Clinical Trials as Topic; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhi | 2005 |
Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: No.
Topics: Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2005 |
The (variable) definition of benefit in the case of clopidogrel vs aspirin.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregat | 2005 |
Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk.
Topics: Adenosine Diphosphate; Adult; Aged; Blood Platelets; Calcium Signaling; Case-Control Studies; Clopid | 2005 |
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesi | 2005 |
Clopidogrel as antithrombotic therapy in atrial fibrillation.
Topics: Atrial Fibrillation; Atrial Flutter; Clopidogrel; Electric Countershock; Evidence-Based Medicine; Fi | 2005 |
[Strokes associated with cervical artery dissection, and systemic mastocytosis: an unfortuitous association? A report of two cases].
Topics: Aspirin; Brain Infarction; Carotid Artery, Internal, Dissection; Carotid Stenosis; Clopidogrel; Fibr | 2005 |
Use of antiplatelet drugs in the stroke unit of a Hong Kong hospital.
Topics: Aged; Analysis of Variance; Clopidogrel; Drug Prescriptions; Drug Utilization; Female; Hong Kong; Ho | 2005 |
Progressive symptomatic carotid dissection treated with multiple stents.
Topics: Angiography; Angioplasty; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Art | 2005 |
[Prophylaxis of stroke].
Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi | 2005 |
Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Ther | 2005 |
Oral clopidogrel load in aspirin-resistant capsular warning syndrome.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Prevention of stroke recurrence.
Topics: Aged; Clopidogrel; Dipyridamole; Endarterectomy, Carotid; Humans; Platelet Aggregation Inhibitors; S | 2003 |
[Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Huma | 2005 |
Feasibility trial of carotid stenting with and without an embolus protection device.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Commo | 2005 |
Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Internal; Carotid Stenosis; Clo | 2005 |
Antiplatelet therapy and the vascular tree.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Dis | 2006 |
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2005 |
Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases.
Topics: Aged; Aspirin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Embolism; F | 2006 |
Spinal cord stroke in a ballet dancer.
Topics: Accidents, Occupational; Adult; Clopidogrel; Dancing; Embolism; Female; Fibrocartilage; Humans; Inte | 2006 |
Antiplatelet therapy in stroke prevention: present and future.
Topics: Aspirin; Blood Platelets; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Random | 2006 |
New modalities and aspects of antiplatelet therapy for stroke prevention.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combi | 2006 |
The risks and safety of clopidogrel in pediatric arterial ischemic stroke.
Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Clopidogrel; Cohort Studies; Drug Ther | 2006 |
High prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic stroke: Buffalo metropolitan area and Erie County stroke study.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Hospitaliz | 2006 |
Clopidogrel (Plavix) revisited.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Plate | 2006 |
Growth in clopidogrel-aspirin combination therapy.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Data Collection; Drug Therapy, Combination; Drug Uti | 2006 |
Good old warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Pla | 2006 |
Antiplatelet therapy prior to carotid endarterectomy--still room for improvement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Austria; Carotid Artery, Internal; Carotid Stenosis; Clopid | 2006 |
Enhanced platelet activation by prolactin in patients with ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Ischemic Attack, Tran | 2006 |
Carotid stenting.
Topics: Aged; Aspirin; Cardiovascular Agents; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Endar | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2006 |
[Physicians and insurance may collaborate on therapy].
Topics: Aspirin; Clopidogrel; Contract Services; Cooperative Behavior; Cost-Benefit Analysis; Drug Costs; Fa | 2006 |
[When ASS, when anticoagulants?].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Clopidogrel; Female; Heart Disease | 2006 |
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary | 2006 |
[Prevention of vascular events after transient ischemic attack or cerebral infarct].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Cerebral Infarction; Clopidogrel; Dipyridamole; Drug | 2006 |
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Dose- | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com | 2006 |
Nontraumatic spinal epidural hematoma associated with clopidogrel.
Topics: Aged; Back Pain; Clopidogrel; Female; Hematoma, Epidural, Spinal; Humans; Hypertension; Magnetic Res | 2006 |
Role of antiplatelets in carotid artery stenting.
Topics: Angioplasty, Balloon; Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Dipyridamole | 2007 |
Antithrombotic therapy and predilection for cerebellar hemorrhage.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis; Aspirin; Blo | 2007 |
Stroke: the dashed hopes of neuroprotection.
Topics: Acute Disease; Aspirin; Benzenesulfonates; Carotid Arteries; Clopidogrel; Dipyridamole; Europe; Huma | 2007 |
Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2006 |
Prevention of vascular events in atrial fibrillation.
Topics: Accidental Falls; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggreg | 2007 |
Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug T | 2007 |
Variability in response to clopidogrel: where is the threshold for 'low response'?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platel | 2007 |
CHARISMA: the antiplatelet saga continues.
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2007 |
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem | 2007 |
Update on the use of antiplatelet agents in secondary stroke prevention.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, Cholester | 2007 |
Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Administration Sche | 2007 |
Rate, degree, and predictors of recovery from disability following ischemic stroke.
Topics: Aged; Brain Ischemia; Causality; Clopidogrel; Cohort Studies; Diabetes Complications; Disability Eva | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Comorbidity; Drug Therapy, Combination; | 2008 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
Antiplatelet agents for stroke prevention following transient ischemic attack.
Topics: Angioplasty, Balloon; Aspirin; Carotid Artery Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2008 |
Prediction and prevention of stroke in patients with symptomatic carotid stenosis: the high-risk period and the high-risk patient.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient; | 2008 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido | 2008 |
Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting.
Topics: Adult; Aged; Basilar Artery; Carotid Artery, Internal; Clopidogrel; Constriction, Pathologic; Drug M | 2008 |
Which patients receiving warfarin can be treated safely with a drug-eluting stent?
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru | 2008 |
Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Prescrip | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platel | 2008 |
[Emergency treatment of transient cerebral ischemia].
Topics: Aspirin; Clopidogrel; Emergency Treatment; Humans; Ischemic Attack, Transient; Platelet Aggregation | 2008 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial | 2008 |
[Creative mathematics with clopidogrel; exaggeration of the preventive effect by manufacturer].
Topics: Advertising; Clopidogrel; Data Interpretation, Statistical; Drug Industry; Humans; Myocardial Infarc | 1999 |
Treatment and secondary prevention of stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ti | 2000 |
Stent-assisted angioplasty of intracranial vertebrobasilar atherosclerosis: an initial experience.
Topics: Abciximab; Adult; Aged; Angiography; Angioplasty; Antibodies, Monoclonal; Anticoagulants; Aspirin; B | 2000 |
Sex differences and similarities in the management and outcome of stroke patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Comorbidity; | 2000 |
Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Humans; Platel | 2000 |
[Clopidogrel].
Topics: Arteriosclerosis; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Strok | 2000 |
Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention.
Topics: Anticoagulants; Arrhythmia, Sinus; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Dipyridamole | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human | 2000 |
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Dipyridamole; Drug Therapy, Combi | 2000 |
[Calculation of costs of stroke, cost effectiveness of stroke units and secondary prevention in patients after a stroke, as recommended by revised CBO practice guideline 'Stroke'].
Topics: Age Factors; Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Costs; Health Care Cost | 2000 |
[Old and new platelet aggregation inhibitors: which to choose for prevention of stroke?].
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2000 |
Ticlopidine-induced cholestatic hepatitis with anti-nuclear antibody in serum.
Topics: Antibodies, Antinuclear; Chemical and Drug Induced Liver Injury; Cholestasis; Humans; Liver; Male; M | 2000 |
Newer antiplatelet therapies in stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2001 |
Results of CURE trial for acute coronary syndrome.
Topics: Clopidogrel; Cost-Benefit Analysis; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Agg | 2001 |
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; D | 2001 |
Platelet aggregation inhibition with ticlopidine in the treatment of stroke.
Topics: Acute Disease; Critical Care; Drug Eruptions; Drug Monitoring; Gastrointestinal Diseases; Humans; Ki | 2001 |
Clinical correlates and drug treatment of residents with stroke in long-term care.
Topics: Aged; Aged, 80 and over; Aspirin; Cognition Disorders; Comorbidity; Cross-Sectional Studies; Databas | 2001 |
Is ticlopidine more effective than aspirin in preventing adverse cardiovascular events after myocardial infarction (MI)?
Topics: Angina Pectoris; Aspirin; Double-Blind Method; Fibrinolytic Agents; Humans; Multicenter Studies as T | 2001 |
Clopidogrel: new preparation. An alternative to aspirin.
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; S | 1999 |
Ticlopidine: a second look. No further use in routine practice.
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Stroke; Ticlopidine; Treatment Outco | 1999 |
Antithrombotic drugs for secondary stroke prophylaxis--a comment.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Fibri | 2001 |
Antiplatelet therapy: a neurology perspective.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Neurology; Platelet Aggregatio | 2000 |
Antiplatelet therapy: a neurology perspective.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Neurology; Platelet Aggregatio | 2000 |
Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Clopidogrel; Combined Modality Therapy; Female; | 2001 |
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2001 |
Multiple fixed-drug eruption and diarrhea with ticlopidine.
Topics: Diarrhea; Drug Eruptions; Humans; Male; Middle Aged; Stroke; Ticlopidine | 2002 |
Oral anticoagulation for acute coronary syndromes.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopi | 2002 |
Hereditary hemorrhagic telangiectasia, factor V Leiden and antiphospholipid syndrome: a case report.
Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Autoantibodies; Factor V; Female; Humans; Is | 2002 |